0001140361-12-008387.txt : 20120215 0001140361-12-008387.hdr.sgml : 20120215 20120214173749 ACCESSION NUMBER: 0001140361-12-008387 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20111231 FILED AS OF DATE: 20120215 DATE AS OF CHANGE: 20120214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEGAL CORP /DE/ CENTRAL INDEX KEY: 0000931059 STANDARD INDUSTRIAL CLASSIFICATION: SPECIAL INDUSTRY MACHINERY, NEC [3559] IRS NUMBER: 680370244 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35141 FILM NUMBER: 12613089 BUSINESS ADDRESS: STREET 1: 2201 SOUTH MCDOWELL BLVD CITY: PETALUMA STATE: CA ZIP: 94954 BUSINESS PHONE: 7077635600 MAIL ADDRESS: STREET 1: 2201 SOUTH MCDOWELL BLVD CITY: PETALUMA STATE: CA ZIP: 94954 10-Q 1 form10q.htm TEGAL CORPORATION 10-Q 12-31-2011 form10q.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 10-Q

 
(Mark One)

 
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the quarterly period ended December 31, 2011

or

 
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 0-26824

TEGAL CORPORATION
(Exact Name of Registrant as Specified in Its Charter)

Delaware
 
68-0370244
(State or Other Jurisdiction of Incorporation or Organization)
 
(I.R.S. Employer Identification No.)

140 2nd Street, Suite 318
Petaluma, California 94954
(Address of Principal Executive Offices)

Telephone Number (707) 763-5600
(Registrant’s Telephone Number, Including Area Code)
 


Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports) and (2) has been subject to such filing requirements for the past 90 days.    Yes þ    No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See definitions of “large accelerated filer“, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large Accelerated Filer   o Accelerated Filer  o
Non-Accelerated Filer o (Do not check if a smaller reporting company) Smaller reporting company þ
                                                                                                    


 
 

 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ
 
As of February 2, 2012, there were 1,688,807 of the Registrant’s common stock outstanding.  The number of shares outstanding reflects a 1-for-5 reverse stock split effected by the Registrant on June 15, 2011.
 
 
 2

 
 
TEGAL CORPORATION AND SUBSIDIARIES


 
 
Page
     
 
PART I. FINANCIAL INFORMATION
 
     
Item 1.
Condensed Consolidated Financial Statements (Unaudited)
 
 
4
 
5
 
6
 
7
Item 2.
21
Item 3.
29
Item 4.
30
     
 
PART II. OTHER INFORMATION
 
     
Item 1.
30
Item 1A.
30
Item 2.
32
Item 3.
32
Item 4.
32
Item 5.
33
Item 6.
33
34
 
 
3

 
PART I — FINANCIAL INFORMATION

Item 1.  Condensed Consolidated Financial Statements

TEGAL CORPORATION AND SUBSIDIARIES
(Unaudited)
(In thousands, except share data)

   
December 31,
   
March 31,
 
   
2011
   
2011
 
ASSETS
        (1)  
Current assets:
             
Cash and cash equivalents
  $ 8,264     $ 7,575  
Restricted cash
    200       200  
Prepaid expenses and other current assets
    92       139  
Other assets of discontinued operations
    443       1,129  
Total current assets
    8,999       9,043  
Property and equipment, net
    58       112  
Investment in unconsolidated affiliate
    1,545       2,046  
Investment in convertible promissory note
    300       --  
Total assets
  $ 10,902     $ 11,201  
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Accounts payable
  $ 81     $ 262  
Common stock warrant liability
    20       26  
Accrued expenses and other current liabilities
    57       94  
Liabilities of discontinued operations
    380       1,410  
Total current liabilities
    538       1,792  
                 
Stockholders’ equity:
               
Preferred stock; $0.01 par value; 5,000,000 shares authorized; none issued and outstanding
    -       -  
Common stock; $0.01 par value; 50,000,000 shares authorized; 1,688,807 and 1,688,943 shares issued and outstanding at December 31, 2011 and March 31, 2011, respectively.
    17       17  
Additional paid-in capital
    129,107       128,977  
Accumulated other comprehensive loss
    (140 )     (167 )
Accumulated deficit
    (118,620 )     (119,418 )
Total stockholders’ equity
    10,364       9,409  
Total liabilities and stockholders’ equity
  $ 10,902     $ 11,201  
 
(1) Derived from the Company's audited consolidated financial statements

See accompanying notes to condensed consolidated financial statements.
 
 
4

 
TEGAL CORPORATION AND SUBSIDIARIES
(Unaudited)
(In thousands, except per share data)

 
 
Three Months Ended
December 31,
   
Nine Months Ended
December 31,
 
 
 
2011
   
2010
   
2011
   
2010
 
                         
Revenue - related party
  $ 38     $ --     $ 75     $ -  
Operating expenses:
                               
General and administrative expenses
    432       306       1,873       1,493  
Total operating expenses
    432       306       1,873       1,493  
Operating loss
    (394 )     (306 )     (1,798 )     (1,493 )
Equity in (earnings) loss of unconsolidated affiliate
    181       --       501       --  
Other income/(expense), net
    8       (3 )     (6 )     (344 )
Loss before income tax expense
    (583 )     (303 )     (2,293 )     (1,149 )
Income tax expense
    --       --       --       --  
Net loss from continuing operations
    (583 )     (303 )     (2,293 )     (1,149 )
Gain on assets disposition     --       --                  
Income (loss) from discontinued operations, net of taxes
    2,852       211       3,091       (1,277 )
                                 
Net income/(loss)
  $ 2,269     $ (92 )   $ 798     $ (2,426 )
                                 
Net loss per share from continuing operations:
                               
Basic and diluted
  $ (0.34 )   $ (0.18 )   $ (1.36 )   $ (0.67 )
                                 
Net income/(loss) income per share from discontinued operations:
                         
Basic and diluted
  $ 1.69     $ 0.13     $ 1.83     $ (0.76 )
                                 
Net income/(loss) per share:
                               
Basic and diluted
  $ 1.35     $ (0.05 )   $ 0.47     $ (1.43 )
                                 
Weighted average shares used in per share computation:
                         
Basic and diluted
    1,689       1,688       1,689       1,688  

See accompanying notes to condensed consolidated financial statements.
 
 
5

 
TEGAL CORPORATION AND SUBSIDIARIES
(Unaudited)
(In thousands)

 
 
Nine Months Ended
December 31,
 
   
2011
   
2010
 
Cash flows from operating activities:
           
Net income/(loss)
  $ 798     $ (2,426 )
Adjustments to reconcile net income/(loss) to net cash (used in)/provided by operating activities:
               
Stock compensation expense
    130       313  
Stock issued under stock purchase plan
    --       1  
Fair value adjustment of common stock warrants EITF 07-05 (Topic 815)
    (6 )     (339 )
Depreciation and amortization - continuing operations
    7       --  
Depreciation and amortization - discontinued operations
    --       553  
Net gain on sale of intangible asset
    (2,737 )     --  
Provision for doubtful accounts and sales returns allowances  - discontinued operations
    (71 )     (144 )
Loss on disposal of property and equipment - continuing operations
    51       --  
Loss on disposal of property and equipment - discontinuing operations
    --       185  
Gain on proceeds received from contingent payments - discontinued operations
    (445 )     --  
Change in value of unconsolidated affiliate
    501       --  
                 
Changes in operating assets and liabilities:
               
Prepaid expenses and other assets
    47       31  
Accounts payable
    (181 )     --  
Accrued expenses and other current liabilities
    (37 )     --  
Current assets and liabilities from discontinued operations
    (330 )     2,140  
Net cash (used in)/provided by operating activities
    (2,273 )     314  
Cash flows from investing activities:
               
Acquisition of property and equipment - continuing operations
    (4 )     --  
Acquisition of property and equipment - discontinued operations
    --       (406 )
Net proceeds received from sale of intangible asset - discontinued operations
    2,737          
Net cash received on OEM asset disposition - discontinued operations
    502       750  
Issuance of note receivable
    (300 )     --  
Net cash provided by investing activities:
    2,935       344  
Cash flows from financing activities:
               
Net cash used in financing activities
    --       --  
                 
Effect of exchange rates on cash and cash equivalents
    27       (66 )
Net increase in cash and cash equivalents
    689       592  
Cash and cash equivalents at beginning of period
    7,575       7,298  
Cash and cash equivalents at end of period
  $ 8,264     $ 7,890  
 
See accompanying notes to condensed consolidated financial statements.
 
 
6

 
TEGAL CORPORATION AND SUBSIDIARIES

(Unaudited)
(All amounts in thousands, except share and per share data)

1. 
Basis of Presentation:

In the opinion of management, the unaudited condensed consolidated interim financial statements have been prepared on the same basis as the March 31, 2011 audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary to fairly state the information set forth herein.  The statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (“SEC”), but omit certain information and footnote disclosures necessary to present the statements in accordance with generally accepted accounting principles (“GAAP”).  These interim financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2011.  The results of operations for the three and nine months ended December 31, 2011 are not necessarily indicative of results to be expected for the entire year.
 
Tegal Corporation and its subsidiaries’ (“Tegal”, “the Company”, “we”, “us” or “our”) consolidated financial statements contemplate the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future.  We incurred net income/(loss) of $798 and ($2,426) for the nine months ended December 31, 2011 and 2010, respectively. We (used)/generated ($2,273) and $314 of cash in operating activities for the nine months ended December 31, 2011 and 2010, respectively.  We believe that our existing balances of cash and cash equivalents, combined with continued cost containment, will be adequate to fund operations through fiscal year 2012.
 
Throughout most of fiscal 2011, our operations consisted mainly of the sale and support of the Deep Reactive Ionic Etch (“DRIE”) product lines which we had acquired from Alcatel Micro Machining Systems (“AMMS”) in fiscal 2009, including the operation of our Tegal France subsidiary, which had been engaged in several joint development projects partially supported by customers and the government of France.  Tegal France had also been the center for the majority of our product and process development efforts and engineering activities related to the improvement of our DRIE product lines.
 
DRIE systems sales and the associated spares and service revenue represented the sole source of the Company’s revenue in fiscal 2011.  For all of fiscal 2010, DRIE sales represented approximately 47% of our total revenues.  Since the DRIE markets were seriously impacted by the downturn in the semiconductor markets and the lack of available capital for new product development globally, DRIE sales alone were not enough to continue supporting the Company, even with significant reductions in our operating expenses resulting from the sale of our legacy etch and PVD business, as well as the implementation of further cost containment measures.  Accordingly, while we focused our efforts on the operation of the DRIE business in the first half of fiscal 2011, we continued to seek and evaluate strategic alternatives, which included the continued operation of the Company as a stand-alone business with a different business plan, a merger with or into another company, a sale of all or substantially all of our remaining assets, and the liquidation or dissolution of the Company, including through a voluntary dissolution or a bankruptcy proceeding.
 
On January 14, 2011, the Company, se2quel Partners and Sequel Power entered into a Formation and Contribution Agreement. The Company contributed $2 million in cash to Sequel Power in exchange for an approximate 25% economic interest in Sequel Power.  Sequel Power is focused on the promotion of solar power plant development projects worldwide, the development of self-sustaining businesses from such projects, including but not limited to activities relating to and supporting, developing, building and operating solar photovoltaic (“PV”) fabrication facilities and solar farms, the consideration of other non-photovoltaic renewable energy projects and engagement in ancillary activities, such as advisory services.  The Sequel Power model for large scale PV-based solar projects is unique in the industry and has won significant acclaim from governments, industrial companies and industry advocates for its innovation and prospect for success.  By investing in this new company, we expect to employ our capital equipment know-how, a portion of our cash and potentially the tax benefits of our NOLs.  We intend to support the activities of Sequel Power through our direct efforts and through related operations and investments that we may make in the future, should the circumstances be favorable.
 
Following our investment in Sequel Power, and as a result of our continuing efforts to reduce our operating losses, on February 9, 2011, the Company and SPP Process Technology Systems Limited (“SPTS”) entered into an Asset Purchase Agreement.  That agreement included the sale of all of the shares of Tegal France, SAS, the Company’s wholly-owned subsidiary and product lines and certain equipment, intellectual property and other assets relating to the DRIE Etch plasma etch systems and certain related technology.  The other major asset remaining after the sale of our legacy etch and physical vapor deposition (“PVD”) business and our DRIE business was our Nano-Layer Deposition (“NLD”) intellectual property portfolio.  Having discontinued the implementation of NLD during fiscal 2010, we instead began to offer this asset for sale to third parties.  Concurrently, we began the process of closing and/or liquidating all of our other wholly-owned subsidiary companies, including SFI and Tegal GmbH, along with branches in Taiwan, Korea and Italy.   As a result, all of our activities related to our legacy etch and PVD business, our DRIE business, our NLD development activities and our subsidiaries and branches are now included in discontinued operations.
 
 
7

 
The process of consolidation and transition, driven by the financial crisis and worsened by our relatively weak strategic and financial position in the semiconductor and micro-electro-mechanical systems (“MEMS”) capital equipment sectors, continues.   Our main objective has been to preserve as much value for stockholders as possible as we transitioned to a business model that avoids high fixed costs, but retains our capabilities to attract and exploit emerging technologies. So far, we have invested in two opportunities.
 
The first investment was made in Sequel Power, and was motivated by a desire to exploit its proprietary model for large scale PV-based solar projects, which is unique in the industry, and has won significant acclaim from governments, industrial companies and industry advocates for its innovation and prospect for success.  Providing a window for us into this market, our investment in Sequel Power has allowed us to evaluate several different aspects of the solar market for the purpose of determining if further investment or business activities would be fruitful.
 
The second investment of $300 in Nano Vibronix, Inc. was completed on November 22, 2011, in the form of a convertible promissory note.  Nano Vibronix is a private company that develops medical devices and products that implement its proprietary therapeutic ultrasound technology which may be utilized for a variety of medical applications requiring low cost therapeutic ultrasound qualities. Nano Vibronix is focused on creating products utilizing its unique, patented approach which enables the transmission of low-frequency, low-intensity ultrasound surface acoustic waves (“SAWs”) through a variety of soft, flexible materials, including skin and tissue, enabling low-cost, breakthrough devices targeted at large, high-growth markets.
 
NanoVibronix is developing a series of products directed at the treatment of chronic, non-healing wounds. The global wound care market is estimated to reach $22.8 billion by 2017, of which approximately one-third is addressed by advanced wound care products, according to a report recently published by Global Industry Analysts, Inc., a research group. The growth of the market is being fueled by an aging population and the rapidly increasing incidence of diabetes world-wide.  Nano Vibronix’ first product, PainShieldTM MD, has gained FDA clearance and CE Mark certification in Europe, and is marketed for the treatment of tendonitis, muscle pain and trigeminal neuralgia. Additionally, Nano Vibronix has developed a family of disposable ultrasound devices to treat catheter-associated infection and injury, accomplished by preventing biofilm formation and decreasing the friction between the catheter and body tissues. The UroShieldTM product is currently CE mark certified, and is the subject of several independent clinical trials being conducted by leading researchers in Europe and the Middle East.
 
At the present time we are engaged primarily in supporting the activities of Sequel Power through our direct efforts and through related operations and investments we may make in the future.  In addition to our investments in Sequel Power and Nano Vibronix, we are actively evaluating opportunities for partnerships with other diversified technology-based companies in order to exploit our shared experience and to enhance our value as a public company.
 
We cannot assure you that we will be successful in pursuing any of these strategic alternatives.   If our efforts do not succeed, we may need to raise additional capital which may include capital raises through the issuance of debt or equity securities.  If additional funds are raised through the issuance of preferred stock or debt, these securities could have rights, privileges or preferences senior to those of our common stock, and debt covenants could impose restrictions on our operations. Moreover, such financing may not be available to us on acceptable terms, if at all.  Failure to raise any needed funds would materially adversely affect us.  It is not possible to predict when our business and results of operations will improve.  In consideration of these circumstances, the Company may be forced to consider a merger with or into another company or the liquidation or dissolution of the Company, including through a bankruptcy proceeding.  We cannot assure you that we will be successful in pursuing any of these strategic alternatives.  If we were to liquidate or dissolve the Company through or outside of a bankruptcy proceeding, you could lose all of your investment in Tegal common stock.
 
Reclassifications
 
As a result of the sale of the Company’s DRIE assets in the prior fiscal year, and in accordance with generally accepted accounting principles, the DRIE business operations related to the designing, manufacturing, marketing and servicing of systems and parts within the semiconductor industry has been reclassified to discontinued operations in our condensed consolidated financial statements.   Amounts for the prior periods have been reclassified to conform to this presentation.  The exit from the DRIE operation was essentially completed by the end of the fourth quarter of our 2011 fiscal year.
 
 
 
8

 
Concentration of Credit Risk
 
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash investments.  Prior to the sale of the DRIE assets, the Company’s accounts receivable balance was also subject to credit risk. Substantially all of the Company’s liquid investments are invested in money market funds. The Company’s accounts receivable are derived primarily from sales to customers located in the United States, Europe and Asia. The Company performs ongoing credit evaluations of its customers and generally requires no collateral. The Company no longer maintains reserves for potential credit losses. Write-offs during the periods presented have been insignificant.
 
As of December 31, 2011 and 2010, two customers accounted for 100% and 73%, respectively of the total accounts receivable balance. Approximately 12% of the total balance in accounts receivable for the period ended December 31, 2011 is related to our semi-conductor business and is included in assets of discontinued operations.  The Company considers this amount collectible.  The total amount of balances in accounts receivable for the period ended December 31, 2010 is included in discontinued operations.
 
For the three and nine months ended December 31, 2011, Sequel Power accounted for 100% of total revenue, which is included in continuing operations.  For the nine months ended December 31, 2010, a leading precision timing device manufacturer, Ulsan National Institute of Science and Technology, STMicroelectronics SA, and Uppsala University accounted for 28%, 20%, 18% and 17%, respectively, of total revenue.  Total revenue for the three and nine months ended December 31, 2010 is included in discontinued operations.
 
Note Receivable
 
The Company’s note receivable consisted of outstanding payments owed by OEM Group in connection with our sale to them of our legacy etch and PVD assets completed in March 2010.
 
The balance of the note receivable at December 31, 2011 consisted of the net outstanding payment owed by OEM Group in the German subsidiary in connection with the sale of legacy assets.  This balance due is included in discontinued assets and will be offset in a non-cash transaction at the final liquidation of the German subsidiary in the first quarter of the next fiscal year per the schedule of the German tax authorities.
 
The outstanding balance of cash owed on the Company’s note receivable from OEM was paid in full during the first quarter of the current fiscal year.  The Company was entitled to receive an additional contingent payment of $440 related to the terms of the sale, which was paid in full in two installments.  The first installment of $300 was paid on July 5, 2011, and the second installment of $140 was paid on October 7, 2011.  In connection with the installment plan, the Company received an additional $5 in interest payment.  Both the first and second installments were classified as a gain on sale of discontinued operations in the second and third quarters of the current fiscal year.
 
Derivative Instruments
 
In June 2008, the Financial Accounting Standards Board (“FASB“)  ratified the Emerging Issues Task Force (“EITF”) consensus on EITF Issue No. 07-05, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock (“EITF Issue 07-05”) (Topic 815) which applies to the determination of whether any freestanding financial instruments or embedded features that have the characteristics of a derivative, as defined by Statement of Financial Accounting Standards (“SFAS”) No. 133 (Topic 815), Accounting for Derivative Instruments and Hedging Activities, and to any freestanding financial instruments are potentially indexed to an entity’s own common stock.  EITF Issue No. 07-05 (Topic 815) became effective for fiscal years beginning after December 15, 2008.  The Company adopted Topic 815 as of April 1, 2009.  As a result, warrants to purchase 285,454 shares of our common stock previously treated as equity pursuant to the derivative treatment exemption were no longer afforded equity treatment. The warrants had exercise prices ranging from $30.00-$495.00 and expired or will expire between February 2010 and September 2013. As such, effective April 1, 2009, the Company reclassified the fair value of these warrants, which had exercise price reset features, from equity to liability status as if these warrants were treated as a derivative liability since their date of issue between February 2000 and January 2006.  On April 1, 2009, the Company reclassified $346 from additional paid-in capital, as a cumulative effect adjustment, to beginning accumulated deficit, and $502 to common stock warrant liability to recognize the fair value of such warrants on such date.  As of March 31, 2011, the fair value of the warrants was estimated using the Black-Scholes pricing model with the following weighted average assumptions:  risk-free interest rate of 2.24%; expected life of 1.1 years; an expected volatility factor of 79.1%; and a dividend yield of 0.0%.  At December 31, 2011, the fair value of the warrants was $20, which was calculated using the Black-Scholes pricing model with the following weighted average assumptions:  risk-free interest rate of 0.83%; expected life of 1.63 years; an expected volatility factor of 155%; and a dividend yield of 0.0%.  For the nine months ended December 31, 2011 and 2010, respectively, the Company recorded non-cash gains of $6 and $344 related to these warrants. The Company recorded a non-cash loss related to the warrants of $8 in the quarter ended December 31, 2011 and a non-cash gain of $3 in the quarter ended December 31, 2010.
 
 
9

 
Investment in Unconsolidated Affiliate
 
The Company evaluates its joint venture arrangements to determine whether they should be recorded on a consolidated basis.  The percentage of economic interest in the joint venture, an evaluation of control and whether a variable interest entity (“VIE”) exists are all considered in the consolidation assessment.
 
We account for our investment in joint ventures where we own a non-controlling interest or where we are not the primary beneficiary of a VIE using the equity method of accounting. Under the equity method, our cost of investment is adjusted for our share of equity in the earnings or losses of the unconsolidated affiliate and reduced by distributions received.
 
Any differences between the cost of our investment in an unconsolidated affiliate and our underlying equity as reflected in the unconsolidated affiliate’s financial statements generally result from a different basis in assets contributed to the joint venture. The net difference between our investment in unconsolidated affiliates and the underlying equity of unconsolidated affiliates is generally amortized over a period of ten years, which is determined to be the estimated useful life of the underlying intangibles which created the difference in carrying amount.  The net difference at March 31, 2011 was $1,730.  The amortization expense related to this difference for the fiscal year ended March 31, 2011 was $45.  The amortization expense related to this difference for the three and nine month periods ended December 31, 2011 was $43 and $129, respectively.  There was no amortization expense related to this investment for the three and nine month periods ended December 31, 2010, respectively.
 
 On a periodic basis, we assess whether there are any indicators that the fair value of our investments in unconsolidated affiliates may be impaired. An investment is impaired only if our estimate of the fair value of the investment is less than the carrying value of the investment, and such decline in value is deemed to be other than temporary. To the extent impairment has occurred, the loss is measured as the excess of the carrying amount of the investment over the fair value of the investment. Our estimates of fair value for each investment are based on a number of assumptions such as future revenue projections, operating forecasts, discount rates and capitalization rates, among others.  These assumptions are subject to economic and market uncertainties. As these factors are difficult to predict and are subject to future events that may alter our assumptions, the fair values estimated in the impairment analyses may not be realized.  No impairments of investments in unconsolidated affiliates were incurred during the year ended March 31, 2011 or the nine month period ended December 31, 2011.

Fair Value Measurements
 
The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and we consider what assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.   The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
 
 
·
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.

 
·
Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.
 
 
10

 
 
·
Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions.
 
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.
 
The Company’s financial instruments consist primarily of money market funds.  At December 31, 2011, 98% of the Company’s current assets in financial instruments investments were classified as cash equivalents in the condensed consolidated balance sheets. Approximately 2% of the Company’s current assets in financial investments were classified as restricted cash.  The investment portfolio at December 31, 2010 was comprised of money market funds.   The carrying amounts of the Company’s cash equivalents are valued using Level 1 inputs.  The Company also has warrant liabilities which are valued using Level 3 inputs.
 
The changes in the fair value of warrants is as follows:

   
Nine Months Ended
 
   
December 31,
 
             
   
2011
   
2010
 
Balance at the beginning of the period
  $ 26     $ 363  
Issuance of warrants
    -       -  
Change in fair value recorded in earnings
    (6 )     (339 )
Balance at the end of the period
  $ 20     $ 24  

Intangible Assets

Intangible assets include patents and trademarks that are amortized on a straight-line basis over periods ranging from 5 years to 7 years.  The Company performs an ongoing review of its identified intangible assets to determine if facts and circumstances exist that indicate the useful life is shorter than originally estimated or the carrying amount may not be recoverable.  If such facts and circumstances exist, the Company assesses the recoverability of identified intangible assets by comparing the projected undiscounted net cash flow associated with the related asset or group of assets over their remaining lives against their respective carrying amounts.  Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets.   As of fiscal year end 2011, all of the Company’s remaining intangible assets were included in the asset sale of the DRIE product line to SPTS, except for those that were internally developed, which have a carrying value of zero.
 
During December 2011, the Company, as part of its proposed sale of its intellectual property portfolio for Nanolayer Deposition Technology (NLD), awarded three of the four offered lots to multiple semiconductor equipment manufacturers for aggregate consideration of approximately $4 million.  The Company finalized the sale transaction of the first of the four lots on December 23, 2011, and for which the Company has received approximately $3.6 million.  The Company finalized the sale transaction of the second lot after December 31, 2011.  While the third lot has been awarded, the Company has not yet finalized that transaction.  NLD is a process technology that bridges the gap between high throughput, non-conformal chemical vapor deposition (CVD) and highly conformal, low throughput atomic layer deposition (ALD).  The portfolio included over 35 US and international patents in the areas of pulsed-CVD, plasma-enhanced ALD, and NLD.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, as well as at fiscal year end. If undiscounted expected future cash flows are less than the carrying value of the assets, an impairment loss is recognized based on the excess of the carrying amount over the fair value of the assets.  No impairment charges were recorded for fixed assets for the nine months ended December 31, 2011.

Pension Obligations

Prior to fiscal year 2011, the Company began the process of closing and/or liquidating all of our wholly-owned subsidiary companies, not already sold, including Tegal Germany.  The subsidiaries are now included in discontinued operations.  The Company has recognized an ongoing liability for pensions related to the Tegal Germany subsidiary.  However, in fiscal year 2011, the Company recognized an additional liability for the independent third-party administration of the pension program.   The total pension liability in the prior period was $700.  The total pension liability for the period ended December 31, 2011 was $0.  The pension liability was settled on October 6, 2011.  The settlement of the pension obligation is classified as a reduction of liabilities of discontinued operations.  The related foreign exchange gain of $23 is classified as a gain or loss on the sale of discontinued operations in the third quarter of the current fiscal year.

Stock-Based Compensation

We have adopted several stock plans that provide for issuance of equity instruments to our employees and non-employee directors. Our plans include incentive and non-statutory stock options and restricted stock awards.  These equity awards generally vest ratably over a four-year period on the anniversary date of the grant, and stock options expire ten years after the grant date. Certain restricted stock awards may vest on the achievement of specific performance targets.  We also have an Employee Stock Purchase Plan (“ESPP”) that allows qualified employees to purchase Tegal shares at 85% of the fair market value on specified dates.
 
 
11


Total stock-based compensation expense related to stock options and restricted stock units (“RSUs”) for the nine months ended December 31, 2011 and 2010 was $130 and $313, respectively.  The total compensation expense related to non-vested stock options and RSUs not yet recognized at December 31, 2011 is $468.
 
The Company utilized the following valuation assumptions to estimate the fair value of options that would have been granted for the three month periods ended December 31, 2011 and 2010, respectively.  No options were granted in the three month period ended December 31, 2011.  The valuation assumptions are included for comparison only.

STOCK OPTIONS:
 
2011
   
2010
 
Expected life (years)
    6.0       6.0  
Volatility
    155.08 %     74.30 %
Risk-free interest rate
    0.83 %     1.51 %
Dividend yield
    0 %     0 %
 
ESPP awards are valued using the Black-Scholes model with expected volatility calculated using a six-month historical volatility.   No ESPP awards were made in the nine month period ended December 31, 2011.  The valuation assumptions are included for comparison only.

ESPP:
 
2011
   
2010
 
Expected life (years)
    0.5       0.5  
Volatility
    116.27 %     86.10 %
Risk-free interest rate
    0.02 %     0.12 %
Dividend yield
    0 %     0 %
 
Valuation and Other Assumptions for Stock Options
 
Valuation and Amortization Method.    We estimate the fair value of stock options granted using the Black-Scholes model. We estimate the fair value using a single option approach and amortize the fair value on a straight-line basis for options expected to vest. All options are amortized over the requisite service periods of the awards, which are generally the vesting periods.
 
Expected Term.   The expected term of options granted represents the period of time that the options are expected to be outstanding. We estimate the expected term of options granted based on our historical experience of exercises including post-vesting exercises and termination.
 
Expected Volatility.    We estimate the volatility of our stock options at the date of grant using historical volatilities.  Historical volatilities are calculated based on the historical prices of our common stock over a period at least equal to the expected term of our option grants.
 
Risk-Free Interest Rate.    We base the risk-free interest rate used in the Black-Scholes option valuation model on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with remaining terms equivalent to the expected term of our option grants.
 
Dividends.    We have never paid any cash dividends on common stock and we do not anticipate paying any cash dividends in the foreseeable future.
 
Forfeitures.    We use historical data to estimate pre-vesting option forfeitures. We record stock-based compensation expense only for those awards that are expected to vest.
 
The Company does not use multiple share-based payment arrangements.
 
During the three months ended December 31, 2011, no stock option awards were granted.
 
 
12


Stock Options & Warrants

A summary of the stock option and warrant activity during the quarter ended December 31, 2011 is as follows:

   
Shares
   
Weighted
Average
Exercise
Price
   
Weighted
Average
Remaining
Contractual
Term (in Years)
   
Aggregate
Intrinsic
Value
 
Beginning outstanding
    151,245     $ 21.63              
Expired
    (5,911 )     20.47              
                             
Ending outstanding
    145,334     $ 21.67       5.22     $ -  
Ending vested and expected to vest
    145,265     $ 21.65       5.22     $ -  
Ending exercisable
    132,544     $ 22.64       5.05     $ -  
 
The aggregate intrinsic value of stock options and warrants outstanding at December 31, 2011 is calculated as the difference between the exercise price of the underlying options and the market price of our common stock as of December 31, 2011.

The following table summarizes information with respect to stock options and warrants outstanding as of December 31, 2011:

Range of
Exercise Prices
 
   
Number
Outstanding
As of
December 31,
2011
   
Weighted
Average
Remaining
Contractual
Term
(in years)
   
Weighted
Average
Exercise
Price
 
   
Number
Exercisable
As of
December 31,
2011
   
Weighted
Average
Exercise
Price
As of
December 31,
2011
 
$ 2.90     $ 6.00       5,831       8.67     $ 4.67       5,204     $ 4.88  
  6.25       11.70       56,685       6.62       11.54       44,591       11.50  
  17.20       26.30       59,401       4.58       21.52       59,376       21.52  
  28.10       61.80       19,421       3.00       42.47       19,413       42.47  
  61.94       151.94       3,936       0.63       90.11       3,914       90.23  
  152.21       285.00       58       1.53       174.08       46       174.00  
  286.72       300.27       2       0.00       293.50       -       -  
                                                     
                                                     
$ 2.90     $ 300.27       145,334       5.22     $ 21.67       132,544     $ 22.64  
 
As of December 31, 2011, there was $12 of total unrecognized compensation cost related to outstanding options and warrants which the Company expects to recognize over a period of 0.79 years.
 
 
13

 
Restricted Stock Units
 
The following table summarizes the Company’s unvested RSU activity for the three months ended December 31, 2011:
 
   
Number
of
Shares
   
Weighted
Avg.
Grant Date
Fair Value
 
Balance October 1, 2011
    272,405     $ 2.18  
Granted
    -     $ -  
Forfeited
    -     $ -  
Vested
    (28,260 )   $ 2.45  
Balance, December 31, 2011
    244,145     $ 2.15  
 
Unvested restricted stock at December 31, 2011

As of December 31, 2011, there was $456 of total unrecognized compensation cost related to outstanding RSUs, which the Company expects to recognize over a period of 3.08 years.

2. 
Inventories:

Inventories are stated at the lower of cost or market. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis and includes material, labor and manufacturing overhead costs. Any excess and obsolete provision is only released if and when the related inventory is sold or scrapped.  The Company did not sell or scrap previously reserved inventory during the nine months ended December 31, 2011 and 2010.  The inventory provision balance for the periods ended December 31, 2011 and 2010 was $0 and $547, respectively.  The inventory provision for the nine month period ended December 31, 2010 was related to the DRIE products, which were sold in the prior fiscal year.
 
Net inventories for the periods presented were zero.  All remaining inventory was included in the sale of the DRIE related assets in the prior fiscal year.

Prior to the sale of the DRIE assets in the prior fiscal year, the Company periodically analyzed any systems that were in finished goods inventory to determine if they were suitable for current customer requirements.  At that time, the Company’s policy was that, if after approximately 18 months, it determines that a sale will not take place within the next twelve months and the system would be useable for customer demonstrations or training, it is transferred to fixed assets.  Otherwise, it was expensed.

3. 
Product Warranty:

Prior to the sale of the DRIE assets in the prior fiscal year, the Company provided warranties on all system sales based on the estimated cost of product warranties at the time revenue was recognized.  The warranty obligation was affected by product failure rates, material usage rates, and the efficiency by which the product failure was corrected.  There is no warranty activity related to continuing operations for the three and nine months ended December 31, 2011 and 2010.
 
As part of the consideration paid in the sale of the DRIE assets in the prior fiscal year, all existing customer contracts, including all installation and warranty obligations of existing customers, were assumed by the buyer of those assets.

4. 
Net Income (Loss) Per Common Share (EPS):

Basic EPS is computed by dividing net income (loss) available to common stockholders (numerator) by the weighted average number of common shares outstanding (denominator) for the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted EPS uses the average market prices during the period. All amounts in the following table are in thousands except per share data.
 
Basic net loss per common share is computed using the weighted-average number of shares of common stock outstanding.
 
 
14

 
The following table represents the calculation of basic and diluted net loss per common share (in thousands, except per share data):
 
   
Three Months Ended
   
Nine Months Ended
 
   
December 31,
   
December 31,
 
   
2011
   
2010
   
2011
   
2010
 
                         
Net loss from continuing operations
  $ (583 )   $ (303 )   $ (2,293 )   $ (1,149 )
                                 
Income income/(loss) from discontinued operations, net of taxes
    2,852       211     $ 3,091     $ (1,277 )
                                 
Net income/(loss) income applicable to common stockholders
  $ 2,269     $ (92 )   $ 798     $ (2,426 )
Basic and diluted:
                               
Weighted-average common shares outstanding
    1,689       1,688       1,689       1,688  
Weighted-average common shares used in diluted net gain/(loss) income per common share
    1,689       1,688       1,689       1,688  
                                 
Net loss per share from continuing operations:
                               
Basic and diluted
  $ (0.34 )     (0.18 )   $ (1.36 )   $ (0.67 )
                                 
Net income/(loss) income per share from discontinued operations:
                               
Basic and diluted
  $ 1.69     $ 0.13     $ 1.83     $ (0.76 )
                                 
Net income/(loss) per share:
                               
Basic and diluted
  $ 1.35       (0.05 )   $ 0.47     $ (1.43 )
 
Outstanding options, RSUs and ESPP’s of 408,006 and 296,260 shares of common stock at a weighted-average exercise price per share of $9.82 and $15.05 on December 31, 2011 and 2010, respectively, were not included in the computation of diluted net (loss) income per common share for the three and nine month periods presented as a result of their anti-dilutive effect.  Such securities could potentially dilute earnings per share in future periods.

5. 
Financial Instruments:

The carrying amount of the Company’s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, notes receivable, accrued expenses and other liabilities approximates fair value due to their relatively short maturity. Prior to February 9, 2010, the Company sold products in various global markets. As a result, the Company was exposed to changes in foreign currency exchange rates.  The Company does not hold derivative financial instruments for speculative purposes.  Foreign currency transaction gains and (losses) included in other income (expense), were $27 and $66 for the nine months ended December 31, 2011 and 2010, respectively.  On December 31, 2011, the Company had no open foreign exchange contracts to sell Euros or any other foreign currencies.  On December 31, 2011, the Company had 41,741 warrants outstanding with an exercise price of $30.00 expiring between June 2013 and September 2013.  For the nine months ended December 31, 2011 and 2010, respectively, the Company recorded non-cash gains of $6 and $344 related to these warrants. The Company recorded a non-cash loss related to the warrants of $8 in the quarter ended December 31, 2011 and a non-cash gain of $3 in the quarter ended December 31, 2010.
 
6. 
MEMS Capital Equipment related Asset Acquisitions and Sales:

On September 16, 2008, the Company acquired certain assets from AMMS and Alcatel Lucent (together, the “Sellers”).  With this acquisition, we entered the DRIE market.  DRIE is a highly anisotropic etch process used to create deep, steep-sided holes and trenches in wafers, with aspect ratios of 20:1 or more.  DRIE was developed for micro-electro-mechanical systems (“MEMS”), which require these features, but is also used to excavate trenches for high-density capacitors for DRAM and more recently for creating TSVs in advanced 3-D wafer level packaging technology. The acquisition was designed to enable us to pursue the high-growth markets in MEMS and certain segments of integrated semiconductor device manufacturing and packaging.  Current end-markets include production of a variety of MEMS and power devices, memory stacking (flash and DRAM), logic, RF-SiP, and CMOS image sensors.  The Company paid $1,000 in cash and $4,000 in shares of the Company’s common stock. The 208,877 shares of common stock issued by the Company was calculated by obtaining  the quotient of (a) $4,000 divided by (b) the average of the closing sales prices of the common stock as reported on the Nasdaq Capital Market on the five (5) consecutive trading days immediately prior to (but excluding) the closing date.
 
 
15

 
In connection with this acquisition, the Company and Alcatel Lucent entered into an intellectual property agreement providing for the transfer of specified intellectual property rights to the Company, a trademark license agreement allowing for the limited use of the AMMS trademark by the Company, and a preferred supplier agreement pursuant to which the Company will purchase certain equipment from an affiliate of the Sellers.  AMMS designated Mr. Gilbert Bellini to serve as a member of the Company’s board of directors. AMMS’ right to designate a member of the Company’s board of directors terminated upon the absorption of AMMS into its parent, Adixen Vacuum Technology, and its subsequent sale to Pfeiffer Vacuum GmbH on December 31, 2010.

The purchase price was allocated as follows (in thousands):
 
Assets acquired:
     
Trademarks
  $ 428  
Patents
    2,648  
Total Intangible Assets
    3,076  
         
Fixed Assets
    24  
Inventory
    1,900  
Total Tangible Assets
    1,924  
         
Total Acquired Assets
  $ 5,000  

Beginning in the fiscal third quarter of 2009, following the acquisition of the DRIE product lines from AMMS, the Company experienced a sharp decline in revenues related to its legacy Etch and PVD products, a result of the overall collapse of the semiconductor capital equipment market and the global financial crisis.  The management and the Board of Directors of the Company considered several alternatives for dealing with this decline in revenues, including the sale of assets which the Company could no longer support.  On March 19, 2010, the Company and its wholly owned subsidiary, SFI, sold inventory, equipment, intellectual property and other assets related to the Company’s legacy Etch and PVD products to OEM Group Inc. (“OEM Group”), a company  based in Phoenix, Arizona that specializes in “life cycle management” of legacy product lines for several semiconductor equipment companies.  The sale included the product lines and associated spare parts and service business of the Company’s 900 and 6500 series plasma etch systems, along with the Endeavor and AMS PVD systems from SFI.  In connection with the sale of the assets, OEM Group assumed the Company’s warranty liability for recently sold legacy Etch and PVD systems.
 
The Company and OEM Group entered into related agreements for the transfer and licensing of patents, trademarks and other intellectual property associated with the legacy Etch and PVD products.  These included a Trademark Assignment Agreement for certain trademarks used in the legacy Etch and PVD Products, a royalty-free Trademark License Agreement allowing for the limited use of the Tegal trademark by the purchaser solely in connection with future sales of legacy Etch and PVD products and solely in combination with the trademarks transferred to purchaser, a Patent Assignment Agreement for the transfer of certain patents related to the Etch and PVD products, and a perpetual, irrevocable, non-exclusive, worldwide, fully-paid, royalty-free, Intellectual Property Cross License Agreement, pursuant to which the Company granted OEM Group a license to certain intellectual property owned by the Company for use in OEM Group’s manufacture and sale of the legacy Etch and PVD products, and OEM Group licensed back to the Company certain intellectual property for the Company’s continued use.

The consideration paid by OEM Group consisted of the following (in thousands):

 
Cash in the amount of $250 paid at closing, which occurred on March 19, 2010;

 
An aggregate of $1,750 cash payable to the Company in four installment payments of $250, $500, $500 and $500 on July 1, 2010, October 1, 2010, January 1, 2011 and April 1, 2011, respectively; and
 
 
16

 
 
A contingent payment in cash of up to $1,000 payable to the Company by April 15, 2011 based on the following percentage of applicable bookings of Etch and PVD products in excess of $6,000 received by the Company or OEM Group during the period beginning March 19, 2010 through March 31, 2011:

 
if applicable bookings are greater than or equal to $6,000 but less than $8,000, the contingent payment will be 5% of the applicable bookings in excess of $6,000;

 
if applicable bookings are greater than or equal to $8,000 but less than $10,000, the contingent payment will be $100 plus 10% of the applicable bookings in excess of $8,000;

 
if applicable bookings are greater than or equal to $10,000 but less than $12,000, the contingent payment will be $300 plus 15% of the applicable bookings in excess of $10,000; and

 
if applicable bookings are greater than or equal to $12,000, the contingent payment will be $600 plus 20% of the applicable bookings in excess of $12,000.
 
In no case will the contingent payment exceed $1,000.
 
Based on the applicable bookings of OEM Group for the designated period, the amount of the contingent payment due was $440.  On June 21, 2011, the Sellers, OEM Group and Purchaser entered into an amendment (the “Amendment”) to the Purchase Agreement which, among other things, revised the payment schedule of the Contingent Payment.  Pursuant to the Amendment, the Company received $300 on July 5, 2011 and $140 plus approximately $5 of interest on October 7, 2011.  The description of the Amendment provided above is qualified in its entirety by reference to the full text of the Amendment, a copy of which was filed as Exhibit 10.1 to the Form 8-K report filed on June 23, 2011.
 
The Company retained the DRIE products which it had acquired from AMMS, along with the Compact™ cluster platform and the NLD technology that it had developed over the past several years.  The DRIE markets were seriously impacted by the downturn in the semiconductor markets, and as those markets recover the Company is not in a position to make the needed investments to improve its competitive position.  In addition, it was not clear that even with additional investment and significant reductions in operating expenses DRIE sales alone would be enough to support the Company.  As a result, the Company evaluated various other alternative strategies, including sale of its DRIE products, Compact™ platform and NLD technology, the transition to a new business model, a sale of all or substantially all of our assets, or  the liquidation or dissolution of the Company, including through a bankruptcy proceeding.  On February 9, 2011, the Company sold its DRIE and Compact related assets to SPTS, but retained its NLD technology.   See “The SPTS Transaction” below.

The SPTS Transaction

On February 9, 2011, Tegal and SPP Process Technology Systems Limited, (“SPTS”), a company incorporated and registered in England and Wales, entered into an Asset Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company sold to SPTS all of the shares of Tegal France, SAS, the Company’s wholly-owned subsidiary, and product lines and certain equipment, intellectual property and other assets relating to the Company’s DRIE systems and certain related technology SPTS also assumed existing customer contracts, including all installation and warranty obligations of existing customers, and other liabilities arising after the closing of the transaction (the “Assumed Liabilities”).
 
In connection with the sale, the Company and SPTS entered into related agreements for the transfer and licensing of patents, trademarks and other intellectual property associated with the business, including a royalty-free Trademark License Agreement allowing for the limited use of the Tegal trademark by SPTS solely in connection with future sales related to the business and solely in combination with the trademarks transferred to SPTS, as well as written assignments to SPTS of all rights in the patents and trademarks that are part of the sale.
 
The transaction closed immediately after execution of the Purchase Agreement. The consideration paid by SPTS totaled approximately $2,100, comprised of approximately $500 of Assumed Liabilities and $1,600 in cash, of which $200 in cash will be held in escrow for one year after the closing of the transaction to satisfy any indemnification obligations of the Company under the Purchase Agreement.
 
 
17

 
The descriptions of the Purchase Agreement and the Trademark License Agreement provided above are qualified in their entirety by reference to the full text of such agreements, copies of which have been filed as Exhibits 10.1 and 10.2, respectively, to the Company’s 8-K filed on February 15, 2011 and are incorporated herein by reference.

Discontinued Operations

The assets and liabilities of discontinued operations are presented separately under the captions “Assets of discontinued operations” and “Liabilities of discontinued operations,” respectively, in the accompanying condensed consolidated balance sheets at December 31, 2011 and March 31, 2011 and consist of the following:

   
December 31,
   
March 31,
 
   
2011
   
2011
 
             
Assets of Discontinued Operations:
           
Accounts receivable and other receivables, net of allowances for sales returns and doubtful accounts of $0 and $71 at December 31, 2011 and March 31, 2011, respectively
    405       591  
Notes receivable
    26       528  
Prepaid expenses and other current assets
    12       10  
Total assets of discontinued operations
  $ 443     $ 1,129  
                 
Liabilities of Discontinued Operations:
               
Accounts payable
  $ -     $ 522  
Deferred revenue
    --       130  
Accrued expenses and other current liabilities
    380       758  
Total liabilities of discontinued operations
  $ 380     $ 1,410  
 
In the nine months ended December 31, 2011, the Company recognized deferred revenue of $130, offset by related commission expense, as well as revenue of $89 from the finalization of the sale of the DRIE assets which occurred in the fourth quarter of the prior fiscal year.  In the same period, the Company received $440 from OEM in installment payments related to the sale of legacy assets, and recognized $64 in foreign currency transactions.  Total revenue from discontinued operations was $1,345 and $4,847 for the three and nine months ended December 31, 2010.  The total loss from discontinued operations for the nine months ended December 31, 2010 was $1,270 and included the reclassification of operating expenses related to the manufacture, design, marketing and servicing of the DRIE operations including foreign exchange adjustments and income tax expense (benefit).
 
The Company also recognized $3,550 from the December 23, 2011 sale of the NLD patents.  As these assets were internally developed, there was a corresponding zero book value.  The NLD revenue is recognized in discontinued operations, along with the related costs of $813, which includes $767 in commission expense.  During December 2011, the Company, as part of its proposed sale of its intellectual property portfolio for Nanolayer Deposition Technology (NLD), awarded three of the four offered lots to multiple semiconductor equipment manufacturers for aggregate consideration of approximately $4 million.  The Company finalized the sale transaction of the first of the four lots on December 23, 2011.  The Company finalized the sale transaction of the second lot after December 31, 2011.  While the third lot has been awarded, the Company has not yet finalized that transaction.  Sales of NLD patents in future periods will also be recognized in discontinued operations, as well all related expenses to finalize the sales.  NLD is a process technology that bridges the gap between high throughput, non-conformal chemical vapor deposition (CVD) and highly conformal, low throughput atomic layer deposition (ALD).  The portfolio included over 35 US and international patents in the areas of pulsed-CVD, plasma-enhanced ALD, and NLD.

7. 
Geographical Information:

Prior to February 9, 2011, the Company operated in one segment for the manufacture, marketing and servicing of integrated circuit fabrication equipment.  Currently, the Company’s sole potential source of revenue is from the project activities of Sequel Power.  The Company’s chief operating decision-maker has been identified as the President and Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.
 
 
18

 
For geographical reporting, revenues are attributed to the geographic location in which the customers’ facilities are located.  Long-lived assets consist of property, plant and equipment and are attributed to the geographic location in which they are located.  Net sales and long-lived assets by geographic region were as follows:

   
Revenue for the
   
Revenue for the
 
   
Three Months Ended
   
Nine Months Ended
 
   
December 31,
   
December 31,
 
   
2011
   
2010
   
2011
   
2010
 
Sales to customers located in:
                       
United States
  $ 38     $ -     $ 75     $ -  
Total sales
  $ 38     $ -     $ 75     $ -  
 
Revenues for the three and nine months ended December 31, 2011 are all part of continuing operations.  Revenues of $1,345 and $4,847 for the three and nine months ended December 31, 2010, respectively, have been reclassified to discontinued operations.

   
December 31
   
March 31
 
Long-lived assets at period-end:
 
2011
   
2011
 
Discontinued Operations:
           
United States
  $ -     $ -  
Europe
    -       -  
Continuing Operations:
               
United States
    58       112  
Total Long-lived assets
  $ 58     $ 112  
 
8. 
Recent Accounting Pronouncements:

In May 2011, the FASB issued ASU 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs, which amends ASC Topic 820, Fair Value Measurement. The purpose of ASU 2011-04 is to clarify the intent about the application of existing fair value measurement and disclosure requirements and to change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements.  This pronouncement is effective for interim or annual periods beginning after December 15, 2011.  We do not expect the provisions of ASU 2011-04 to have a material impact to our consolidated financial statements.
 
In June 2011, the FASB issued ASU 2011-05, Presentation of Comprehensive Income, which amends ASC Topic 220, Comprehensive Income. The objective of ASU 2011-05 is to improve the comparability, consistency and transparency of financial reporting and to increase the prominence of items reported in other comprehensive income. The update will require entities to present items of net income, items of other comprehensive income and total comprehensive income in one continuous statement or two separate consecutive statements, and entities will no longer be allowed to present items of other comprehensive income in the statement of stockholders’ equity. Reclassification adjustments between other comprehensive income and net income will be presented separately on the face of the financial statements. This pronouncement is effective for interim or annual periods beginning after December 15, 2011.  We do not expect the provisions of ASU 2011-05 to have a material impact to our consolidated financial statements.
 
In September 2011, the FASB issued ASU 2011-08, Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment, which permits an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. This pronouncement is effective for interim or annual periods beginning after December 15, 2011.  We do not expect the provisions of ASU 2011-05 to have a material impact to our consolidated financial statements.
 
 
19


In December 2011, the FASB issued ASU 2011-11, Balance Sheet - Disclosures about Offsetting Assets and Liabilities(Topic 210), which requires entities to disclose both gross information and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting arrangement. This scope would include derivatives, sale and repurchase agreements and reverse sale and repurchase agreements, and securities borrowing and securities lending arrangements. The objective of this disclosure is to facilitate comparison between those entities that prepare their financial statements on the basis of U.S. GAAP and those entities that prepare their financial statements on the basis of IFRS.   Even though this pronouncement is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods, disclosures required by those amendments are expected to be provided retrospectively for all comparative periods presented.  We do not expect the provisions of ASU 2011-11 to have a material impact on our consolidated financial statements.

9. 
Investments

The Nano Vibronix Transaction
 
On November 22, 2011, the Company completed a $300 strategic investment in the form of a convertible promissory note from Nano Vibronix, Inc., a private company that develops medical devices and products that implement its proprietary therapeutic ultrasound technology.  Nano Vibronix is focused on creating products utilizing its proprietary low-intensity surface acoustic wave (SAW) technology. The company's unique, patented approach enables the transmission of low-frequency, low-intensity ultrasound waves through a variety of soft, flexible materials, including skin and tissue, enabling low-cost, breakthrough devices targeted at large, high-growth markets.  A copy of the Company’s press release was filed as an exhibit to the Company’s Form 8-K filed on November 29, 2011 and is incorporated herein by reference.
 
The Company’s investment in Nano Vibronix is in the form of a convertible promissory note that bears interest at a rate of 10% per year compounded annually and matures on November 15, 2014.  Principal and accrued interest under the note automatically convert into shares of Series B-1 Participating Convertible Preferred Stock of Nano Vibronix upon the earlier to occur of (i) a $3 million (or larger) equity financing by Nano Vibronix or (ii) a sale of Nano Vibronix.  In addition, the Company may convert principal and accrued interest under the note into shares of Nano Vibronix Series B-1 Participating Convertible Preferred Stock at its election at any time.  In either case, the conversion price is $0.284 per share.

The Sequel Power Transaction
 
On January 14, 2011,  Tegal, se2quel Partners LLC, a California limited liability company, and Sequel Power LLC, a newly formed Delaware limited liability company (“Sequel Power”), entered into a Formation and Contribution Agreement.  Sequel Power is focused on the promotion of solar power plant development projects worldwide, the development of self-sustaining businesses from such projects, including but not limited to activities relating to and supporting, developing, building and operating solar photovoltaic fabrication facilities and solar farms, and the consideration of other non-photovoltaic renewable energy projects.  se2quel Partners is owned by Ferdinand Seemann, who previously served as an independent member of the Company’s Board of Directors.  Pursuant to the Formation and Contribution Agreement, Tegal contributed $2 million in cash to Sequel Power in exchange for an approximate 25% economic interest in Sequel Power.  In addition, Tegal issued warrants (“Warrants”) to se2quel Partners and se2quel Management GmbH, a German limited liability company, to purchase an aggregate of 185,777 shares of the Company’s common stock at an exercise price of $3.15 per share.  The Warrants are exercisable for a period of four years.
 
The descriptions of the Formation and Contribution Agreement and the Warrants are qualified in their entirety by reference to the full text of such documents, copies of which were filed as exhibits to the Form 8-K report filed on January 21, 2011.

Results of Sequel Power Operations

Revenue
 
Revenue for Sequel Power operations of $0 for the three months ended December 31, 2011 decreased by $2 from revenue for the three months ended September 30, 2011.  Revenue for the nine months ended December 31, 2011 was $4.  All Sequel revenue was generated from project services.
 
Sequel Power’s net loss for the three month period ended December 31, 2011 was $553.   The Company’s share of net loss is $138.   Sequel Power’s net loss for the nine month period ended December 31, 2011 was $1,490.   The Company’s share of net loss is $373.
 
 
20

 

Special Note Regarding Forward Looking Statements

Information contained or incorporated by reference in this report contains forward-looking statements.  These forward-looking statements are based on current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations.  These forward-looking statements should not be relied upon as predictions of future events as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur.  You can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will”, “expect,” “anticipate,” “estimate” or “continue” or the negative thereof or other variations thereon or comparable terminology which constitutes projected financial information.  These forward-looking statements are subject to risks, uncertainties and assumptions about Tegal Corporation including, but not limited to, industry conditions, economic conditions and acceptance of new technologies.  For a discussion of the factors that could cause actual results to differ materially from the forward-looking statements, see “Part II, Item 1A.—Risk Factors“ and the “Liquidity and Capital Resources“ section set forth in this section and such other risks and uncertainties as set forth below in this report or detailed in our other SEC reports and filings. We assume no obligation to update forward-looking statements.
 
Until February 9, 2011, Tegal Corporation, a Delaware corporation (“Tegal” or the “Company”), designed, manufactured, marketed and serviced specialized plasma etch systems used primarily in the production of micro-electrical mechanical systems (“MEMS”) devices, such as sensors and accelerometers as well as power devices.  The Company’s Deep Reactive Ion Etch (“DRIE”) systems were also employed in certain sophisticated manufacturing techniques, such as 3-D interconnect structures formed by intricate silicon etching, also known as Deep Silicon Etch (“DSE”) for so-called Through Silicon Vias (“TSVs”). Prior to its fiscal year 2011, Tegal also sold systems for the etching and deposition of materials found in other devices, such as integrated circuits (“ICs”) and optoelectronic devices found in products like smart phones, networking gear, solid-state lighting, and digital imaging.
 
In the recent past, our business objective has been to utilize the technologies that we have developed internally or acquired externally in order to increase our market share in process equipment for MEMS and power device fabrication, advanced 3-D packaging, and certain areas of semiconductor manufacturing.  In September 2008, we acquired the products lines of AMMS and the related intellectual property of Alcatel, in order to pursue more fully the smaller, but higher-growth markets of MEMS and 3-D packaging.  Our acquisition of these products served two purposes: (i) to increase revenue, and (ii) to enable us to focus our various technologies on specific applications that served the common markets of MEMS and 3-D device manufacturing and packaging.
 
Beginning in the fiscal third quarter of 2009, following the acquisition of the DRIE product lines from AMMS, the Company experienced a sharp decline in revenues related to its legacy Etch and PVD products, a result of the collapse of the semiconductor capital equipment market and the global financial crisis.  The management and the Board of Directors of the Company considered several alternatives for dealing with this decline in revenues, including the sale of assets which the Company could no longer support.  On March 19, 2010, the Company and its wholly owned subsidiary, SFI, sold inventory, equipment, intellectual property and other assets related to the Company’s legacy Etch and PVD products to OEM Group Inc. (“OEM Group”), a company  based in Phoenix, Arizona that specializes in “life cycle management“ of legacy product lines for several semiconductor equipment companies.  The sale included the product lines and associated spare parts and service business of the Company’s 900 and 6500 series plasma etch systems, along with the Endeavor and AMS PVD systems from SFI.  In connection with the sale of the assets, OEM Group assumed the Company’s warranty liability for recently sold legacy Etch and PVD systems.
 
 
21


At that time, the Company retained the DRIE products which it had acquired from AMMS, along with the Compact™ cluster platform and the NLD technology that it had developed over the past several years.  However, the DRIE products and a small amount of associated spares and service revenue until recently represented the sole source of the Company’s revenue.  The DRIE markets were seriously impacted by the downturn in the semiconductor markets and as those markets recovered, the Company determined that it was not in a position to make the needed investments to improve its competitive position.  In addition, it was not clear that even with additional investment and significant reductions in operating expenses DRIE sales alone would be enough to support the Company.  As a result, the Company evaluated various other alternative strategies, including sale of its DRIE products, Compact™ platform and NLD technology, the transition to a new business model, a sale of all or substantially all of its assets, or the liquidation or dissolution of the Company, including through a bankruptcy proceeding.  On February 9, 2011, the Company sold its DRIE and Compact™ related assets to SPTS, but retained its NLD technology.   See “Impairment of Long-Lived Assets” below.
 
At the present time we are engaged primarily in supporting the activities of Sequel Power through our direct efforts and through related operations and investments we may make in the future.  In addition, we are actively evaluating opportunities for partnerships, mergers or acquisitions with other diversified technology-based companies in order to exploit our shared experience and to enhance our value as a public company.
 
We cannot assure you that we will be successful in pursuing any of these strategic alternatives.  As we pursue various strategic alternatives and determine that some are more or less likely than others, the consequences of such determinations will be reflected in our financial statements in accordance with generally accepted accounting principles (“GAAP”) in the United States of America.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.
 
The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, bad debts, sales returns allowance, inventory, intangible and long lived assets, warranty obligations, restructure expenses, deferred taxes and freight charged to customers. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe the following critical accounting policies are the most significant to the presentation of our consolidated financial statements:

Revenue Recognition

Until February 9, 2011, each sale of our equipment was evaluated on an individual basis in regard to revenue recognition.  We had integrated in our evaluation the related interpretative guidance included in Topic 13 of the codification of staff accounting bulletins, and recognized the role of the consensus on Emerging Issues Task Force Issue No. 00-21, Accounting for Revenue Arrangements with Multiple Deliverables (“EITF Issue 00-21”) (Topic 605).  We first referred to EITF Issue 00-21 (Topic 605) in order to determine if there is more than one unit of accounting and then we referred to Staff Accounting Bulletin (“SAB”) 104 (Topic 605) for revenue recognition topics for the unit of accounting. We recognized revenue when persuasive evidence of an arrangement existed, the seller’s price was fixed or determinable and collectability was reasonably assured.
 
For products produced according to our published specifications, where no installation was required or installation was deemed perfunctory and no substantive customer acceptance provisions existed, revenue was recognized when title passed to the customer, generally upon shipment. Installation was not deemed to be essential to the functionality of the equipment since installation did not involve significant changes to the features or capabilities of the equipment or building complex interfaces and connections.  In addition, the equipment could be installed by the customer or other vendors and generally the cost of installation approximated only 1% of the sales value of the related equipment.
 
Prior to February 9, 2011, for products produced according to a particular customer’s specifications, revenue was recognized when the product had been tested and it had been demonstrated that it met the customer’s specifications and title passed to the customer.  The amount of revenue recorded was reduced by the amount (generally 10%), which was not payable by the customer until installation was completed and final customer acceptance was achieved.
 
Prior to February 9, 2011, for new products, new applications of existing products, or for products with substantive customer acceptance provisions where performance cannot be fully assessed prior to meeting customer specifications at the customer site, 100% of revenue was recognized upon completion of installation and receipt of final customer acceptance.  Since title to goods generally passed to the customer upon shipment and 90% of the contract amount became payable at that time, inventory was relieved and accounts receivable was recorded for the entire contract amount.  The Company relieved the entire amount from inventory at the time of sale, and the related deferred revenue liability was recognized upon installation and customer acceptance.  The revenue on these transactions was deferred and recorded as deferred revenue.  We reserved for warranty costs at the time the related revenue was  recognized.
 
The Company’s return policy applied to spare parts and components only.  A right of return did not exist for systems. Customers were allowed to return spare parts if they were defective upon receipt. The potential returns were offset against gross revenue on a monthly basis.  Management reviewed outstanding requests for returns on a quarterly basis to determine that the reserves are adequate.
 
 
22

 
After February 9, 2011, revenues related to rendering services to our unconsolidated affiliate are recognized at the end of each fiscal quarter, when services are completed and invoiced.
 
All revenue for fiscal 2011 has been reclassified to discontinued operations.  Revenue for fiscal 2012 is related to services provided to Sequel Power, the Company’s unconsolidated affiliate.
 
Accounting for Stock-Based Compensation

The Company has adopted several stock plans that provide for issuance of equity instruments to our employees and non-employee directors. Our plans include incentive and non-statutory stock options and restricted stock awards.  These equity awards generally vest ratably over a four-year period on the anniversary date of the grant, and stock options expire ten years after the grant date. Certain restricted stock awards may vest on the achievement of specific performance targets.  The Company also has an Employee Stock Purchase Plan (“ESPP”) that allows qualified employees to purchase Tegal shares at 85% of the fair market value on specified dates.  The stock-based compensation for our ESPP, stock options and restricted stock awards was determined using the Black-Scholes option pricing model and the provisions of SFAS No. 123 (revised 2004), Share Based Payment (“SFAS 123R”) (Topic 718).  Valuation and Other Assumptions for Stock Options is provided on page 12.

Accounts Receivable – Allowance for Sales Returns and Doubtful Accounts

The Company maintained an allowance for doubtful accounts receivable for estimated losses resulting from the inability of the Company’s customers to make required payments. If the financial condition of the Company’s customers were to deteriorate, or even a single customer was otherwise unable to make payments, additional allowances may be required.  As of December 31, 2011, two customers accounted for 100% of the accounts receivable balance.  As of December 31, 2010, three customers accounted for approximately 82% of the accounts receivable balance.  With the sale of the DRIE etch product line and our exit from our historical core operations, we currently have one customer related to continuing operations.  Accounts receivable balances related to prior operations are captured in Discontinued Operations in our Condensed Consolidated Balance Sheets.  Accounts receivable balances related to ongoing operations are captured in Current Assets in our Condensed Consolidated Balance Sheets.
 
The Company no longer maintains reserves for returns. These liabilities were included in the consideration for the DRIE and associated asset sale to SPTS on February 9, 2011
 
All revenue for the period ended December 31, 2011 is related to services provided to Sequel Power.
 
Inventories

Until February 9, 2011, inventories were stated at the lower of cost or market. Cost was computed using standard cost, which approximates actual cost on a first-in, first-out basis and includes material, labor and manufacturing overhead costs. Any excess and obsolete provision is only released if and when the related inventory is sold or scrapped. During the nine months ended December 31, 2011 and 2010, the Company did not sell or scrap previously reserved inventory.  The inventory provision balance at December 31, 2011 and 2010 was $0 and $547, respectively.  The inventory provision for the period ended December 31, 2010 was related to DRIE products, which were sold in the prior fiscal year.
 
Prior to the sale of the DRIE assets in the prior fiscal year, the Company periodically analyzed any systems that were in finished goods inventory to determine if they were suitable for current customer requirements.  At that time, the Company’s policy was that, if after approximately 18 months, it determines that a sale will not take place within the next twelve months and the system would be useable for customer demonstrations or training, it is transferred to fixed assets.  Otherwise, it was expensed.
 
The carrying value of systems used for demonstrations or training was determined by assessing the cost of the components that were suitable for sale.  Any parts that might have been rendered unsellable as a result of such use were removed from the system and were not included in finished goods inventory. The remaining saleable parts were valued at the lower of cost or market, representing the system’s net realizable value.   The depreciation period for systems that were transferred to fixed assets was determined based on the age of the system and its remaining useful life (typically five to eight years).
 
 
23

 
Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable as well as at fiscal year end. If undiscounted expected future cash flows are less than the carrying value of the assets, an impairment loss is recognized based on the excess of the carrying amount over the fair value of the assets.  No impairment charges were recorded for fixed assets for the nine months ended December 31, 2011.  No impairment charges were recorded for intangible assets since all intangible assets, other than those internally developed, were included in the sale of the DRIE assets to SPTS in the prior fiscal year.  
 
During December 2011, the Company, as part of its proposed sale of its intellectual property portfolio for Nanolayer Deposition Technology (NLD), awarded three of the four offered lots to multiple semiconductor equipment manufacturers for aggregate consideration of approximately $4 million.  The Company finalized the sale transaction of the first of the four lots on December 23, 2011, and for which the Company has received approximately $3.6 million.  The Company finalized the sale transaction of the second lot after December 31, 2011.  While the third lot has been awarded, the Company has not yet finalized that transaction.  NLD is a process technology that bridges the gap between high throughput, non-conformal chemical vapor deposition (CVD) and highly conformal, low throughput atomic layer deposition (ALD).  The portfolio included over 35 US and international patents in the areas of pulsed-CVD, plasma-enhanced ALD, and NLD.
 
Warranty Obligations

Prior to the sale of the DRIE assets in the prior fiscal year, the Company provided for the estimated cost of our product warranties at the time revenue was recognized. Our warranty obligation was affected by product failure rates, material usage rates and the efficiency by which the product failure was corrected.  The warranty reserve was based on historical cost data related to warranty.  If actual product failure rates, material usage rates and labor efficiencies differed from our estimates, revisions to the estimated warranty liability might have been required.  Actual warranty expense was typically low in the period immediately following installation.  As of fiscal 2011, the Company had no warranty liabilities as these liabilities were included in the consideration for the DRIE and associated asset sale to SPTS on February 9, 2011.

Pension Obligations

Going into fiscal year 2011, the Company began the process of closing and/or liquidating all of our wholly-owned subsidiary companies, not already sold, including Tegal Germany.  The subsidiaries are now included in discontinued operations.  The Company has recognized an ongoing liability for pensions related to the Tegal Germany subsidiary.  However, in fiscal year 2011, the Company recognized an additional liability for the independent third-party administration of the pension program.   The total pension liability in the prior period was $700.  The total pension liability for the period ended December 31, 2011 was $0.  The pension liability was settled on October 6, 2011.  The settlement of the pension obligation is classified as a reduction of liabilities of discontinued operations.  The related foreign exchange gain or loss is classified as a gain or loss on the sale of discontinued operations in the third quarter of the current fiscal year.

Deferred Taxes

We record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. Based on the uncertainty of future taxable income, we have fully reserved our deferred tax assets. In the event we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset would increase income in the period such determination was made.

Results of Operations

The following table sets forth certain financial items for the three and nine months ended December 31, 2011 and 2010:
 
 
24

 
 
 
Three Months Ended
December 31,
   
Nine Months Ended
December 31,
 
 
 
2011
   
2010
   
2011
   
2010
 
                         
Revenue - related party
  $ 38     $ --     $ 75     $ -  
Operating expenses:
                               
General and administrative expenses
    432       306       1,873       1,493  
Total operating expenses
    432       306       1,873       1,493  
Operating loss
    (394 )     (306 )     (1,798 )     (1,493 )
Equity in (earnings) loss of unconsolidated affiliate
    181       --       501       --  
Other income/(expense), net
    8       (3 )     (6 )     (344 )
Loss before income tax expense
    (583 )     (303 )     (2,293 )     (1,149 )
Income tax expense
    --       --       --       --  
Net loss from continuing operations
    (583 )     (303 )     (2,293 )     (1,149 )
Gain on asset disposition     --       --                  
Income (loss) from discontinued operations, net of taxes
    2,852       211       3,091       (1,277 )
                                 
Net income/(loss)
  $ 2,269     $ (92 )   $ 798     $ (2,426 )
                                 
Net loss per share from continuing operations:
                               
Basic and diluted
  $ (0.34 )   $ (0.18 )   $ (1.36 )   $ (0.67 )
                                 
Net income/(loss) income per share from discontinued operations:
                         
Basic and diluted
  $ 1.69     $ 0.13     $ 1.83     $ (0.76 )
                                 
Net income/(loss) per share:
                               
Basic and diluted
  $ 1.35     $ (0.05 )   $ 0.47     $ (1.43 )
                                 
Weighted average shares used in per share computation:
                         
Basic and diluted
    1,689       1,688       1,689       1,688  
 
Revenue

Prior to February 9, 2011, our revenue was derived from sales of new and refurbished systems, spare parts and non-warranty service.  Comparing revenue for the prior period before reclassification into discontinued operations, revenue of $38 for the three months ended December 31, 2011 decreased by $1,308 from revenue for the three months ended December 31, 2010 of $1,345.  Revenue of $75 for the nine months ended December 31, 2011 decreased by $4,772 from revenue for the nine months ended December 31, 2010 of $4,847.  The revenue decreases were due to our exit from our core historical operations, when the Company sold its DRIE assets to SPTS in the fourth quarter of the prior fiscal year.
 
Prior to February 9, 2011, all revenue was generated from the DRIE systems business and a small amount of associated spares and service.  At the present time, our sole potential source of revenue is from the project activities of Sequel Power.  In fiscal 2012, Sequel Power generated $75 in service revenues for the Company.  For fiscal year 2011, DRIE sales represented 100% of our total revenues.
 
 
25

 
As a percentage of total revenue for the three and nine months ended December 31, 2011, international sales were 0%.  As a percentage of total revenue for the three and nine months ended December 31, 2010, international sales were approximately 92% and 90%, respectively.  The decrease in international sales in both period comparisons as a percentage of revenue can be attributed to the sale of our legacy Etch and PVD assets to OEM Group and the sale of our DRIE assets to SPTS.
 
We expect that international sales will once again account for a significant portion of any future revenue, since Sequel Power’s development projects are located in several countries outside the United States.
 
All DRIE related revenues and product costs are captured in Discontinued Operations in our income statement.

Gross Profit

Comparing gross profit for the prior period before reclassification into discontinued operations, gross profit of $38 for the three months ended December 31, 2011 decreased from our gross profit $925 for the three months ended December 31, 2010.   Gross profit of $75 for the nine months ended December 31, 2011 decreased from our gross profit of $1,925 for the nine months ended December 31, 2010.
 
Our gross margin for the three months ended December 31, 2011 was 100% compared to 69% for the same period last year.   Our gross margin for the nine months ended December 31, 2011 was 100% compared to 40% for the same period last year.
 
Prior to February 9, 2011, our gross margin as a percentage of revenue was affected by a variety of factors, including the mix and average selling prices of systems sold and the costs to manufacture, service and support new product introductions and enhancements.
 
At the present time we are engaged primarily in supporting the activities of Sequel Power through our direct efforts and through related operations and investments we may make in the future.  In addition, we are actively evaluating opportunities for partnerships, mergers or acquisitions with other diversified technology-based companies in order to exploit our shared experience and to enhance our value as a public company.
 
Research and Development
 
 Prior to the sale of the DRIE related assets, research and development (“R&D”) expenses consisted primarily of salaries, prototype material and other costs associated with our ongoing systems and process technology development, applications and field process support efforts for our DRIE product line. The spending decrease of $102 and $1,358 for the three and nine months ended December 31, 2011, compared to the same period in 2010, resulted from the exit from our core historical operations.  The decrease was offset by the sales commission expense related to the sale of the NLD patents.  As a result of the sale of the Company’s DRIE related assets, and in accordance with generally accepted accounting principles, the DRIE business operation, including related and continuing R&D expenses, have all been reclassified to discontinued operations.  At the time of the sale, all the Company’s R&D expenses were related to the DRIE operations.  Currently the Company’s R&D expenses are related to the NLD product line, the assets of which are held for sale to third parties, as well as analyzing and evaluating various opportunities that we are reviewing that either support our investment in Sequel Power or represent merger or acquisition opportunities in other diversified technologies.

Sales and Marketing

 Prior to the sale of the DRIE related assets, sales and marketing expenses consisted primarily of salaries, commissions, trade show promotion and travel and living expenses associated with those functions. The decrease in sales and marketing spending of $211 and $519 for the three and nine months ended December 31, 2011, respectively, as compared to the same period in 2010, was due to the exit from our core historical operations.  As a result of the sale of the Company’s DRIE related assets in fiscal year 2011, and in accordance with generally accepted accounting principles, the DRIE business operation, including related sales and marketing expenses, have been reclassified to discontinued operations.  At the time of the sale, all the Company’s sales and marketing expenses were related to the DRIE operations.

General and Administrative

General and administrative expenses consist of salaries, legal, accounting and related administrative services and expenses associated with general management, finance, information systems, human resources and investor relations activities.  The increase of continuing general and administrative expenses of $126 for the three month period ended December 31, 2011 as compared to the same period in 2010 was due primarily to higher accounting fees and travel expenses, partially offset by decreases in legal and stock related compensation expenses.  The increase of $380 for the nine months ended December 31, 2011 as compared to the nine months ended December 31, 2010 was due primarily to employee bonuses for key employees in the first quarter of the current fiscal year, partially offset by decreases in legal and stock related compensation expenses.  As a result of the sale of the Company’s DRIE related assets, and in accordance with generally accepted accounting principles, the DRIE business operation, including related general and administrative (“G&A”) expenses, have been reclassified to discontinued operations.  At the time of the sale, approximately 45% of the Company’s G&A expenses were related to the DRIE operations.
 
 
26


Equity in (earnings) loss of unconsolidated affiliate

The Company recorded a net $138 loss in earnings of the unconsolidated affiliate and $43 of amortization expenses related to the difference between the net book value of Sequel’s assets and the cost of the investment for the three months ended December 31, 2011.  The Company recorded a net $372 loss in earnings of the unconsolidated affiliate and $129 of amortization expenses related to the difference between the net book value of Sequel’s assets and the cost of the investment for the nine months ended December 31, 2011.  The Company did not have an investment in an unconsolidated affiliate during the three and nine months ended December 31, 2010.

Other Income (expense), net

Other income (expense), net consists of the change in fair value of the common stock warrant liability.

Income Taxes

At March 31, 2011, the Company had net operating loss carryforwards of approximately $99.9 million and $49.0 million for federal and state tax purposes, respectively.  The federal net operating loss carryforward will begin to expire in the year ended March 31, 2020 and the state of California will start to expire in the year ended March 31, 2013.  At March 31, 2011, the Company also had research and experimentation credit carryforwards of $1.3 million and $0.8 million for federal and state income tax purposes, respectively.  The federal credit will begin to expire in the year ended March 31, 2011 and the state of California will never expire under current law.   Net operating loss carryforwards and R&D credits can only offset 90% of taxable income.  In the current fiscal year, the Company will be subject to the Alternative Minimum Tax requirements.  As a result of the sale of the NLD patents, the estimated alternative minimum tax on the Company’s current calendar year income is $16.
 
Discontinued Operations

Discontinued operations consists of interest income, other income, reimbursements for expenses from the French government for research and development, gains and losses on the disposal of fixed assets of discontinued operations, gains and losses on foreign exchange and interest income on money market accounts, as well as the reclassification of net expenses associated with our exit from our historical core operations.  For the three months ended December 31, 2011 compared to the three months ended December 31, 2010, discontinued operations, net increased by $2,636.  In the period just ended, discontinued operations included the receipt of OEM’s installment payment, offset by R&D expense and foreign exchange loss, the recognition of deferred revenue offset by the related commission expense.  Most significantly, the Company also recognized $3,550 from the December 23, 2011 sale of some of its NLD patents.  As these assets were internally developed, there was a corresponding zero book value.  The NLD revenue is recognized in discontinued operations, along with the related costs of $813, which includes $767 in commission expense.  In the prior period, discontinued operations included gains and losses on foreign exchange as well as the reclassification of net expenses associated with our historical core operations.

Contractual Obligations

The following summarizes our contractual obligations at December 31, 2011, and the effect such obligations are expected to have on our liquidity and cash flows in future periods (in thousands).

Contractual obligations:
       
Less than
               
After
 
   
Total
   
1 Year
   
1-3 Years
   
3-5 Years
   
5 Years
 
Non-cancelable operating lease obligations
  $ 56     $ 53     $ 3     $ -     $ -  
Total contractual cash obligations
  $ 56     $ 53     $ 3     $ -     $ -  
 
 
27

 
We maintain our headquarters, encompassing our executive office and storage areas in Petaluma, California.  We have a primary lease for office space, consisting of 2,187 square feet, which expires in August of 2012.  We rent storage/workspace areas on a monthly basis.  Previously we had a primary lease which encompassed our executive office, manufacturing, engineering and research and development operations, in one leased 39,717 square foot facility in Petaluma, California.  Our primary lease expired in September 2010, and we did not extend it further.    We own all of the equipment used in our facilities.  Such equipment consists primarily of computer related assets.
 
We had office space in a leased 13,300 square foot facility in San Jose, California.  As of February 2010, we no longer leased or rented space in this facility.
 
We leased sales, service and process support space in Maisach, Germany until January 2010.  Thereafter, we rented space on a monthly basis, but discontinued use of this space at the end of March 2010.
 
We also had a lease for research and development space in a facility in Annecy, France until it was taken over by SPTS as part of the asset sale of Tegal’s DRIE etch business.
 
 Certain of our past sales contracts included provisions under which customers would be indemnified by us in the event of, among other things, a third party claim against the customer for intellectual property rights infringement related to our products. There were no limitations on the maximum potential future payments under these guarantees. We have accrued no amounts in relation to these provisions as no such claims have been made, and we believe we have valid, enforceable rights to the intellectual property embedded in its products.

Liquidity and Capital Resources

For the nine months ended December 31, 2011, and the fiscal year ended March 31, 2011, we financed our operations from existing cash on hand.  Net cash used in operating activities during the nine months ended December 31, 2011, was $2,273.  The primary significant changes in our cash flow statement for the nine months ended December 31, 2011 were due to the income of $3,550 recognized from the December 23, 2011 sale of the NLD patents.  As these assets were internally developed, there was a corresponding zero book value.  The monies from the patent sale were offset by the net loss from continuing operations of ($2,293), and decreases in the net value of current assets and liabilities of discontinued operations and other assets related to our Sequel Power investment, offset by the decrease in accounts payable.  Net cash provided by operating activities during the nine months ended December 31, 2010 was $314, due primarily to a $2,140 increase in current assets from discontinued operations, partially offset by a net loss of ($2,426).
 
The consolidated financial statements contemplate the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future. We incurred a net income/(loss) of $798 and ($2,426) for the nine months ended December 31, 2011 and 2010, respectively. We (used)/generated cash flows from operations of ($2,273) and $314 for the nine months ended December 31, 2011 and 2010, respectively.  Although we believe that our existing cash balances will be adequate to fund operations through fiscal year 2012, we cannot assure you that we will be successful in pursuing any of the strategic alternatives indicated in Note 1 - Basis of Presentation on page 7.  We intend to engage in supporting the activities of Sequel Power through our direct efforts and through related operations and investments that we may make in the future, should favorable circumstances promote that investment.  In addition, Tegal is actively evaluating opportunities for partnerships with other diversified technology-based companies in order to exploit our shared experience and to enhance our value as a public company.  We cannot assure you that we will be successful in pursuing any of these strategic alternatives. It is not possible to predict when our business and results of operations will improve.  In consideration of these circumstances, the Company may be forced to consider a merger with or into another company or the liquidation or dissolution of the company, including through a bankruptcy proceeding.  We cannot assure you that we will be successful in pursuing any of these strategic alternatives.  If we were to liquidate or dissolve the company through or outside of a bankruptcy proceeding, you could lose all of your investment in Tegal common stock.

Off-Balance Sheet Arrangements
 
We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

 
28

 

Foreign Currency Exchange Risk

With the sale of the DRIE related assets and the closure of the Tegal France subsidiary, our exposure to foreign currency fluctuations has been mostly eliminated.  Prior to the sale of the Company’s operating assets, our exposure to foreign currency fluctuations was primarily related to purchases in Europe and Japan, which were denominated in the Euro and Yen. Foreign currency transaction gains and (losses) included in other income (expense), net were $65 and $80 for the nine months ended December 31, 2011 and 2010, respectively.  Changes in the exchange rate between the Euro and the U.S. dollar could adversely affect our operating results. Exposure to foreign currency exchange rate risk may increase over time as our business evolves.  Periodically, the Company enters into foreign exchange contracts to sell Euros, which are used to hedge a sales transaction in which costs are denominated in U.S. dollars and the related revenue is generated in Euros.  As of December 31, 2011, there were no outstanding foreign exchange contracts.

Fair Value Measurements
 
The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and we consider what assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.   The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
 
 
·
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.

 
·
Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.

 
·
Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions.
 
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.
 
The Company’s financial instruments consist primarily of money market funds.  At December 31, 2011, 98% of the Company’s current assets in financial instruments investments were classified as cash equivalents in the condensed consolidated balance sheets. Approximately 2% of the Company’s current assets in financial investments were classified as restricted cash.  The investment portfolio at December 31, 2010 was comprised of money market funds.   The carrying amounts of the Company’s cash equivalents are valued using Level 1 inputs.    The Company also has warrant liabilities which are valued using Level 3 inputs.
 
Interest Rate Risk

We are only marginally exposed to interest rate risk through interest earned on money market accounts. Interest rates that may affect these items in the future will depend on market conditions and may differ from the rates we have experienced in the past. We do not hold or issue derivatives, commodity instruments or other financial instruments for trading purposes.
 
 
29

 
 
Disclosure Controls and Internal Controls for Financial Reporting
 
Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Internal controls for financial reporting are procedures which are designed with the objective of providing reasonable assurance that our transactions are properly authorized, our assets are safeguarded against unauthorized or improper use and our transactions are properly recorded and reported, all to permit the preparation of our financial statements in conformity with U.S. GAAP.

Evaluation of Disclosure Controls and Procedures  

As of the period covered by this quarterly report, management performed, with the participation of our Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act.  Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the report we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.   Based on the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of December 31, 2011, such disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2011 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. 

From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business.  We believe there is no litigation pending that could, individually or in the aggregate, have a material adverse effect on our Company.

Item 1A. 

We wish to caution you that there are risks and uncertainties that could affect our business. A description of the risk factors associated with our business that you should consider when evaluating our business is included under “Risk Factors” contained in Item 1A. of our Annual Report on Form 10-K for the year ended March 31, 2011.  In addition to those factors and to other information in this Form 10-Q, the following updates to the risk factors should be considered carefully when evaluating Tegal or our business.
 
Tegal Risk Factors

We have incurred operating losses and may not be profitable in the future.  Our plans to maintain and increase liquidity may not be successful.

We had net income (loss) of ($3,130), ($18,469) and ($7,902), for the years ended March 31, 2011, 2010, and 2009, respectively.  We used cash flows from operations of ($74), ($4,887), and ($5,541), in these respective years.  For the nine months ended December 31, 2011 and 2010, we had a net income/(loss) of $798 and ($2,426) respectively.  Our net income in the nine months ended December 31, 2011 was due to the sale of our intellectual property portfolio for NLD and is non-recurring.  Although we believe that our existing cash balances will be adequate to fund operations through fiscal year 2012, we cannot assure you that we will be successful in pursuing any of the strategic alternatives described in this report.  We intend to engage in supporting the activities of Sequel Power through our direct efforts and through related operations and investments that we may make in the future, should favorable circumstances promote that investment.  In addition, Tegal is actively evaluating opportunities for partnerships with other diversified technology-based companies in order to exploit our shared experience and to enhance our value as a public company.
 
 
30


If our efforts do not succeed, we may need to raise additional capital which may include capital raises through the issuance of debt or equity securities.  If additional funds are raised through the issuance of preferred stock or debt, these securities could have rights, privileges or preferences senior to those of our common stock, and debt covenants could impose restrictions on our operations. Moreover, such financing may not be available to us on acceptable terms, if at all.  Failure to raise any needed funds would materially adversely affect us.  In consideration of these circumstances, the Company may be forced to consider a merger with or into another company or the liquidation or dissolution of the company, including through a bankruptcy proceeding.
 
We cannot assure you that we will be successful in pursuing any of these strategic alternatives.  It is not possible to predict when our business and results of operations will improve, if ever.  If we were to liquidate or dissolve the company through or outside of a bankruptcy proceeding, you could lose all of your investment in Tegal common stock.  Please also see the risks described in our Annual Report on Form 10-K for fiscal year ended March 31, 2011.

Sequel Power Risk Factors

If PV technology is not suitable for widespread adoption at economically attractive rates of return, or if sufficient demand for solar modules does not develop or takes longer to develop than we anticipate, Sequel Power may not become a viable entity and may never be able to sustain profitability.
 
The solar energy market is at a relatively early stage of development, and the extent to which solar modules will be widely adopted is uncertain. If PV technology proves unsuitable for widespread adoption at economically attractive rates of return or if demand for solar modules fails to develop sufficiently or takes longer to develop than we anticipate, Sequel Power may be unable to grow its business or generate sufficient net sales to sustain profitability. In addition, demand for solar modules in our targeted markets — including the United States, Latin America and the Middle East — may develop to a lesser extent than we anticipate. Many factors may affect the viability of widespread adoption of PV technology and demand for solar modules, including the following:
 
 
·
cost-effectiveness of the electricity generated by PV power systems compared to conventional energy sources and products, including conventional energy sources, such as natural gas and coal, and other non-solar renewable energy sources, such as wind;

 
·
availability, substance, and magnitude of government subsidies, incentives, and renewable portfolio standards to accelerate the development of the solar energy industry;

 
·
performance and reliability of PV systems and thin-film technology compared to conventional and other non-solar renewable energy sources and products;

 
·
success of other renewable energy generation technologies, such as hydroelectric, tidal, wind, geothermal, solar thermal, concentrated PV, and biomass;

 
·
fluctuations in economic and market conditions that affect the price of, and demand for, conventional and non-solar renewable energy sources, such as increases or decreases in the price of natural gas, coal, oil, and other fossil fuels; and

 
·
fluctuations in capital expenditures by end-users of solar modules, which tend to decrease when the economy slows and when interest rates increase.

We face intense competition from other companies producing solar energy and other renewable energy products.
 
The solar energy market is intensely competitive and rapidly evolving. The number of solar energy product manufacturers is rapidly increasing due to the growth of actual and forecast demand for solar energy products and the relatively low barriers to entry. If we fail to attract and retain customers in our target markets for our current and future development projects, we will be unable to increase our revenue and market share. Some of our competitors have established more prominent market positions, and if we fail to attract and retain customers and establish successful development projects in our target markets, we will be unable to increase our sales.
 
 
31

 
We may also face competition from new entrants to the solar energy market, including those that offer more advanced technological solutions or that have greater financial resources.  Solar development projects are often funded by solar cell or module manufacturers who have significantly greater financial resources and have the ability to finance pre-development, development and project activities, and are inherently more competitive than we are.  Furthermore, the entire solar energy industry also faces competition from conventional energy (for example a decline in base grid electricity prices), and non-solar renewable energy providers. Due to the relatively high manufacturing costs compared to most other energy sources, solar energy is generally not competitive without government incentive programs.
 
Many of our existing and potential competitors have substantially greater financial, technical, manufacturing and other resources than we do. Our competitors’ greater size in some cases provides them with a competitive advantage with respect to manufacturing because of their economies of scale and their ability to purchase raw materials at lower prices. As a result, those competitors may have stronger bargaining power with their suppliers and may have an advantage over us in negotiating favorable pricing, as well as securing supplies in times of shortages. Many of our competitors also have greater brand name recognition, more established distribution networks, balance of system capabilities, and larger customer bases. In addition, many of our competitors have well-established relationships with our current and potential developers and have extensive knowledge of our target markets. As a result, they may be able to devote more resources to the research, development, promotion and sale of their products or respond more quickly to evolving industry standards and changes in market conditions than we can. Our failure to adapt to changing market conditions and to compete successfully with existing or new competitors may materially and adversely affect our financial condition and results of operations.

Developing solar power projects may require significant upfront investment prior to the signing of a power purchase agreement or an EPC contract, which could adversely affect our business and results of operations.
 
Solar power project development cycles, which span the time between the identification of land and the commercial operation of a PV power plant project, vary substantially and can take many months or years to mature. As a result of these long project cycles, we may need to make significant upfront investments of resources (including, for example, large transmission deposits or other payments, which may be non-refundable) in advance of the signing of PPAs and EPC contracts and the receipt of any revenue, much of which is not recognized for several additional months or years following contract signing. Our potential inability to enter into sales contracts with potential customers after making such upfront investments could adversely affect our business and results of operations.
 
Our liquidity may be adversely affected to the extent the project sale market weakens and we are unable to sell our solar projects on pricing, terms and timing commercially acceptable to us.

We are exposed to risks associated with the ongoing financial crisis and weakening global economy.

The recent severe tightening of the credit markets, turmoil in the financial markets and weakening global economy are contributing to slowdowns in the industries in which we operate, which slowdowns are expected to worsen if these economic conditions are prolonged or deteriorate further.  The markets for international photovoltaic projects depend largely on government spending.  Economic uncertainty and government debt levels exacerbates negative trends in credit availability for these projects and may cause our customers to push out, cancel or refrain from placing project orders, which may reduce our revenue.  Difficulties in obtaining capital and deteriorating market conditions may also lead to the inability of some customers to obtain affordable financing.  These conditions may also similarly affect key suppliers, which could affect their ability to deliver parts and result in delays for our products.  Further, these conditions and the uncertainty about future economic conditions make it challenging for us to forecast operating results, make business decisions and identify the risks that may affect our business, financial condition and results of operations.  If we are not able to timely and appropriately adapt to changes resulting from the difficult economic environment, our business, financial condition or results of operations will be materially and adversely affected.


None.


None.


 
32



None.

Item 6. 
 
Exhibit
Number
 
Description
     
 
Certifications of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
Certifications of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS   Instance Document
101.SCH
  XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB  
XBRL Taxonomy Extension Label Linkbase Document
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document
 
 
33

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
TEGAL CORPORATION
 
(Registrant)
   
 
/s/  CHRISTINE T. HERGENROTHER
 
Christine T. Hergenrother
 
Chief Financial Officer
Date: February 14, 2012
 
 
 
34
 
EX-31.1 2 ex31_1.htm EXHIBIT 31.1 ex31_1.htm

EXHIBIT 31.1
 
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Thomas R. Mika, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Tegal Corporation;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
 
Date: February 14, 2012
/s/    Thomas R. Mika
 
President and Chief Executive Officer
 
 

EX-31.2 3 ex31_2.htm EXHIBIT 31.2 ex32_2.htm


EXHIBIT 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Christine Hergenrother, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Tegal Corporation;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: February 14, 2012
/s/    Christine T. Hergenrother
 
Vice President and Chief Financial Officer
 
 

EX-32 4 ex32.htm EXHIBIT 32 ex32.htm

EXHIBIT 32

CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Tegal Corporation, a Delaware corporation (the “Company“), on Form 10-Q for the quarter ended December 31, 2011 as filed with the Securities and Exchange Commission (the “Report“), I, Thomas R. Mika, President and Chief Executive Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
 
/s/    Thomas R. Mika
 
Chief Executive Officer and President
 
February 14, 2012
 
 
CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)
 
In connection with the Quarterly Report of Tegal Corporation, a Delaware corporation (the “Company“), on Form 10-Q for the quarter ended December 31, 2011 as filed with the Securities and Exchange Commission (the “Report“), I, Christine Hergenrother, Chief Financial Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/    Christine Hergenrother
 
Chief Financial Officer
 
February 14, 2012
 
 
 

EX-101.INS 5 tgal-20111231.xml INSTANCE DOCUMENT 0000931059 2011-12-31 0000931059 2011-03-31 0000931059 2011-10-01 2011-12-31 0000931059 2010-10-01 2010-12-31 0000931059 2011-04-01 2011-12-31 0000931059 2010-04-01 2010-12-31 0000931059 2010-03-31 0000931059 2010-12-31 0000931059 2012-02-02 iso4217:USD iso4217:USD xbrli:shares xbrli:shares -140000 -167000 129107000 128977000 -51000 0 8264000 7575000 7298000 7890000 -47000 -31000 -181000 0 -37000 0 50000000 50000000 1688807 1688943 1688807 1688943 17000 17000 538000 1792000 -181000 0 -501000 0 27000 -66000 130000 313000 -2737000 0 0 -185000 432000 306000 1873000 1493000 -583000 -303000 -2293000 -1149000 1545000 2046000 380000 1410000 10902000 11201000 0 0 2935000 344000 -2273000 314000 2269000 -92000 798000 -2426000 689000 592000 -8000 3000 6000 344000 300000 0 -394000 -306000 -1798000 -1493000 5000000 5000000 0 0 0 0 0.01 0.01 <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">2.&#160;</font></font></font></div></td><td align="left"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Inventories:</font></font></font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;">Inventories are stated at the lower of cost or market. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis and includes material, labor and manufacturing overhead costs. Any excess and obsolete provision is only released if and when the related inventory is sold or scrapped.&#160;&#160;The Company did not sell or scrap previously reserved inventory during the nine months ended December 31, 2011 and 2010<font style="display: inline; font-family: times new roman; font-weight: normal;">.&#160;&#160;The inventory provision balance for the periods ended December 31, </font>2011 and 2010 was <font style="display: inline; font-family: times new roman; font-weight: normal;">$0 and $547, respectively.&#160;&#160;The inventory provision for the nine month period ended December 31, 2010 was related to the DRIE products, which were sold in the prior fiscal year.</font></font></font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-indent: 0pt; display: block;">&#160;</div></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Net inventories for the periods presented were zero.&#160;&#160;All remaining inventory was included in the sale of the DRIE related assets in the prior fiscal year.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Prior to the sale of the DRIE assets in the prior fiscal year, the Company periodically analyzed any systems that were in finished goods inventory to determine if they were suitable for current customer requirements.&#160;&#160;At that time, the Company's policy was that, if after approximately 18 months, it determines that a sale will not take place within the next twelve months and the system would be useable for customer demonstrations or training, it is transferred to fixed assets.&#160;&#160;Otherwise, it was expensed.</font></font></font></div></div> 58000 112000 -71000 -144000 300000 0 4000 0 -118620000 -119418000 38000 0 75000 0 <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">2.&#160;</font></font></font></div></td><td align="left"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Inventories:</font></font></font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;">Inventories are stated at the lower of cost or market. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis and includes material, labor and manufacturing overhead costs. Any excess and obsolete provision is only released if and when the related inventory is sold or scrapped.&#160;&#160;The Company did not sell or scrap previously reserved inventory during the nine months ended December 31, 2011 and 2010<font style="display: inline; font-family: times new roman; font-weight: normal;">.&#160;&#160;The inventory provision balance for the periods ended December 31, </font>2011 and 2010 was <font style="display: inline; font-family: times new roman; font-weight: normal;">$0 and $547, respectively.&#160;&#160;The inventory provision for the nine month period ended December 31, 2010 was related to the DRIE products, which were sold in the prior fiscal year.</font></font></font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-indent: 0pt; display: block;">&#160;</div></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Net inventories for the periods presented were zero.&#160;&#160;All remaining inventory was included in the sale of the DRIE related assets in the prior fiscal year.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Prior to the sale of the DRIE assets in the prior fiscal year, the Company periodically analyzed any systems that were in finished goods inventory to determine if they were suitable for current customer requirements.&#160;&#160;At that time, the Company's policy was that, if after approximately 18 months, it determines that a sale will not take place within the next twelve months and the system would be useable for customer demonstrations or training, it is transferred to fixed assets.&#160;&#160;Otherwise, it was expensed.</font></font></font></div></div> <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">7.&#160;</font></font></font></div></td><td align="left"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Geographical Information:</font></font></font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Prior to February 9, 2011, the Company operated in one segment for the manufacture, marketing and servicing of integrated circuit fabrication equipment.&#160;&#160;Currently, the Company's sole potential source of revenue is from the project activities of Sequel Power.&#160;&#160;The Company's chief operating decision-maker has been identified as the President and Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">For geographical reporting, revenues are attributed to the geographic location in which the customers' facilities are located.&#160;&#160;Long-lived assets consist of property, plant and equipment and are attributed to the geographic location in which they are located.&#160;&#160;Net sales and long-lived assets by geographic region were as follows:</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" width="90%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" width="42%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" nowrap="nowrap" valign="bottom" width="22%"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Revenue for the</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" nowrap="nowrap" valign="bottom" width="22%"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Revenue for the</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td valign="bottom" width="42%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" nowrap="nowrap" valign="bottom" width="22%"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Three Months Ended</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" nowrap="nowrap" valign="bottom" width="22%"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Nine Months Ended</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td valign="bottom" width="42%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" nowrap="nowrap" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">December 31,</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" nowrap="nowrap" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">December 31,</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td valign="bottom" width="42%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2011</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2010</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2011</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2010</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td align="left" valign="bottom" width="42%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Sales to customers located in:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="42%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">United States</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">38</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">75</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="42%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total sales</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">38</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">75</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Revenues for the three and nine months ended December 31, 2011 are all part of continuing operations.&#160;&#160;Revenues of $1,345 and $4,847 for the three and nine months ended December 31, 2010, respectively, have been reclassified to discontinued operations.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" width="80%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" width="56%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">December 31</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">March 31</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td align="left" valign="bottom" width="56%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Long-lived assets at period-end:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td align="left" valign="bottom" width="56%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Discontinued Operations:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="56%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 27pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">United States</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="56%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 27pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Europe</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="56%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Continuing Operations:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="56%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 27pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">United States</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">58</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">112</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="56%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 36pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total Long-lived assets</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">58</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">112</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div></div> 8999000 9043000 443000 1129000 10902000 11201000 20000 26000 -501000 0 432000 306000 1873000 1493000 0.01 0.01 10364000 9409000 -445000 0 0 0 0 0 0 0 0 -1000 <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">4.&#160;</font></font></font></div></td><td align="left"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Net Income (Loss) Per Common Share (EPS):</font></font></font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-align: justify; text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Basic EPS is computed by dividing net income (loss) available to common stockholders (numerator) by the weighted average number of common shares outstanding (denominator) for the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted EPS uses the average market prices during the period. All amounts in the following table are in thousands except per share data.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Basic net loss per common share is computed using the weighted-average number of shares of common stock outstanding.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The following table represents the calculation of basic and diluted net loss per common share (in thousands, except per share data):</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Three Months Ended</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Nine Months Ended</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2011</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2010</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2011</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2010</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%" style="padding-bottom: 2px;"><div align="justify" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Net loss from continuing operations</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">(583</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">(303</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">(2,293</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">(1,149</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%" style="padding-bottom: 2px;"><div align="justify" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Income income/(loss) from discontinued operations, net of taxes</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">2,852</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">211</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">3,091</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">(1,277</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Net income/(loss) income applicable to common stockholders</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">2,269</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">(92</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">798</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">(2,426</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Basic and diluted:</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted-average common shares outstanding</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,689</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,688</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,689</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,688</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted-average common shares used in diluted net gain/(loss) income per common share</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">1,689</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">1,688</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">1,689</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">1,688</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Net loss per share from continuing operations:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Basic and diluted</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(0.34</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(0.18</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1.36</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(0.67</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Net income/(loss) income per share from discontinued operations:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Basic and diluted</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.69</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.13</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.83</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(0.76</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Net income/(loss) per share:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Basic and diluted</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.35</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(0.05</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.47</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1.43</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr></table></div></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Outstanding options, RSUs and ESPP's of 408,006 and 296,260 shares of common stock at a weighted-average exercise price per share of $9.82 and $15.05 on December 31, 2011 and 2010, respectively, were not included in the computation of diluted net (loss) income per common share for the three and nine month periods presented as a result of their anti-dilutive effect.&#160;&#160;Such securities could potentially dilute earnings per share in future periods.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div></div> 2852000 211000 3091000 -1277000 7000 0 200000 200000 81000 262000 57000 94000 -583000 -303000 -2293000 -1149000 92000 139000 <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">8.&#160;</font></font></font></div></td><td align="left"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Recent Accounting Pronouncements:</font></font></font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-align: justify; text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">In May 2011, the FASB issued ASU 2011-04, <font style="font-style: italic; display: inline; font-weight: normal;">Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs</font>, which amends ASC Topic 820, <font style="font-style: italic; display: inline; font-weight: normal;">Fair Value Measurement</font>. The purpose of ASU 2011-04 is to clarify the intent about the application of existing fair value measurement and disclosure requirements and to change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements.&#160;&#160;This pronouncement is effective for interim or annual periods beginning after December 15, 2011.&#160;&#160;We do not expect the provisions of ASU 2011-04 to have a material impact to our consolidated financial statements.</font></font></font></div><div align="center" style="text-align: justify; text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="center" style="text-align: justify; text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">In June 2011, the FASB issued ASU 2011-05, <font style="font-style: italic; display: inline; font-weight: normal;">Presentation of Comprehensive Income</font>, which amends ASC Topic 220, <font style="font-style: italic; display: inline; font-weight: normal;">Comprehensive Income</font>. The objective of ASU 2011-05 is to improve the comparability, consistency and transparency of financial reporting and to increase the prominence of items reported in other comprehensive income. The update will require entities to present items of net income, items of other comprehensive income and total comprehensive income in one continuous statement or two separate consecutive statements, and entities will no longer be allowed to present items of other comprehensive income in the statement of stockholders' equity. Reclassification adjustments between other comprehensive income and net income will be presented separately on the face of the financial statements. This pronouncement is effective for interim or annual periods beginning after December 15, 2011.&#160;&#160;We do not expect the provisions of ASU 2011-05 to have a material impact to our consolidated financial statements.</font></font></font></div><div align="center" style="text-align: justify; text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="center" style="text-align: justify; text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">In September 2011, the FASB issued ASU 2011-08, Intangibles &#8211; <font style="font-style: italic; display: inline; font-weight: normal;">Goodwill and Other (Topic 350): Testing Goodwill for Impairment</font>, which permits an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. This pronouncement is effective for interim or annual periods beginning after December 15, 2011.&#160;&#160;We do not expect the provisions of ASU 2011-05 to have a material impact to our consolidated financial statements.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-align: justify; text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;">In December 2011, the FASB issued ASU 2011-11, Balance Sheet - <font style="font-style: italic; display: inline; font-weight: normal;">Disclosures about Offsetting Assets and Liabilities</font> &#8211; <font style="font-style: italic; display: inline; font-weight: normal;">(Topic 210), </font>which requires entities to disclose both gross information and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting arrangement. This scope would include derivatives, sale and repurchase agreements and reverse sale and repurchase agreements, and securities borrowing and securities lending arrangements. The objective of this disclosure is to facilitate comparison between those entities that prepare their financial statements on the basis of U.S. GAAP and those entities that prepare their financial statements on the basis of IFRS.&#160;&#160;&#160;Even though this pronouncement is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods, disclosures required by those amendments are expected to be provided retrospectively for all comparative periods presented.&#160;&#160;We do not expect the provisions of ASU 2011-11 to have a material impact on our consolidated financial statements.</font></font></font></font></div></div> <div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">1.&#160;</font></font></font></div></td><td align="left"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Basis of Presentation:</font></font></font></div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">In the opinion of management, the unaudited condensed consolidated interim financial statements have been prepared on the same basis as the March 31, 2011 audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary to fairly state the information set forth herein.&#160;&#160;The statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;), but omit certain information and footnote disclosures necessary to present the statements in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;).&#160;&#160;These interim financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2011.&#160;&#160;The results of operations for the three and nine months ended December 31, 2011 are not necessarily indicative of results to be expected for the entire year.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Tegal Corporation and its subsidiaries' (&#8220;Tegal&#8221;, &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;) consolidated financial statements contemplate the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future.&#160;&#160;We incurred net income/(loss) of $798 and ($2,426) for the nine months ended December 31, 2011 and 2010, respectively. We (used)/generated ($2,273) and $314 of cash in operating activities for the nine months ended December 31, 2011 and 2010, respectively.&#160;&#160;We believe that our existing balances of cash and cash equivalents, combined with continued cost containment, will be adequate to fund operations through fiscal year 2012.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;">Throughout most of fiscal 2011, our operations consisted mainly of the sale and support of the Deep Reactive Ionic Etch (&#8220;DRIE&#8221;) product lines which we had acquired from Alcatel Micro Machining Systems (&#8220;AMMS&#8221;) in fiscal 2009, including the operation of our Tegal France subsidiary, which had been engaged in several joint development projects partially supported by customers and the government of France.&#160;&#160;Tegal France had also been the center for the majority of our product and process development efforts and engineering activities related to the improvement of our DRIE product lines.</font></font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">DRIE systems sales and the associated spares and service revenue represented the sole source of the Company's revenue in fiscal 2011.&#160;&#160;For all of fiscal 2010, DRIE sales represented approximately 47% of our total revenues.&#160;&#160;Since the DRIE markets were seriously impacted by the downturn in the semiconductor markets and the lack of available capital for new product development globally, DRIE sales alone were not enough to continue supporting the Company, even with significant reductions in our operating expenses resulting from the sale of our legacy etch and PVD business, as well as the implementation of further cost containment measures.&#160;&#160;Accordingly, while we focused our efforts on the operation of the DRIE business in the first half of fiscal 2011, we continued to seek and evaluate strategic alternatives, which included the continued operation of the Company as a stand-alone business with a different business plan, a merger with or into another company, a sale of all or substantially all of our remaining assets, and the liquidation or dissolution of the Company, including through a voluntary dissolution or a bankruptcy proceeding.</font></font></font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">On January 14, 2011, the Company, se2quel Partners and Sequel Power entered into a Formation and Contribution Agreement. The Company contributed $2 million in cash to Sequel Power in exchange for an approximate 25% economic interest in Sequel Power.&#160;&#160;Sequel Power is focused on the promotion of solar power plant development projects worldwide, the development of self-sustaining businesses from such projects, including but not limited to activities relating to and supporting, developing, building and operating solar photovoltaic (&#8220;PV&#8221;) fabrication facilities and solar farms, the consideration of other non-photovoltaic renewable energy projects and engagement in ancillary activities, such as advisory services.&#160;&#160;The Sequel Power model for large scale PV-based solar projects is unique in the industry and has won significant acclaim from governments, industrial companies and industry advocates for its innovation and prospect for success.&#160;&#160;By investing in this new company, we expect to employ our capital equipment know-how, a portion of our cash and potentially the tax benefits of our NOLs.&#160;&#160;We intend to support the activities of Sequel Power through our direct efforts and through related operations and investments that we may make in the future, should the circumstances be favorable.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Following our investment in Sequel Power, and as a result of our continuing efforts to reduce our operating losses, on February 9, 2011, the Company and SPP Process Technology Systems Limited (&#8220;SPTS&#8221;) entered into an Asset Purchase Agreement.&#160;&#160;That agreement included the sale of all of the shares of Tegal France, SAS, the Company's wholly-owned subsidiary and product lines and certain equipment, intellectual property and other assets relating to the DRIE Etch plasma etch systems and certain related technology.&#160;&#160;The other major asset remaining after the sale of our legacy etch and physical vapor deposition (&#8220;PVD&#8221;) business and our DRIE business was our Nano-Layer Deposition (&#8220;NLD&#8221;) intellectual property portfolio.&#160;&#160;Having discontinued the implementation of NLD during fiscal 2010, we instead began to offer this asset for sale to third parties.&#160;&#160;Concurrently, we began the process of closing and/or liquidating all of our other wholly-owned subsidiary companies, including SFI and Tegal GmbH, along with branches in Taiwan, Korea and Italy.&#160;&#160;&#160;As a result, all of our activities related to our legacy etch and PVD business, our DRIE business, our NLD development activities and our subsidiaries and branches are now included in discontinued operations.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The process of consolidation and transition, driven by the financial crisis and worsened by our relatively weak strategic and financial position in the semiconductor and micro-electro-mechanical systems (&#8220;MEMS&#8221;)&#160;capital equipment sectors, continues.&#160;&#160;&#160;Our main objective has been to preserve as much value for stockholders as possible as we transitioned to a business model that avoids high fixed costs, but retains our capabilities to attract and exploit emerging technologies. So far, we have invested in two opportunities.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The first investment was made in Sequel Power, and was motivated by a desire to exploit its proprietary model for large scale PV-based solar projects, which is unique in the industry, and has won significant acclaim from governments, industrial companies and industry advocates for its innovation and prospect for success.&#160;&#160;Providing a window for us into this market, our investment in Sequel Power has allowed us to evaluate several different aspects of the solar market for the purpose of determining if further investment or business activities would be fruitful.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The second investment of $300 in Nano Vibronix, Inc. was completed on November 22, 2011, in the form of a convertible promissory note.&#160;&#160;Nano Vibronix is a private company that develops medical devices and products that implement its proprietary therapeutic ultrasound technology which may be utilized for a variety of medical applications requiring low cost therapeutic ultrasound qualities. Nano Vibronix is focused on creating products utilizing its unique, patented approach which enables the transmission of low-frequency, low-intensity ultrasound surface acoustic waves (&#8220;SAWs&#8221;) through a variety of soft, flexible materials, including skin and tissue, enabling low-cost, breakthrough devices targeted at large, high-growth markets.</font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">NanoVibronix is developing a series of products directed at the treatment of chronic, non-healing wounds. The global wound care market is estimated to reach $22.8 billion by 2017, of which approximately one-third is addressed by advanced wound care products, according to a report recently published by Global Industry Analysts, Inc., a research group. The growth of the market is being fueled by an aging population and the rapidly increasing incidence of diabetes world-wide.&#160;&#160;Nano Vibronix' first product, PainShield<font style="display: inline; font-size: 70%; vertical-align: text-top; font-weight: normal;">TM</font> MD, has gained FDA clearance and CE Mark certification in Europe, and is marketed for the treatment of tendonitis, muscle pain and trigeminal neuralgia. Additionally, Nano Vibronix has developed a family of disposable ultrasound devices to treat catheter-associated infection and injury, accomplished by preventing biofilm formation and decreasing the friction between the catheter and body tissues. The UroShield<font style="display: inline; font-size: 70%; vertical-align: text-top; font-weight: normal;">TM </font>product is currently CE mark certified, and is the subject of several independent clinical trials being conducted by leading researchers in Europe and the Middle East.</font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">At the present time we are engaged primarily in supporting the activities of Sequel Power through our direct efforts and through related operations and investments we may make in the future.&#160;&#160;In addition to our investments in Sequel Power and Nano Vibronix, we are actively evaluating opportunities for partnerships with other diversified technology-based companies in order to exploit our shared experience and to enhance our value as a public company.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">We cannot assure you that we will be successful in pursuing any of these strategic alternatives.&#160;&#160;&#160;If our efforts do not succeed, we may need to raise additional capital which may include capital raises through the issuance of debt or equity securities.&#160;&#160;If additional funds are raised through the issuance of preferred stock or debt, these securities could have rights, privileges or preferences senior to those of our common stock, and debt covenants could impose restrictions on our operations. Moreover, such financing may not be available to us on acceptable terms, if at all.&#160;&#160;Failure to raise any needed funds would materially adversely affect us.&#160;&#160;It is not possible to predict when our business and results of operations will improve.&#160;&#160;In consideration of these circumstances, the Company may be forced to consider a merger with or into another company or the liquidation or dissolution of the Company, including through a bankruptcy proceeding.&#160;&#160;We cannot assure you that we will be successful in pursuing any of these strategic alternatives.&#160;&#160;If we were to liquidate or dissolve the Company through or outside of a bankruptcy proceeding, you could lose all of your investment in Tegal common stock.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Reclassifications</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">As a result of the sale of the Company's DRIE assets in the prior fiscal year, and in accordance with generally accepted accounting principles, the DRIE business operations related to the designing, manufacturing, marketing and servicing of systems and parts within the semiconductor industry has been reclassified to discontinued operations in our condensed consolidated financial statements.&#160;&#160;&#160;Amounts for the prior periods have been reclassified to conform to this presentation.&#160;&#160;The exit from the DRIE operation was essentially completed by the end of the fourth quarter of our 2011 fiscal year.</font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Concentration of Credit Risk</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="font-weight: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash investments.&#160;&#160;Prior to the sale of the DRIE assets, the Company's accounts receivable balance was also subject to credit risk. Substantially all of the Company's liquid investments are invested in money market funds. The Company's accounts receivable are derived primarily from sales to customers located in the United States, Europe and Asia. The Company performs ongoing credit evaluations of its customers and generally requires no collateral. The Company no longer maintains reserves for <font style="font-weight: normal;">potential</font></font><font style="font-weight: normal;">&#160;credit losses. </font><font style="font-weight: normal;"><font style="font-weight: normal;">Write</font>-offs during the periods presented have been insignificant.</font></font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">As of December 31, 2011 and 2010, two customers accounted for 100% and 73%, respectively of the total accounts receivable balance.&#160;Approximately 12% of the total balance in accounts receivable for the period ended December 31, 2011 is related to our semi-conductor business and is included in assets of discontinued operations.&#160;&#160;The Company considers this amount collectible.&#160;&#160;The total amount of balances in accounts receivable for the period ended December 31, 2010 is included in discontinued operations.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">For the three and nine months ended December 31, 2011, Sequel Power accounted for 100% of total revenue, which is included in continuing operations.&#160;&#160;For the nine months ended December 31, 2010, a leading precision timing device manufacturer, Ulsan National Institute of Science and Technology, STMicroelectronics SA, and Uppsala University accounted for 28%, 20%, 18% and 17%, respectively, of total revenue.&#160;&#160;Total revenue for the three and nine months ended December 31, 2010 is included in discontinued operations.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note Receivable</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The Company's note receivable consisted of outstanding payments owed by OEM Group in connection with our sale to them of our legacy etch and PVD assets completed in March 2010.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The balance of the note receivable at December 31, 2011 consisted of the net outstanding payment owed by OEM Group in the German subsidiary in connection with the sale of legacy assets.&#160;&#160;This balance due is included in discontinued assets and will be offset in a non-cash transaction at the final liquidation of the German subsidiary in the first quarter of the next fiscal year per the schedule of the German tax authorities.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The outstanding balance of cash owed on the Company's note receivable from OEM was paid in full during the first quarter of the current fiscal year.&#160;&#160;The Company was entitled to receive an additional contingent payment of $440 related to the terms of the sale, which was paid in full in two installments.&#160;&#160;The first installment of $300 was paid on July 5, 2011, and the second installment of $140 was paid on October 7, 2011.&#160;&#160;In connection with the installment plan, the Company received an additional $5 in interest payment.&#160;&#160;Both the first and second installments were classified as a gain on sale of discontinued operations in the second and third quarters of the current fiscal year.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Derivative Instruments</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">In June 2008, the Financial Accounting Standards Board (&#8220;FASB&#8220;)&#160;&#160;ratified the Emerging Issues Task Force (&#8220;EITF&#8221;) consensus on EITF Issue No. 07-05, <font style="font-style: italic; display: inline; font-weight: normal;">Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock</font> (&#8220;EITF Issue 07-05&#8221;) (Topic 815) which applies to the determination of whether any freestanding financial instruments or embedded features that have the characteristics of a derivative, as defined by Statement of Financial Accounting Standards (&#8220;SFAS&#8221;) No. 133 (Topic 815), <font style="font-style: italic; display: inline; font-weight: normal;">Accounting for Derivative Instruments and Hedging Activities</font>, and to any freestanding financial instruments are potentially indexed to an entity's own common stock.&#160;&#160;EITF Issue No. 07-05 (Topic 815) became effective for fiscal years beginning after December 15, 2008.&#160;&#160;The Company adopted Topic 815 as of April 1, 2009.&#160;&#160;As a result, warrants to purchase 285,454 shares of our common stock previously treated as equity pursuant to the derivative treatment exemption were no longer afforded equity treatment. The warrants had exercise prices ranging from $30.00-$495.00 and expired or will expire between February 2010 and September 2013. As such, effective April 1, 2009, the Company reclassified the fair value of these warrants, which had exercise price reset features, from equity to liability status as if these warrants were treated as a derivative liability since their date of issue between February 2000 and January 2006.&#160;&#160;On April 1, 2009, the Company reclassified $346 from additional paid-in capital, as a cumulative effect adjustment, to beginning accumulated deficit, and $502 to common stock warrant liability to recognize the fair value of such warrants on such date.&#160;&#160;As of March 31, 2011, the fair value of the warrants was estimated using the Black-Scholes pricing model with the following weighted average assumptions:&#160;&#160;risk-free interest rate of 2.24%; expected life of 1.1 years; an expected volatility factor of 79.1%; and a dividend yield of 0.0%.&#160;&#160;At December 31, 2011, the fair value of the warrants was $20, which was calculated using the Black-Scholes pricing model with the following weighted average assumptions:&#160;&#160;risk-free interest rate of 0.83%; expected life of 1.63 years; an expected volatility factor of 155%; and a dividend yield of 0.0%.&#160;&#160;For the nine months ended December 31, 2011 and 2010, respectively, the Company recorded non-cash gains of $6 and $344 related to these warrants. The Company recorded a non-cash loss related to the warrants of $8 in the quarter ended December 31, 2011 and a non-cash gain of $3 in the quarter ended December 31, 2010.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Investment in Unconsolidated Affiliate</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The Company evaluates its joint venture arrangements to determine whether they should be recorded on a consolidated basis.&#160;&#160;The percentage of economic interest in the joint venture, an evaluation of control and whether a variable interest entity (&#8220;VIE&#8221;) exists are all considered in the consolidation assessment.</font></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;">We account for our investment in joint ventures where we own a non-controlling interest or where we are not the primary beneficiary of a VIE using the equity method of accounting. Under the equity method, our cost of investment is adjusted for our share of equity in the earnings </font><a name="jump_exp_1"><!--EFPlaceholder--></a><font style="font-weight: normal;">or losses of </font><a name="jump_exp_2"><!--EFPlaceholder--></a><font style="font-weight: normal;">the </font><a name="jump_exp_3"><!--EFPlaceholder--></a><font style="font-weight: normal;">unconsolidated affiliate </font><a name="jump_exp_4"><!--EFPlaceholder--></a><font style="font-weight: normal;">and reduced by distributions received.</font></font></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Any differences between the cost of our investment in an unconsolidated affiliate and our underlying equity as reflected in the unconsolidated affiliate's financial statements generally result from a different basis in assets contributed to the joint venture. The net difference between our investment in unconsolidated affiliates and the underlying equity of unconsolidated affiliates is generally amortized over a period of ten years, which is determined to be the estimated useful life of the underlying intangibles which created the difference in carrying amount.&#160;&#160;The net difference at March 31, 2011 was $1,730.&#160;&#160;The amortization expense related to this difference for the fiscal year ended March 31, 2011 was $45.&#160;&#160;The amortization expense related to this difference for the three and nine month periods ended December 31, 2011 was $43 and $129, respectively.&#160;&#160;There was no amortization expense related to this investment for the three and nine month periods ended December 31, 2010, respectively.</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">&#160;On a periodic basis, we assess whether there are any indicators that the fair value of our investments in unconsolidated affiliates may be impaired. An investment is impaired only if our estimate of the fair value of the investment is less than the carrying value of the investment, and such decline in value is deemed to be other than temporary. To the extent impairment has occurred, the loss is measured as the excess of the carrying amount of the investment over the fair value of the investment. Our estimates of fair value for each investment are based on a number of assumptions such as future revenue projections, operating forecasts, discount rates and capitalization rates, among others.&#160;&#160;These assumptions are subject to economic and market uncertainties. As these factors are difficult to predict and are subject to future events that may alter our assumptions, the fair values estimated in the impairment analyses may not be realized.&#160;&#160;No impairments of investments in unconsolidated affiliates were incurred during the year ended March 31, 2011 or the nine month period ended December 31, 2011.</font></font></font></div><div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Fair Value Measurements</font></font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and we consider what assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.&#160;&#160;&#160;The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-family: Symbol, serif;">&#183;</font></font></div></td><td><div align="justify"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.</font></font></div></td></tr></table></div><div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-family: Symbol, serif;">&#183;</font></font></div></td><td><div align="justify"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</font></font></div></td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-family: Symbol, serif;">&#183;</font></font></div></td><td><div align="justify"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management's estimates of market participant assumptions.</font></font></div></td></tr></table></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The Company's financial instruments consist primarily of money market funds.&#160;&#160;At December 31, 2011, 98% of the Company's current assets in financial instruments investments were classified as cash equivalents in the condensed consolidated balance sheets.&#160;Approximately 2% of the Company's current assets in financial investments were classified as restricted cash.&#160;&#160;The investment portfolio at December 31, 2010 <font style="display: inline; font-family: times new roman; font-weight: normal;">was</font> comprised of money market funds.&#160;&#160;&#160;The carrying amounts of the Company's cash equivalents are valued using Level 1 inputs.&#160;&#160;The Company also has warrant liabilities which are valued using Level 3 inputs.</font></font></font></div></div></div><div>&#160;</div><div><div align="left" style="text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The changes in the fair value of warrants is as follows:</font></font></font></div><div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center"><table cellpadding="0" cellspacing="0" width="60%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" width="36%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" valign="bottom" width="22%"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Nine Months Ended</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td valign="bottom" width="36%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="6" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">December 31,</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td valign="bottom" width="36%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom" width="36%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2011</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: center; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: center; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2010</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="36%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance at the beginning of the period</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">26</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">363</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="36%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Issuance of warrants</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="36%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value recorded in earnings</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">(6</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">(339</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="36%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance at the end of the period</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">20</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline;">24</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Intangible Assets</font></font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Intangible assets include patents and trademarks that are amortized on a straight-line basis over periods ranging from 5 years to 7 years.&#160;&#160;The Company performs an ongoing review of its identified intangible assets to determine if facts and circumstances exist that indicate the useful life is shorter than originally estimated or the carrying amount may not be recoverable.&#160;&#160;If such facts and circumstances exist, the Company assesses the recoverability of identified intangible assets by comparing the projected undiscounted net cash flow associated with the related asset or group of assets over their remaining lives against their respective carrying amounts.&#160;&#160;Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets.&#160;&#160;&#160;As of fiscal year end 2011, all of the Company's remaining intangible assets were included in the asset sale of the DRIE product line to SPTS, except for those that were internally developed, which have a carrying value of zero.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">During December 2011, the Company, as part of its proposed sale of its intellectual property portfolio for Nanolayer Deposition Technology (NLD), awarded three of the four offered lots to multiple semiconductor equipment manufacturers for aggregate consideration of approximately $4 million.&#160;&#160;The Company finalized the sale transaction of the first of the four lots on December 23, 2011, and for which the Company has received approximately $3.6 million.&#160;&#160;The Company finalized the sale transaction of the second lot after December 31, 2011.&#160;&#160;While the third lot has been awarded, the Company has not yet finalized that transaction.&#160;&#160;NLD is a process technology that bridges the gap between high throughput, non-conformal chemical vapor deposition (CVD) and highly conformal, low throughput atomic layer deposition (ALD).&#160;&#160;The portfolio included over 35 US and international patents in the areas of pulsed-CVD, plasma-enhanced ALD, and NLD.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Impairment of Long-Lived Assets</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Long-lived assets are reviewed for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, as well as at fiscal year end. If undiscounted expected future cash flows are less than the carrying value of the assets, an impairment loss is recognized based on the excess of the carrying amount over the fair value of the assets.&#160;&#160;No impairment charges were recorded for fixed assets for the nine months ended December 31, 2011.</font></font></font></div><div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Pension Obligations</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Prior to fiscal year 2011, the Company began the process of closing and/or liquidating all of our wholly-owned subsidiary companies, not already sold, including Tegal Germany.&#160;&#160;The subsidiaries are now included in discontinued operations.&#160;&#160;The Company has recognized an ongoing liability for pensions related to the Tegal Germany subsidiary.&#160;&#160;However, in fiscal year 2011, the Company recognized an additional liability for the independent third-party administration of the pension program.&#160;&#160;&#160;The total pension liability in the prior period was $700.&#160;&#160;The total pension liability for the period ended December 31, 2011 was $0.&#160;&#160;The pension liability was settled on October 6, 2011.&#160;&#160;The settlement of the pension obligation is classified as a reduction of liabilities of discontinued operations.&#160;&#160;The related foreign exchange gain of $23 is classified as a gain or loss on the sale of discontinued operations in the third quarter of the current fiscal year.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Stock-Based Compensation</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">We have adopted several stock plans that provide for issuance of equity instruments to our employees and non-employee directors. Our plans include incentive and non-statutory stock options and restricted stock awards.&#160;&#160;These equity awards generally vest ratably over a four-year period on the anniversary date of the grant, and stock options expire ten years after the grant date. Certain restricted stock awards may vest on the achievement of specific performance targets.&#160;&#160;We also have an Employee Stock Purchase Plan (&#8220;ESPP&#8221;) that allows qualified employees to purchase Tegal shares at 85% of the fair market value on specified dates.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Total stock-based compensation expense related to stock options and restricted stock units (&#8220;RSUs&#8221;) for the nine months ended December 31,<font style="display: inline; font-family: times new roman; font-weight: normal;"> 2011 and 2010 </font>was $130 and $313, respectively.&#160;&#160;The total compensation expense related to non-vested stock options and RSUs not yet recognized at December 31, 2011 is $468.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The Company utilized the following valuation assumptions to estimate the fair value of options that would have been granted for the three month periods ended December 31, 2011 and 2010, respectively.&#160;&#160;No options were granted in the three month period ended December 31, 2011.&#160;&#160;The valuation assumptions are included for comparison only.</font></font></font></div></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" width="60%" style="font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" width="36%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">STOCK OPTIONS:</font></div></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2011</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2010</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="36%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected life (years)</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6.0</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6.0</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="36%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Volatility</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">155.08</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">74.30</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="36%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Risk-free interest rate</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.83</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.51</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="36%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Dividend yield</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">ESPP awards are valued using the Black-Scholes model with expected volatility calculated using a six-month historical volatility.&#160;&#160;&#160;No ESPP awards were made in the nine month period ended December 31, 2011.&#160;&#160;The valuation assumptions are included for comparison only.</font></font></font></div></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" width="60%" style="font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" width="36%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">ESPP:</font></div></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2011</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2010</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="36%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected life (years)</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.5</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.5</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="36%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Volatility</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">116.27</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">86.10</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="36%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Risk-free interest rate</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.02</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.12</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="36%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Dividend yield</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Valuation and Other Assumptions for Stock Options</font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;"><font style="font-style: italic; display: inline; font-weight: normal;">Valuation and Amortization Method.</font>&#160;&#160;&#160;&#160;We estimate the fair value of stock options granted using the Black-Scholes model. We estimate the fair value using a single option approach and amortize the fair value on a straight-line basis for options expected to vest. All options are amortized over the requisite service periods of the awards, which are generally the vesting periods.</font></font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;"><font style="font-style: italic; display: inline; font-weight: normal;">Expected Term.</font>&#160;&#160;&#160;The expected term of options granted represents the period of time that the options are expected to be outstanding. We estimate the expected term of options granted based on our historical experience of exercises including post-vesting exercises and termination.</font></font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;"><font style="font-style: italic; display: inline; font-weight: normal;">Expected Volatility.</font>&#160;&#160;&#160;&#160;We estimate the volatility of our stock options at the date of grant using historical volatilities.&#160;&#160;Historical volatilities are calculated based on the historical prices of our common stock over a period at least equal to the expected term of our option grants.</font></font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;"><font style="font-style: italic; display: inline; font-weight: normal;">Risk-Free Interest Rate.</font>&#160;&#160;&#160;&#160;We base the risk-free interest rate used in the Black-Scholes option valuation model on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with remaining terms equivalent to the expected term of our option grants.</font></font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;"><font style="font-style: italic; display: inline; font-weight: normal;">Dividends.</font>&#160;&#160;&#160;&#160;We have never paid any cash dividends on common stock and we do not anticipate paying any cash dividends in the foreseeable future.</font></font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;"><font style="font-style: italic; display: inline; font-weight: normal;">Forfeitures.</font>&#160;&#160;&#160;&#160;We use historical data to estimate pre-vesting option forfeitures. We record stock-based compensation expense only for those awards that are expected to vest.</font></font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The Company does not use multiple share-based payment arrangements.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">During the three months ended December 31, 2011, no stock option awards were granted.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Stock Options &amp; Warrants</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="font-weight: normal;"><font style="display: inline; font-family: times new roman; font-weight: normal;">A summary of the </font>stock option and warrant activity during the quarter ended December 31, 2011 is as follows:</font></font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" width="90%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" width="42%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Shares</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Weighted</font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Average</font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Exercise</font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Price</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Weighted</font></font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Average</font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Remaining</font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Contractual</font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Term (in Years)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Aggregate</font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Intrinsic</font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Value</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="42%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Beginning outstanding</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">151,245</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">21.63</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="42%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expired</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(5,911</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">20.47</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="42%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="42%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Ending outstanding</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">145,334</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">21.67</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.22</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="42%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Ending vested and expected to vest</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">145,265</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">21.65</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.22</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="42%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Ending exercisable</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">132,544</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">22.64</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.05</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The aggregate intrinsic value of stock options and warrants outstanding at December 31, 2011 is calculated as the difference between the exercise price of the underlying options and the market price of our common stock as of December 31, 2011.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The following table summarizes information with respect to stock options and warrants outstanding as of December 31, 2011:</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td align="left" colspan="6" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Range of</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Exercise Prices</font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Number</font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Outstanding</font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">As of</font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">December </font><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">31,</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Weighted</font></font></font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Average</font></font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Remaining</font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Contractual</font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Term</font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">(in years)</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Weighted</font></font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Average</font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Exercise</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Price</font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Number</font></font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Exercisable</font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">As of</font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">December 31,</font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Weighted</font></font></font></font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Average</font></font></font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Exercise</font></font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Price</font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">As of</font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">December 31,</font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2.90</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6.00</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,831</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8.67</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4.67</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,204</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4.88</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6.25</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">11.70</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">56,685</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6.62</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">11.54</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">44,591</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">11.50</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">17.20</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">26.30</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">59,401</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4.58</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">21.52</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">59,376</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">21.52</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">28.10</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">61.80</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">19,421</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3.00</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">42.47</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">19,413</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">42.47</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">61.94</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">151.94</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,936</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.63</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">90.11</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,914</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">90.23</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">152.21</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">285.00</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">58</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.53</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">174.08</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">46</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">174.00</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">286.72</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">300.27</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.00</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">293.50</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2.90</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">300.27</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">145,334</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.22</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">21.67</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">132,544</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">22.64</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">As of <font style="display: inline; font-family: times new roman; font-weight: normal;">December 31, 2011</font>, there was $12 of total unrecognized compensation cost related to outstanding options and warrants which the Company expects to recognize over a period of 0.79 years.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Restricted Stock Units</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The following table summarizes the Company's unvested RSU activity for the three months ended December 31, 2011:</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" width="80%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" width="56%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Number</font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">of</font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">Shares</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Weighted </font></font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Avg.</font></font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Grant Date</font></font></font></div><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">Fair Value</font></font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="56%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance October 1, 2011</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">272,405</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2.18</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="56%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Granted</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="56%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Forfeited</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="56%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Vested</font></div></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(28,260</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2.45</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="56%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2011</font></div></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">244,145</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2.15</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Unvested restricted stock at December 31, 2011</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">As of December 31, <font style="display: inline; font-family: times new roman; font-weight: normal;">2011, </font>there was $456 of total unrecognized compensation cost related to outstanding RSUs, which the Company expects to recognize over a period of 3.08 years.</font></font></font></div></div> <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">9.&#160;</font></font></font></div></td><td align="left"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Investments</font></font></font></div></td></tr></table></div></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-weight: normal; text-decoration: underline;">The Nano Vibronix Transaction</font></font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">On November 22, 2011, the Company completed a $300 strategic investment in the form of a convertible promissory note from Nano Vibronix, Inc., a private company that develops medical devices and products that implement its proprietary therapeutic ultrasound technology.&#160;&#160;Nano Vibronix is focused on creating products utilizing its proprietary low-intensity surface acoustic wave (SAW) technology. The company's unique, patented approach enables the transmission of low-frequency, low-intensity ultrasound waves through a variety of soft, flexible materials, including skin and tissue, enabling low-cost, breakthrough devices targeted at large, high-growth markets.&#160;&#160;A copy of the Company's press release was filed as an exhibit to the Company's Form 8-K filed on November 29, 2011 and is incorporated herein by reference.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The Company's investment in Nano Vibronix is in the form of a convertible promissory note that bears interest at a rate of 10% per year compounded annually and matures on November 15, 2014.&#160;&#160;Principal and accrued interest under the note automatically convert into shares of Series B-1 Participating Convertible Preferred Stock of Nano Vibronix upon the earlier to occur of (i) a $3 million (or larger) equity financing by Nano Vibronix or (ii) a sale of Nano Vibronix.&#160;&#160;In addition, the Company may convert principal and accrued interest under the note into shares of Nano Vibronix Series B-1 Participating Convertible Preferred Stock at its election at any time.&#160;&#160;In either case, the conversion price is $0.284 per share.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-weight: normal; text-decoration: underline;">The Sequel Power Transaction</font></font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">On January 14, 2011,&#160;&#160;Tegal, se2quel Partners LLC, a California limited liability company, and Sequel Power LLC, a newly formed Delaware limited liability company (&#8220;Sequel Power&#8221;), entered into a Formation and Contribution Agreement.&#160;&#160;Sequel Power is focused on the promotion of solar power plant development projects worldwide, the development of self-sustaining businesses from such projects, including but not limited to activities relating to and supporting, developing, building and operating solar photovoltaic fabrication facilities and solar farms, and the consideration of other non-photovoltaic renewable energy projects.&#160;&#160;se2quel Partners is owned by Ferdinand Seemann, who previously served as an independent member of the Company's Board of Directors.&#160;&#160;Pursuant to the Formation and Contribution Agreement, Tegal contributed $2 million in cash to Sequel Power in exchange for an approximate 25% economic interest in Sequel Power.&#160;&#160;In addition, Tegal issued warrants (&#8220;Warrants&#8221;) to se2quel Partners and se2quel Management GmbH, a German limited liability company, to purchase an aggregate of 185,777 shares of the Company's common stock at an exercise price of $3.15 per share.&#160;&#160;The Warrants are exercisable for a period of four years.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The descriptions of the Formation and Contribution Agreement and the Warrants are qualified in their entirety by reference to the full text of such documents, copies of which were filed as exhibits to the Form 8-K report filed on January 21, 2011.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Results of Sequel Power Operations</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Revenue</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Revenue for Sequel Power operations of $0 for the three months ended December 31, 2011 decreased by $2 from revenue for the three months ended September 30, 2011.&#160;&#160;Revenue for the nine months ended December 31, 2011 was $4.&#160;&#160;All Sequel revenue was generated from project services.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Sequel Power's net loss for the three month period ended December 31, 2011 was $553.&#160;&#160;&#160;The Company's share of net loss is $138.&#160;&#160;&#160;Sequel Power's net loss for the nine month period ended December 31, 2011 was $1,490.&#160;&#160;&#160;The Company's share of net loss is $373.</font></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div></div> <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">5.&#160;</font></font></font></div></td><td align="left"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Financial Instruments:</font></font></font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The carrying amount of the Company's financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, notes receivable, accrued expenses and other liabilities approximates fair value due to their relatively short maturity. Prior to February 9, 2010, the Company sold products in various global markets. As a result, the Company was exposed to changes in foreign currency exchange rates.&#160;&#160;The Company does not hold derivative financial instruments for speculative purposes.&#160;&#160;Foreign currency transaction gains and (losses) included in other income (expense), were $27 and $66 for the nine months ended December 31, 2011 and 2010, respectively.&#160;&#160;On December 31, 2011, the Company had no open foreign exchange contracts to sell Euros or any other foreign currencies.&#160;&#160;On December 31, 2011, the Company had 41,741 warrants outstanding with an exercise price of $30.00 expiring between June 2013 and September 2013.&#160;&#160;For the nine months ended December 31, 2011 and 2010, respectively, the Company recorded non-cash gains of $6 and $344 related to these warrants. The Company recorded a non-cash loss related to the warrants of $8 in the quarter ended December 31, 2011 and a non-cash gain of $3 in the quarter ended December 31, 2010.</font></font></font></div></div> -0.34 -0.18 -1.36 -0.67 1.69 0.13 1.83 -0.76 1.35 -0.05 0.47 -1.43 false --03-31 2011-12-31 No No Yes Smaller Reporting Company 5066421 TEGAL CORP /DE/ 0000931059 1688807 2011 Q3 10-Q 0 553000 0 406000 502000 750000 -6000 -339000 1689000 1688000 1688000 1688000 -330000 2140000 2737000 <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 18pt;"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">6.&#160;</font></font></font></div></td><td align="left"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">MEMS Capital Equipment related Asset Acquisitions and Sales:</font></font></font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">On September 16, 2008, the Company acquired certain assets from AMMS and Alcatel Lucent (together, the &#8220;Sellers&#8221;).&#160;&#160;With this acquisition, we entered the DRIE market.&#160;&#160;DRIE is a highly anisotropic etch process used to create deep, steep-sided holes and trenches in wafers, with aspect ratios of 20:1 or more.&#160;&#160;DRIE was developed for <font style="display: inline; font-weight: normal;">micro-electro-mechanical systems</font> (&#8220;MEMS&#8221;), which require these features, but is also used to excavate trenches for high-density capacitors for DRAM and more recently for creating TSVs in advanced 3-D wafer level packaging technology. The acquisition was designed to enable us to pursue the high-growth markets in MEMS and certain segments of integrated semiconductor device manufacturing and packaging.&#160;&#160;Current end-markets include production of a variety of MEMS and power devices, memory stacking (flash and DRAM), logic, RF-SiP, and CMOS image sensors.&#160;&#160;The Company paid $1,000 in cash and $4,000 in shares of the Company's common stock. The 208,877 shares of common stock issued by the Company was calculated by obtaining&#160;&#160;the quotient of (a) $4,000 divided by (b) the average of the closing sales prices of the common stock as reported on the Nasdaq Capital Market on the five (5) consecutive trading days immediately prior to (but excluding) the closing date.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">In connection with this acquisition, the Company and Alcatel Lucent entered into an intellectual property agreement providing for the transfer of specified intellectual property rights to the Company, a trademark license agreement allowing for the limited use of the AMMS trademark by the Company, and a preferred supplier agreement pursuant to which the Company will purchase certain equipment from an affiliate of the Sellers.&#160;&#160;AMMS designated Mr. Gilbert Bellini to serve as a member of the Company's board of directors. AMMS' right to designate a member of the Company's board of directors terminated upon the absorption of AMMS into its parent, Adixen Vacuum Technology, and its subsequent sale to Pfeiffer Vacuum GmbH on December 31, 2010.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="left" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The purchase price was allocated as follows (in thousands):</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" width="80%" style="font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" width="68%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Assets acquired:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="68%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Trademarks</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">428</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="68%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Patents</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,648</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="68%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total Intangible Assets</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,076</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="68%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="68%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Fixed Assets</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">24</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="68%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Inventory</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,900</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="68%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total Tangible Assets</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,924</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="68%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="68%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total Acquired Assets</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Beginning in the fiscal third quarter of 2009, following the acquisition of the DRIE product lines from AMMS, the Company experienced a sharp decline in revenues related to its legacy Etch and PVD products, a result of the overall collapse of the semiconductor capital equipment market and the global financial crisis.&#160;&#160;The management and the Board of Directors of the Company considered several alternatives for dealing with this decline in revenues, including the sale of assets which the Company could no longer support.&#160;&#160;On March 19, 2010, the Company and its wholly owned subsidiary, SFI, sold inventory, equipment, intellectual property and other assets related to the Company's legacy Etch and PVD products to OEM Group Inc. (&#8220;OEM Group&#8221;), a company&#160;&#160;based in Phoenix, Arizona that specializes in &#8220;life cycle management&#8221; of legacy product lines for several semiconductor equipment companies.&#160;&#160;The sale included the product lines and associated spare parts and service business of the Company's 900 and 6500 series plasma etch systems, along with the Endeavor and AMS PVD systems from SFI.&#160;&#160;In connection with the sale of the assets, OEM Group assumed the Company's warranty liability for recently sold legacy Etch and PVD systems.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The Company and OEM Group entered into related agreements for the transfer and licensing of patents, trademarks and other intellectual property associated with the legacy Etch and PVD products.&#160;&#160;These included a Trademark Assignment Agreement for certain trademarks used in the legacy Etch and PVD Products, a royalty-free Trademark License Agreement allowing for the limited use of the Tegal trademark by the purchaser solely in connection with future sales of legacy Etch and PVD products and solely in combination with the trademarks transferred to purchaser, a Patent Assignment Agreement for the transfer of certain patents related to the Etch and PVD products, and a perpetual, irrevocable, non-exclusive, worldwide, fully-paid, royalty-free, Intellectual Property Cross License Agreement, pursuant to which the Company granted OEM Group a license to certain intellectual property owned by the Company for use in OEM Group's manufacture and sale of the legacy Etch and PVD products, and OEM Group licensed back to the Company certain intellectual property for the Company's continued use.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="left" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The consideration paid by OEM Group consisted of the following (in thousands):</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-family: Symbol, serif;"><font style="display: inline; font-family: Times New Roman;">&#9679;</font></font></font></div></td><td><div align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Cash in the amount of $250 paid at closing, which occurred on March 19, 2010;</font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-family: Symbol, serif;"><font style="display: inline; font-family: Times New Roman;">&#9679;</font></font></font></div></td><td><div align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">An aggregate of $1,750 cash payable to the Company in four installment payments of $250, $500, $500 and $500 on July 1, 2010, October 1, 2010, January 1, 2011 and April 1, 2011, respectively; and</font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 18pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div></td><td style="width: 18pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-family: Symbol, serif;"><font style="display: inline; font-family: Times New Roman;">&#9679;</font></font></font></div></td><td><div align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">A contingent payment in cash of up to $1,000 payable to the Company by April 15, 2011 based on the following percentage of applicable bookings of Etch and PVD products in excess of $6,000 received by the Company or OEM Group during the period beginning March 19, 2010 through March 31, 2011:</font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 40.5pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div></td><td style="width: 36pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-family: Times New Roman;"><font style="display: inline; font-family: Times New Roman;">&#9679;</font></font></font></div></td><td><div align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">if applicable bookings are greater than or equal to $6,000 but less than $8,000, the contingent payment will be 5% of the applicable bookings in excess of $6,000;</font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 40.5pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div></td><td style="width: 36pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-family: Times New Roman;"><font style="display: inline; font-family: Times New Roman;">&#9679;</font></font></font></div></td><td><div align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">if applicable bookings are greater than or equal to $8,000 but less than $10,000, the contingent payment will be $100 <font style="font-style: italic; display: inline;">plus</font> 10% of the applicable bookings in excess of $8,000;</font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 40.5pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div></td><td style="width: 36pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-family: Times New Roman;"><font style="display: inline; font-family: Times New Roman;">&#9679;</font></font></font></div></td><td><div align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">if applicable bookings are greater than or equal to $10,000 but less than $12,000, the contingent payment will be $300 <font style="font-style: italic; display: inline;">plus</font> 15% of the applicable bookings in excess of $10,000; and</font></div></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td style="width: 40.5pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160; </font></div></td><td style="width: 36pt;"><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-family: Times New Roman;"><font style="display: inline; font-family: Times New Roman;">&#9679;</font></font></font></div></td><td><div align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">if applicable bookings are greater than or equal to $12,000, the contingent payment will be $600 <font style="font-style: italic; display: inline;">plus </font>20% of the applicable bookings in excess of $12,000.</font></div></td></tr></table></div><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="text-indent: 0pt; display: block; margin-left: 72pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">In no case will the contingent payment exceed $1,000.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">Based on the applicable bookings of OEM Group for the designated period, the amount of the contingent payment due was $440.&#160;&#160;On June 21, 2011, the Sellers, OEM Group and Purchaser entered into an amendment (the &#8220;Amendment&#8221;) to the Purchase Agreement which, among other things, revised the payment schedule of the Contingent Payment.&#160;&#160;Pursuant to the Amendment, the Company received $300 on July 5, 2011 and $140 plus approximately $5 of interest on October 7, 2011.&#160;&#160;The description of the Amendment provided above is qualified in its entirety by reference to the full text of the Amendment, a copy of which was filed as Exhibit 10.1 to the Form 8-K report filed on June 23, 2011.</font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The Company retained the DRIE products which it had acquired from AMMS, along with the Compact&#8482;<font style="font-style: italic; display: inline; font-weight: normal;">&#160;</font>cluster platform and the NLD technology that it had developed over the past several years.&#160;&#160;The DRIE markets were seriously impacted by the downturn in the semiconductor markets, and as those markets recover the Company is not in a position to make the needed investments to improve its competitive position.&#160;&#160;In addition, it was not clear that even with additional investment and significant reductions in operating expenses DRIE sales alone would be enough to support the Company.&#160;&#160;As a result, the Company evaluated various other alternative strategies, including sale of its DRIE products, Compact&#8482;<font style="font-style: italic; display: inline; font-weight: normal;">&#160;</font>platform and NLD technology, the transition to a new business model, a sale of all or substantially all of our assets, or&#160;&#160;the liquidation or dissolution of the Company, including through a bankruptcy proceeding.&#160;&#160;On February 9, 2011, the Company sold its DRIE and Compact related assets to SPTS, but retained its NLD technology.&#160;&#160;&#160;See &#8220;The SPTS Transaction&#8221; below.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">The SPTS Transaction</font></font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">On February 9, 2011, Tegal and SPP Process Technology Systems Limited, (&#8220;SPTS&#8221;), a company incorporated and registered in England and Wales, entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which the Company sold to SPTS all of the shares of Tegal France, SAS, the Company's wholly-owned subsidiary, and product lines and certain equipment, intellectual property and other assets relating to the Company's DRIE systems and certain related technology SPTS also assumed existing customer contracts, including all installation and warranty obligations of existing customers, and other liabilities arising after the closing of the transaction (the &#8220;Assumed Liabilities&#8221;).</font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">In connection with the sale, the Company and SPTS entered into related agreements for the transfer and licensing of patents, trademarks and other intellectual property associated with the business, including a royalty-free Trademark License Agreement allowing for the limited use of the Tegal trademark by SPTS solely in connection with future sales related to the business and solely in combination with the trademarks transferred to SPTS, as well as written assignments to SPTS of all rights in the patents and trademarks that are part of the sale.</font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The transaction closed immediately after execution of the Purchase Agreement. The consideration paid by SPTS totaled approximately $2,100, comprised of approximately $500 of Assumed Liabilities and $1,600 in cash, of which $200 in cash will be held in escrow for one year after the closing of the transaction to satisfy any indemnification obligations of the Company under the Purchase Agreement.</font></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The descriptions of the Purchase Agreement and the Trademark License Agreement provided above are qualified in their entirety by reference to the full text of such agreements, copies of which have been filed as Exhibits 10.1 and 10.2, respectively, to the Company's 8-K filed on February 15, 2011 and are incorporated herein by reference.</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Discontinued Operations</font></font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The assets and liabilities of discontinued operations are presented separately under the captions &#8220;Assets of discontinued operations&#8221; and &#8220;Liabilities of discontinued operations,&#8221; respectively, in the accompanying condensed consolidated balance sheets at December 31, 2011 and March 31, 2011 and consist of the following:</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><br /></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">December 31,</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">March 31,</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2011</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"><font style="display: inline;">2011</font></font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Assets of Discontinued Operations:</font></div></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" width="76%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accounts receivable and other receivables, net of allowances for sales returns and doubtful accounts of $0 and $71 at December 31, 2011 and March 31, 2011, respectively</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">405</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">591</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" width="76%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Notes receivable</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">26</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">528</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" width="76%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Prepaid expenses and other current assets</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">12</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">10</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="76%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total assets of discontinued operations</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">443</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,129</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="76%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="76%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Liabilities of Discontinued Operations:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="76%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accounts payable</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">522</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="76%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred revenue</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">--</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">130</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="76%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accrued expenses and other current liabilities</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">380</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">758</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="76%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total liabilities of discontinued operations</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">380</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,410</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 18pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">In the nine months ended December 31, 2011, the Company recognized deferred revenue of $130, offset by related commission expense, as well as revenue of $89 from the finalization of the sale of the DRIE assets which occurred in the fourth quarter of the prior fiscal year.&#160;&#160;In the same period, the Company received $440 from OEM in installment payments related to the sale of legacy assets, and recognized $64 in foreign currency transactions.&#160;&#160;Total revenue from discontinued operations was $1,345 and $4,847 for the three and nine months ended December 31, 2010.&#160;&#160;The total loss from discontinued operations for the nine months ended December 31, 2010 was $1,270 and included the reclassification of operating expenses related to the manufacture, design, marketing and servicing of the DRIE operations including foreign exchange adjustments and income tax expense (benefit).</font></font></font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 27pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: normal;">The Company also recognized $3,550 from the December 23, 2011 sale of the NLD patents.&#160;&#160;As these assets were internally developed, there was a corresponding zero book value.&#160;&#160;The NLD revenue is recognized in discontinued operations, along with the related costs of $813, which includes $767 in commission expense.&#160;&#160;During December 2011, the Company, as part of its proposed sale of its intellectual property portfolio for Nanolayer Deposition Technology (NLD), awarded three of the four offered lots to multiple semiconductor equipment manufacturers for aggregate consideration of approximately $4 million.&#160;&#160;The Company finalized the sale transaction of the first of the four lots on December 23, 2011.&#160;&#160;The Company finalized the sale transaction of the second lot after December 31, 2011.&#160;&#160;While the third lot has been awarded, the Company has not yet finalized that transaction.&#160;&#160;Sales of NLD patents in future periods will also be recognized in discontinued operations, as well all related expenses to finalize the sales.&#160;&#160;NLD is a process technology that bridges the gap between high throughput, non-conformal chemical vapor deposition (CVD) and highly conformal, low throughput atomic layer deposition (ALD).&#160;&#160;The portfolio included over 35 US and international patents in the areas of pulsed-CVD, plasma-enhanced ALD, and NLD.</font></font></font></div></div> Derived from the Company's audited consolidated financial statements EX-101.SCH 6 tgal-20111231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 001010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 006010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 006020 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 006030 - Disclosure - Product Warranty link:presentationLink link:calculationLink link:definitionLink 006040 - Disclosure - Net Income Loss Per Common Share (EPS) link:presentationLink link:calculationLink link:definitionLink 006050 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 006060 - Disclosure - MEMS Capital Equipment related Asset Acquisitions and Sales link:presentationLink link:calculationLink link:definitionLink 006070 - Disclosure - Geographical Information link:presentationLink link:calculationLink link:definitionLink 006080 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 006090 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 000990 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 tgal-20111231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 8 tgal-20111231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accumulated other comprehensive loss Additional paid-in capital Loss on disposal of property and equipment - continuing operations Gain (Loss) on Sale of Other Assets CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract] Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Changes in operating assets and liabilities: Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, shares outstanding (in shares) Common stock; $0.01 par value; 50,000,000 shares authorized; 1,688,807 and 1,688,943 shares issued and outstanding at December 31, 2011 and March 31, 2011, respectively. Total current liabilities Liabilities, Current Current liabilities: Equity in (earnings) loss of unconsolidated affiliate Income (Loss) from Equity Method Investments Effect of exchange rates on cash and cash equivalents Stock compensation expense Net gain on sale of intangible asset Loss on disposal of property and equipment - discontinuing operations Gain (Loss) on Disposition of Property General and administrative expenses CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) [Abstract] Net loss from continuing operations Income (Loss) from Continuing Operations Attributable to Parent Investment in unconsolidated affiliate Liabilities of discontinued operations Total liabilities and stockholders' equity Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net cash provided by investing activities: Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities: Net cash (used in)/provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net income/(loss) Net income/(loss) Net Income (Loss) Attributable to Parent Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Other income/(expense), net Nonoperating Income (Expense) Investment in convertible promissory note Operating loss Operating Income (Loss) Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, shares outstanding (in shares) Preferred stock, par value (in dollars per share) Product Warranty Product Warranty Disclosure [Text Block] Product Warranty [Abstract] Property and equipment, net Provision for doubtful accounts and sales returns allowances - discontinued operations Issuance of note receivable Payments to Acquire Notes Receivable Acquisition of property and equipment - continuing operations Payments to Acquire Property, Plant, and Equipment Accumulated deficit Revenue - related party Inventories Inventory Disclosure [Text Block] Geographical Information Segment Reporting Disclosure [Text Block] CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) [Abstract] Stockholders' equity: Stockholders' equity: Total current assets Assets, Current Current assets: Assets, Current [Abstract] Other assets of discontinued operations Total assets Assets Common stock warrant liability Change in value of unconsolidated affiliate Income (Loss) from Equity Method Investments, Net of Dividends or Distributions ASSETS Assets [Abstract] Investments [Abstract] Investments, All Other Investments [Abstract] Operating expenses: Total operating expenses Operating Expenses Net income/(loss) per share: Net Income Loss Per Common Share (EPS) [Abstract] Common stock, par value (in dollars per share) Total stockholders' equity Stockholders' Equity Attributable to Parent Gain on proceeds received from contingent payments - discontinued operations Income tax expense Preferred stock; $0.01 par value; 5,000,000 shares authorized; none issued and outstanding Stock issued under stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Net Income Loss Per Common Share (EPS) Earnings Per Share [Text Block] Weighted average shares used in per share computation: Income (loss) from discontinued operations, net of taxes Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Depreciation and amortization - continuing operations Depreciation, Depletion and Amortization Restricted cash Adjustments to reconcile net income/(loss) to net cash (used in)/provided by operating activities: Accounts payable Accounts Payable, Current Accrued expenses and other current liabilities Accrued Liabilities, Current Loss before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Recent Accounting Pronouncements Description of New Accounting Pronouncements Not yet Adopted [Text Block] Basis of Presentation Basis of Presentation and Significant Accounting Policies [Text Block] Investments Investments and Other Noncurrent Assets [Text Block] Inventories [Abstract] Financial Instruments Financial Instruments Disclosure [Text Block] Geographical Information [Abstract] Basic and diluted Income (Loss) from Continuing Operations, Per Basic and Diluted Share Basic and diluted Income (Loss) from Discontinued Operations, Net of Tax, Per Basic and Diluted Share Basic and diluted Earnings Per Share, Basic and Diluted Amendment Flag Current Fiscal Year End Date Document Period End Date Entity [Text Block] Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Net (loss) income per share from continuing operations: [Abstract] Net loss per share from continuing operations: Net (loss) income per share from discontinued operations: [Abstract] Net income/(loss) income per share from discontinued operations: Depreciation and amortization - discontinued operations The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, to periods that benefit from use of the assets - discontinued operations Acquisition of property and equipment - discontinued operations The cash outflow associated with the acquisition of long-lived, physical assets for operations that are classified as discontinued. Acquisition of property and equipment - discontinued operations Net cash received on OEM asset disposition - discontinued operations The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets of operations that are classified as discontinued. Fair value adjustment of common stock warrants The net change of fair value of common stock warrants. Fair value adjustment of common stock warrants EITF 07-05 (Topic 815) Basis of Presentation [Abstract] Weighted Average Shares Basic and diluted The weighted average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS. Basic and diluted Increase Decrease In Current Assets And Liabilities From Discontinued Operations The increase (decrease) during the reporting period in current assets and liabilities from discontinued operations. Current assets and liabilities from discontinued operations Proceeds From Sale Of Intangible Asset Discontinued Operations The cash inflow from the disposal of assets without physical form usually arising from contractual or other legal rights related to discontinued operations. Net proceeds received from sale of intangible asset - discontinued operations Financial Instruments [Abstract] Capital Equipment Related Asset Acquisitions and Sales [Text Block] The entire disclosure for the acquisition of certain capital equipment and sales of other assets and discontinued operations. MEMS Capital Equipment related Asset Acquisitions and Sales Capital Equipment Related Asset Acquisitions and Sales [Abstract] MEMS Capital Equipment related Asset Acquisitions and Sales [Abstract] Recent Accounting Pronouncements [Abstract] EX-101.PRE 9 tgal-20111231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ZIP 10 0001140361-12-008387-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-12-008387-xbrl.zip M4$L#!!0````(`&@P3T"+Q8Q[$XT``+N4!P`1`!P`=&=A;"TR,#$Q,3(S,2YX M;6Q55`D``_.0.T_SD#M/=7@+``$$)0X```0Y`0``[#UK<^(XMM^W:O^#EIU7 M5T%B`WF0[O16.DE/Y=Z>3BKIF7NKMO:#L`5HQ]BL9"=A?OV>(]G&@`DVKYB, M=G9J"-;1>>B\)8L/_W@>>N21"/CT]'>`W!X'H'S8MJW7(?1E2WV&U>+S' M_=]?&(Z/NU2FPY_GQC^UU&B[T^DD`/XCD^'TW)(Y!_W@\5`_`S#;;EAVHV4G M0"#I/J6C%*I'95=AB!_D@+B,YR.!!SG#_6B8SX,;BL-P/&*',(()[J0`@5\` M)O`;,W!.$/FA&.?3%C_,H<^)A%@``T]`)_.`?,H=F0^E'N6`2.[D`\"#O.'A M:`%9^"0'@#T[@WP`?)(#$/:IEP*$#/XZ<(*A&F@WTV%%C`V,E)`/:!UG4NG] M/>L192UGN%CG-?._M8\6_*_3LJVCSH?# M6>`$U6$.KAC3"/0O<.?P*[F$'Y7([2:(/)T\?C(]:0IP+\(K&K)85RRPT&26R;,9(.:[&9"L>B5/-B%.*Q6GM9_B MM,J+T]J>.&VKO>_::;4KI)VI./=6.TN+UC++&V%TOV1ZFFY+&U7*-I MP3_[)H]FP\+_;T(>D<^U,'Z%H#@CAR&C,A+L8UR-G?WZ<)7,E#S*SHY3+9IZ M5L0N?P21S+*($%^Q]*%A(-*'9>G)"B%_Q@RZ*^8'0^Z_C##V9`,JF"R"<7[2 MY&F&[R)B:RU8D64$S<_]MT;CPG&B8>2!9W5)$`Y`CZ$H&@DV8+[DCXQX@92- MAAX>U\AG&9A;!+G,0MSX,`'[`F!?67C;^T:?2:QA]U@&34H;@G2H[Y26$9GK,JCBRXL,JL6\"=FP82.SQR>;8=9U><@#GWID M1+G;X#YQZ(B'4'K.LIB.O(.!-_ZE'K;26MG-CFW-,)`__38)+2/S)A)]VCDI M1_3/%,C\"07_C@0^>:`>(T&/J!4B%U*R<$Z3$`0!;GT^"[^YWHR MZB*\I$*,N=__C7H16TG/3YO'[2F9%T*U,P[*&`!PU8:W``D4!`@&?DIRNF/[TC8.%W@J%3)=?/(X@83/'XDHTGTR23 MW/CQ#%>LQX1@;CP1$+9!_]6>=KZK$5%1493SA%#%[$`4D%/@IH`D=W1,NQY; MSGH"$0.LN^#VZ3(V9Q#NGJ.5(]@F>!$1I*A?..UR#](05D`W8Z`,S+IKU%IF ME/,H7XNSS:[5(J8@\QY"JB3#P/F]3G1Q16@4#@+!_P"N?@(.];?OYL*&`GU` MR`G MULD+9.NY=T;R42A%]VT&;BORSB!X!0XV(?YE'+PG MWUD'E@VUL2"/F/*])T=6'8P'_YVWXO?$K@/..HA-93CZ+R!A1OOP658F-"3@ M!-FP"_E0RZX39$\-^H4*9Y!^5276":JUF7]$0P)%B3A6/R"P.=>YF,K=*,E>W<67NV;FMDVB48N^[UP'MB0Q)/<%&_SXB@(89Q7[=HBO1J M]"2WO>MXBGN8X=;/;ZNLN8[-:0="[9JC@^7I]I%:34-@SS)<6..W"O M.AJSG*ELZ1/4:.YE=O1ZZV:WILN0?"3;H[:SY"0;ROPML&]C**,36S M)Y,!0O;N1#!B(AP79"L9ON92+6A=3`$GC>;U4K]V:SEJ78-LE(^62NI9U7%5&2@:1 MTY-653DI9R5VN[,:)SF)Z"50POT(J^;;$9ZO`?N2Y"(,!>]&H6JYAP&YHWG5 MWG2R.)DI,]&:]=+1:>N%O#L/8X5X+6=GC9:UQ[R632R:G3UFMFQ,`WM=G=FD MZL*-F0@`?1EXW%6'HVBOQST.'^=Y2FNU&_\B&24?HJ[D+J>",PDY3>"H;\%K M_$\`2=EO,#P2>1M215S24?MHAL"Y3,BX';62Y5L=:V&#-A?-UJDN MLS"GP('=G&GO%>8`ZUMU*`D*$CP1[)+NF/ST*Y3ZX*_>D<_D"-QER M=])A"IPAF>#3&*%O_!1T`KFY$K$XSHIPNG)MOWE.M3=?B=,4=&-K"FG4=-@M MCKDB_)9LK;7;6V8W]K*KL)N";FQY(4^>J5F+HZX(PV5;IX76=QF[TR5"L3H` MX"9Y^9IU:[-YW)GE8S+YEDDM67;.[*[NDM)RQG`R^2,X!O6)'G37\[+FY-5?@^'1:J\N@KA#3Y1;S:,9`5F(: M4O8@];.)>L;=N3GFLH/UV,VTI!LS]K,(S;:I+MM_K@31)2VE&D2OF5PM)7NZ M/0/8'YD(U<[>2`1#+F4@QL0/YCLT7P/=ZO@24%_>,X>!'0$8%+]2KMMZF#FR M6@S5Z[%4IECM3-@ MLNPK&;-IT*Z$6;+G/;M%]1*9=R)^2V:E0^\I]*;/[4^(?QG%*_%1^/S^QOA8 M?B(^#\'JY_B74#YS(GXW5"^7^F:H+G@0/@_#FJ?YE]"?=Q!^UTRLO0B%F$@/ MJ2O:W<#SJ)!DA!>'X"1+V(`R\U8\A+A3I4YW0X6@8'"_`"S3(/[_A!3&?/)CG7_,,*;@$ M;`*%,`ID:9S^^(,7OG?YXP_]\'W\D5"/]_WSVK\C&?+>N`;B'GOLO(;S-+B/ M=\><$6L4OL==JY%'QV>DZZFW(H94]+G?\%@O&1%_(WA_$']52S#I3D8W$"X3 MJ.S$89XWHJZ^F33^6XZHD_S]Q-UP<%Z#&/Y]2E,/V&OTZ)![0$7(AV"M/GLB MD.-2_SU13R4$A3-B3^-6BJ.X#(/1Y&LWX5T1G&)1F&&.T^P_$"'H_=_MX\MA?(0QR7X M7_@C8P>'H3NO%;A<9OVKCP:K7S\,\$C"V?KK?QB*R4=T6GGC,]K@`&XFC#(4 M0=,5Y+#0A`.\!NL)$K:@ M!YF*#$D@<$%^9^$!N<2_N50O0$0($$G,HE7"2X6KQM?)TX`[`T)'(Q$\0SZ& M;[!0)XS4/4TXGT\HZ7$A43'J\2?(YTF72JZ/:W!U2@7@$%IPZM6)1R$M40^! M_:B'$PK$'3PR,6!4XY8'Y,(?X^LS3.J9@JX,/!:J'MLCQPO7D?[`]\9$,`\[ MZ8"MIX8^#9BOV(<'2AH\%M(806`:%T4A'0&<,3<;SM)/WP`:W\2@0(3+7>SF M$0DI4PH(9+!''D12X9=,/$[A<35/2(0/.D"&L'X#29B/>ZOY[YUBVZ2<*N6G M9'E:LI#'"<43L7:IAQ=BPVQ",:!O%\PE?LJ93'%"GJ@DVV+G.TOA^>ZH?3+S M?FX9/A/^)@L4L[I@F31/B4Z%@0*^NK^YQCFQ5)")Q8#1,:UG7"OB"*858"#2 M`=L9,RH.RD3.LJY[NS$2$16=60--IXO9/,"$GEVB65K"+;8XW#+GF5`SZQM& MZ`-]M`NE^W\P$>3:X@6X4,&&E/OH'B=6B985QXK4:)*7P5(S2TR/ZI>[-F); M)LLT6>;>B'HGIGZG["D.;W,VN,3VZNKK)'/2WH'#0\B2J$^]\1_J)HXQD6,9 MLJ&$T9"I*IAI@#%-47ZC^#2`H\[VC/AF+K*+GM`138A!K[L MTSB[@Q'AA,Z8-ZI%^,3!\6$2&=+?06P>=?"[$&>//Z>. M-%"JCG!1ZR"XN5-: MR=`[R&+#"]^]3D9C#%OI_I/3F0VRQ?-OG]Y2=Q!;^N#Z*M1GY7HA MJBIS77I'O;T"VW2L+P@!MW#A*(=)U+$1,CDO,L=$#/,MB"$4P&3\FLLW>SYG M&;K=\K+RBP9KL9$8;ITHTZVG;\,HZUW*U$*[7W.IVB\OU$*TU>!U&L+8TX8&&4PO=^] MMSMSPL"<,#`G#,P)@ZKNCYH3!OL:>LP)@VI84.44PV29^R%J<\+`G#!X0R<, M7NJMIAW;!]97FT/W;!0(]29TP"^)1>_,IH3T\"MYL+L",W/ M+.@+.AI@7"8W?@]C/\8-T\VM[)*9/+NB:#:19W]F71%12',[R8_:97-H?59- M5\4!I+\RSH>2"GS21(543;=WU0_HX7$X)AZYNM)5_V@+Z^N9'"XF=RUA4<`L)W7&$)F+<@`,M4N M8S[AJ-N\QU6:J]#?"2;5M_KR.C7/]3-S(O5#$+>]'G>8P!9>@-1S]B0S:``V M\O0Y*$24HH5$O8LM;SQLZ*1#E1AT#H\YME3-=9A+^=IL;Q5I%"E[U>Y<+&SC M&3]393_S&52MGPWY(JF(ZHF5ZJTC&E^S.6EN3\"(UF[<=/'C)C<.2`I0^2,X M$R>]"5PP/7[!YLJ7P.\W//XX:>7AKP)PJ7Z3;92>+ASA8;WI(]K:HE:B=;R4 M+.QQZA/$B,6;([([SB(1K(\H5!>"8D,43QNOO"-N4W_M[:(DV9&S!4T[)5EEASJC).7$AV"@H*SOY^6CAIU1E`` M.V6TL'(853:J_!94.=.W,7'$&-^69?9M(!@COP1JG^L:S]K\V>W/://^:O-7 MW)0VRKQ6,$GHCDNEAAYR1IJCYZTPN+%(LVO"7\MP$_+UAG3*9M>CSN_(+%$_ MZOC^31KX,C1J4/:PZ$I;9YOQ!F1O%-'8E+$I8U,F[/[)7$2SL(NP+>,BEKH( MW"\WKN%/&FZ-+6W:EBQC2\:6C"V9N&1LR=A2A6S)Q*65R[_LX?PB^WD9]=(P M>% M-^B,7AB],'IA],+HQ=O2BZDLC73[L!*!.*_]W7$8Z_5J&5Z+YFV%RJ1]3>I^ M]3DF<.H'1&6)'&[Z/>7JU)B;KHV7U(QD=^K_W6J\=%;C12WL]IAIG6[?$>VL MK"RG<\9RC.6LP4S#&(XQ'&,XY9DY.3*68RS'6(X).>M5DD\#J)@V64>VWT(= M^2T(\78*W"+88179?GTM6=TQ`?'J5[8\]@8\TR)FWF(=60VM,[9C;&?OPGHU ME,Z8CC&=_:LEJZ%UQG:,[9BPLU8U^=H7=YIKYO;RFKG[Y"JYY&K#4-WR@%>I M%?H%'+Q&S?/4ST3J'RQ2/]:L+J],?ZTY]]JV%#%`?6?76^TC_>,P[?II^V0E M:JSI'Y6IDP%]9/I62<$>&I!45_9]F]=R/6_1I>2_X_KGNNO,Z*_1WWW6WZK%,=V[VV$@ MN\HV<&[3!DYE`YAYT6<_7O0Q>F'T8OLO@&W#!3=/WMA+7J^NM572TO5W:]_6 M9NSK:X=18Z/&^Z[&FSR,_B9BVG6$/V-F@ED5E-.X`Q/5C#X;?7[+1=O.^V:7 M07H^Z\UUS?9/0:OF$OY$#1VCRD:5WX@J;[J**W2N:&]+/',WU;Y<=[!!QU.A M>P^.S"55QH2,":W#E6TW_YPVM/F"MM`+E9N*]:WC5[D_9.[0XPZC?@7>$30O MIK[FBZFO$NZKH77&=HSM[&&DO0"&0GV#;C^A!'YXU__0LB'OS4:%RH2ULEE)`3`-!KZ23*5?AP_5&_U MP@SWK'=><_#\K=ULV34202FMOOO5LN!/ESE\2#UY7FNT:A]/.YV.95D3ZJ:F MW!`=5FL9'82[Y[6;D`T;=K/VL6.U6P6(N@T'3"1O2`2]1:\+SQ(+\AX%DGH_ MBR`:W?B.%[GQ*B3`:<]=88C1:AI6$G)[AIVU**@8^Z76%F0!\NIL01CZSWR] M7&G-;*MC-7.4<$6,I<345F*R[)?07P;#8>"#TP-W09ZH$!0LS^.TRST>CF?) M4I+[$C_E;"V7@5+)T+5@ZFT36DJ@1T#U<2FJ01&#(2,_?0FD?$=Z$"S(]7\B M()C\PL)!X)(;_Y')$!TYN,6O3%VK<,4?.919+IBC@#]D*'@WRC5"/3U._AFF MUC/KB3/SPJRWO73.6S$U8XY$VI8=!@47L7$THU[K4[3'LK-2V5D%9+<=J<5> MSN^3Z^<1\R6;8SP=D0S(,5^KA`ZT6],.;F[^C=)FI;05D7'+.MXA;>5LQSX] M:>U2<*64TVYWBA*7]S=+N(9^0.`[ M*FZ%VJIQ?\,9[IAX0)@BX:699>#FZV2/B1.]"+7W4'>?A`&!67)2\BQH#+A:&M0Z;D_IT_S$NR*W5,@_AC*B;76* MDOXS!1T!W1F)P&$,HI!@#E/-2!6_="[:QTQD1,?*JY-&T8P;@H1@5+(KIO][ MXU]"&C2&^=2JW_9T:G"_ M80K?BF#7R0RV)=(XOPKI,V':I^>G2-_H<^SS/S&?]7A>NE\F7YC+>^80;('$ M1XKK);B+2;P3K,>@=')UU'U/OL-H-XF][\E1'5P-_JO#KB0T M@OQ8\#^8^Y[X@<\(EQ+M'*^/"Z)0AO`!.WTSK*:8E!=71K121,LPES-E51DK M%?M."G.IOB(WFLZK2&"F>J? MV*$FJD7]KUE^D^%)$ILVLY>N[\=X]SIG(_O%JT@W=7^@WDQ)KPXL<)4@B'D# M=PFF^R!A,,HY%1#OR,58%.;X*'K>EO^6)55\AV4?KK3<`9KVP4N;2(O_6';& M01WM,.M?>338UIQNA*(;C3L4VIO^='WW\"[GK8ZRRE&AZZ7?U!(BFHU??OO? M]KZTQW$C2?3[`OL?N+UMN!N0U+KJLL<#5%^>GNFCMJML8_'P\)`B4Q*G*:;, MHZKE7_\B(C/)I$26I"H=E"H'&+=*(O.(C#OC4)?:BES51;TMKKW/XMJO6>R[ M#A`C*.R@K$RF*8:>#V9P$+<^J@(P;`*S2F(.B)C9+?,#[=)R#;^C>L'M%A<_,B_A7?Y<,C=!%>%!;\]_!V^=Z8B`0SS67#/5)[4> M)(`B:Z2?1!HSO!#BWUT^37+/K>.QA-6["+@MLW_`G`"I':F<,,XDEP)_0*_< MJ$#7S46ZUE0V+/`(D^HL'EL\WC@>WY2PU8A/`17)P8Y(Z[+`38.,JP\(\]%3 MI?E[-16\,+ESHYP]/UBOK0]>;U=--N9MQ"7; M[ZBBWU%Y!XCMTO&!-#BRE/'4*:-M*<-2AJ4,*S,L95C*L#+#.K_V433E'GK< M^]KJ9,G7S9ED3WG_*Z\;).TIVU.VI[S5:HU5!1J[ZQ=COC=FJH8=J3_K8"`C M:9?:$^3)N6OHH[;"[*XKS&ZIXMQ^"LNN9"^].#GO+;&7#KL6[Y M+-W595.'3'=+X]XMU5FJLZ[^C1!;K]&^L.1FR`XCK@:J6X"S![<"Q>+'WJ^JM(NJVTV(LE5DJ6TYE9Q?G1TUE5JA9 ME1QN^!\"5ZN;GL2ZV0Y#% M>U_H04+7(G;=0&]1V:+RD8#>HK)%Y8,"_>YN]*J2XP[*8/ECOAUR9S"\OF2C8BTCYH=S4:E3'A5>W*$):\,':L?Q MZAQ'4*%=[)9)U@-G+>59RMLQY=F0.4MYEO*LS+.49RGOJ5">E7GKW!7;:B\V M=,.&;M@HI".!IT5EB\I'`D^+RA:5CP2>%I4/[`I.OW*HMVQ9HW"\**,;LGM: MAJ^3R689AF48Q\`P+"I;5+:H;%'9HO)A@-ZBLD7E@P+]YK/5-FV3=,[W74)C M#;MCU7O4O6-NG3#U\65[=L@;7K1;O?X!LX5-58FS&'SP8@Y0N;.#6'B+RH>$ MRH?%C#NM7DGQ,XO!%H,/!8/;K=.29E?'@<&VE=73H;K#5(&>D*5O4=FBLD5E MB\H6E0\#]!:5+2H?%.CK?Y50FVY5<^%.,)>*>.*>#7C:/R9;)E)#T%M4MJA\ M)*"WJ&Q1^4A`;U'9HO)!@;[N*1@VW.G86<1!W4]V6F5-:H^,)UA,?@*8W&YU M>A:3+28?/B9W6N<6DRTF'P$FOVBWSHXV?L\6=WI*=&<-_X,%O45EB\I'`GJ+ MRA:5CP3T%I4M*A\4Z.M^L[#_Z*PF/R4Q-V+=JM]R#AM"^(\=:;< M;O4/N1Z.9JE`;GPT;P@5[@4?E5D1[J1'1 MOL^&*")U^?3_3N/$'\[*YY9>&?MXY`37*@;'> MZ@T`_#5"]N__^1^.\[?_:C8_2#1]\9&0E@I7O#4+5WS)"E1S8'S<6'4+T,8TQSQ1GSE4Q'! MHZ-W\$(RH^9!L/BO?`A8A#3;:;<[B:!/W5[GF9.&OOSU-_CAF>-QUP=.%/_R MK-E[]O?N^4FWW6[G@-G8P@X>D.T,D.U5`(EPMW`L0\AV?PV$[+4O+"`K$#(# MY"H(V>QTS\ZV#,FW'.2QZ].K#=`>I@$GP8_"^W*"K_Q%O\W#R'PO>^LR],QW M'HE'Q:VO,N%^=K7>H3YT2U]Y#.?IHM[DLG@\O_+\YS?P*PR"_[S[,_7!0`,4 MCTN$S`H$3YJ=\T>L_-(%/1*7<,5F2#D- MYTT:E3$)_:!Z3CWU(#"?%]EE^-1Q\#UY.S^766#[[MI:X#X&[[V=\O^FNNNT07+>NT=V;G2I3^P@UE.KF[VV/8@M4<1:^E2SV[VP)[$E MDEA3L>_T+W9^$E<1GS+?`YA.>1A+_]R79,PCYS*.>5(MZM2+ZCU0GN@M^=)C MY/-%48]889H][64M`=YY]O=.[^+!.WO+8S?RI]K[B@XVI6`AKE]%(H3/+I^0 MGOQ9),X,[-M+3TQ1V?X_Z`1SR`OV?Q=MFVS@+T,8-A^U."B,^;\\T2,N8SE_ M5U[0=:\M'N\1E4;\`"B`1[\\:S]S7!X$4^:A3S[[.YXR5_^MKZ;:[?QRZB'W MD#)<35]\)6):$JFF;DG5+#2SNJHIBU';,J2.RW>\@VG.6_==-J_FKRZ[.Z=8 M1'O^M9_F*\?+G&J^6Y(-MBY2K'0=;6^7=G2[M`30*GI!D>G/CKV`W_L%_(?0 M^<1F=,/=H#OG]Y?7KQT_CM%_GOE.R@LI^7<`+BG:305,84A&-"&`T"PN`&+@%#H7/PP(1@,1)K0%VPZ MA45EX07\NQ\3BQWBU+%X.O,@$'OZ&TXU9.(*!G2F+$M]-878,EPA= M?PH:HHC,ERA&08X_-RE\C[^IN?!'/QPB:.3-`:V_?(UQ:7S"S=C'8`=#;B!T M9$`#AC;@9`B(*" M.OAW#/4@@,,:;OV8;.RYTP+8C=DM0@YV"1/#_/X$-.8$?Q$I1G>$L0A\CZ$I M,`1+$V`*#\4)?*%VOI6XB:TRW%5"KJP4.!0I\,\TY$O%P,FF^>25#&+*N!@( M@&G$QV#>(VE++\UJ3+R[>2:^=#&2A8O!OQ4K*K"%$\7$@1,`X^!92!B+Y/W# MK$%L`;@V#]V9Y,$1"\'2CN@+&"SG%)&^=M:\&KAR!)R3:\XT@:T`>\2W?/1A MJ3=D-)H@CXY;V(Z,/9,[2*?(F<"P#P+-XQV,_J)X,)A,A9JID6&*,*OPT,B_ MK)Y%+1H.H/QG7&+('74)+](XYXS(TI,[X<0<`9?00QBL1O#.^6>#ILC63#L) MA1,($&@1"`'@1X&XXU[I;NY9N`KE,Y8SE&&&8R!2'L4_.@BN9-8";02D=1S[ M0RV3F8<<3@K8`4_N.+_O(&247P96N8,!-Z+\-`2"&<8GXJJ&3!XX?2X3*D[M M9>>)E9WU650=A=I!R,YK/DTD92P3H.<-O&8!-=L?!#"AQ(/S;J?S\X9EUZ]" M>,1#R?MEP!7+JV%[#ED!1^`\/QHP5+1,A?XPL0GEH#Q M05P#/B2*O>4VQ9`BG+4,Q!L$?#_`.>E%7);+HFA&W&J"[B89%CU@(&&E0:(6 M@4\4EQ$"7XMCO!A#Z<`CM%9D_/6=@!/@4V>DH>1G$`+2BQ/+86U4M_6['1GX M-SA-Z9CW29*,`2P1)/CC:Q8P5/FOQQSTQN:&!4CN:(N5T^;+-.9C)U1).*XZ)C*].]Y M9Q6]X(=Q$J6&NPQ-->"AQ'`YT!<*=.+V@L!4:CGDO'4J8C^;]MZQXY3,2]P" MR#DVBK@<+O8!!UE$WP-MQB@^0G4\(`C1DX?/*0D5NV(*TI=2>U2>$@C$R+\E M60WF4\P":8.`E$TC=XRF9399K'ZY!8N'+WE46F)&/M%`1)&XTZ:K\4/`9=Z7 ML=JXQ*).TA'8[G])0J&TBIR!6E1OT#W2J2TC'\R M>!RT'9G9UFLH))1*BG[USH>9-22+:DO#.(Y84YOG#&;ZZ=RWC["12HJTO0=* M4<$TN8@G0(59)IW<21!H)PGM;B'9[=$*4:=SCT*$4-JX0E1YB[F0BO6@T)(L MXN6UQK""4PW/]AK$/SDFYBYC88\NHO)]X2XTZI>A.>9EZ!DC&HM4XV499(^) M>MFNPKB/B6PT\8@$D32!K]:!PQY&.WM%K52KZZ4F!VFW`S2$E'WB:2LD M!MU%=G9TVS]?OWN3_=7Y^67# M&:1@6$S\!!2P*&$P[[S;82A$`L8++YA51:>TNK),BMLJV<.(ASRBJAWP"Z?0 MC$ M"P56\'Z>A;,?8^=2VJ1REB?B4: MR<(J\J(XS[*YKT1+K"8HJ2&C2L7HPP5&`IOQZ,I8>COT;-)6SDQG/1UZ'V`, MW,5CG/+KR5-;6^D@I_Y@'\\_K'`">@=@Q4T M'.-'@^:J'KGC5;^DL?$+^J*,WT0:F>QG!<9`CH4)P$T)".`W@:XK@)>%N7]: M2KW$CX?2HXH_![G/6O,2)9V`4T8R&G.0QG`:<4[IF#865T!U"@F`UB5)\5(7J+$%2J-$"2KU)]TZ`SS8`!"$-`H4AC4 M8-_`MLF[:DH%V$SW@)BJM8-KPIB?@R<#&HS/GDNY$`G<@=RQ")ZUE,\7'F+)>? M/ET79L'Z;WJK[8N&TM#P=6G?J$V3[@10D!+I?43J:B:$9CJ^!!='2CH/1V`- MD9X7XZ43O/1O`9JGX\%?@9C2+0CL$&^)8AFM3BJO@IR\BW"!>(#S1KD8&`D8 M*]27<7(9Y6J?N4X"61`+N32*XB2/<<8L)^S?(L)H&+5+#7J<%CZCIE=8.!^B M^1*KB$4@3LZC.3X<\8"I&Q,R?V0(J5XY3H('7CSDC=Q)6.7PD!C9(Y1#PI]8 MT3BRGIQ,0'D26$T)8TZG5&)37MQ&MU@Y$V^!0?#B96,6FDKL2P3XGS3*8U)S M^TR_9/*+"I/KO;H%+'!14#+D@FFAYM1L"D3PW9_(P-C^V0^:0&2XL9JX/+/D MVD?Z)AZ+@P."?4.MD0IZQGCQF,9HG]'5H+[?Q)O&NQ"TOS"[X><3'YTT*8:[ M98-H8`;,_48:Z2WS`](=73;%D`=B'WATFHA-%C$*Q``Y6F';+,`@Z:S<*`_E M_;#(E"'-_S3_5?!O.`@$J3?%QDT@B(!4!1GXH2FEX'4N4^QC98]2B@]*BTQ0 M*2@'P"G=F<-1'N&6KWY_FVG.#70QW7%T#<6:C07$Q#*A,$PC%1%=5.)T5E#Y MN5V2SP/6%$C1$2!4`)XN*L!2N50L5H2+@B@[[TS#5PJ2%=:D3DZ&+5!BW M*4\]6RN=(@-V.1QR*K*0_0)\(FS@G3:/,.:='I3!AQ@YDD>>$T:P[!2)UB*2 MQ@G3%5\5`2(H(XYJ"LDG51$B0VT?]`A/K9\2OH`'I"7;*>H%4O%FSBT\#`<> MS8IO1A2T&7Z+TFD"F$4"E..K&PA"O%<.]4YM!>HG*`B_A'D\3+]AQ-UER!OS M[I\I:,A7H&>&6I^\YO([`?S8(7U0.N4Q&NM]P;N+16BH@"1^<:GCI&2@DZ9W M5S\#@SSO.K"I`)]&!RH:PC!J83[XGFLOM(S_,>6@TSWYP>$PI`#!)!VV6&K' M#PN#E$O$PBQQSE/#+,](:`('DL7\4'H4>4^%=GXGHL"[\STNH6H^@X/P8-B, M@2H4C]'<#'T1*&]B+$ZMQS+Y"#K540H&_L17FO*\_DSL1I@F%7S3T"N@SX/4 M#SP=FI9+/[6UL4@$<"E8FULP@ZY^+QA!0S:(=-*/"DO3=P5RH"&+L-R2XOU@ M])AF$?'E4(3-PG3`VOD=J0OHS1G-1'%)L+C4D>!D0'-4!AR$._-`4.$4!#2BP)424,0!UG"%/`T M.-1(IK6-40_`FQM#^6"N&S"\1\!3S@TS.F-ZU5?)8BS4P,S']&X%&JW27^73 M14@H;G.2FZJX,OH=`($F6.FV7Z/[_5:E0M#2?H3J!;;X"9'+:E<;[D,;O!>9I MTK5Q&AGX-R^]I!8ZU_A`A6[JFG@:T8%:R-3AN214^)U(1]$I`)LJ*:$,HH>N=*QU#GND$Y MA\;&%EGX=\&B*.CRRIN8-<BS)IBUR-@SKYSFI(8; MD3SSZA([8WP-XDI!`+R%8H0CA'`B7Y?23=W&F$(Y,\+(DPFX%$^8M"*U3\*< M*W.'98"O%&)R1G+)R7E-`X:BGY>9L-/Q+/;1]+ME4TH;RV+UBSK`V\+99F88 M;5L[Z'*S#5"5F#M88LV/;$:Y7J4#?_Y8'+@*N%A>EON.&4EOHX\Z8JM4#%` M#W9EC3[9-44/+/5*(BR\`5(U0P",KU#YT#8F?I4;I?*4JQ`W4QM,A?'Z_04!TL=8W@?>,/\.;>E_B8@S64P&1'TYSAE>B9P9-5:DS%I^=X+U6DR,'A7\G',UF8N]QR077IW?%"ZX<-Q?U M_9A3?G,C\^>5L[W\TYR_BTB*.@C;5IDX=' MX'`)3*#NL\`6"H0/1@1Z&4F6:Y&,;-^YQMB]J"%O&JFV!2IP*F+K#K@>&2V8 MONVO>6%EC8&GR62D4]XP!%"3FC"/EUL$]*M(,*]1,A,&PC+&D#DTWQ7RHK&- MFA3(1_(_K^7KR%SZ52Z/1LU]'E>4?T<*%:@^H0?J`+Z2QM(N(?U.WF(UEAAA MM$E=6""?7NG,M MZ$['H`ZCU$^&:6#YC.4S2_E,C`YSKX!>0^=YK]U&I$>KS?G='T0B]+]C!1>W M19P&:37@B720?\8(#4K=[VHG@G:183`RE3"!.8`L$I+=5+0K)M7TFIA M8F0Y#$.X;[.LYW`F9;LR"(!PN4?*#7R!OE[3AE^%9, M*(O(D#ZQL'_C0@+KGZF@=K4_N2)B&(GFS@VP21,C5(!A'!1M@X>,:O"0'Q8U M*!W,CP&BXJXYQ!5C);8&_4FNUQC#?(REQFE$1;B8*Y"L7<"*V[G8^NO+/^*" M06_<@.8@B\40V.TPX-\)-W1>F:A`-N0,%T29"%'0Y`,HW/8-& M@@2E&D$@D1*N05I@[K7-GH&Y;!U0&^:R!,ZDBDX7@(C"OFM+-A8S8\R*\IY1* MIG>+WE7/G%COJ*%2=/1MI*K2@'E0Y`H#G0>(.![+D7Z5&_B@U;[+D`4SLM)0 MZ#2DAXE3X@I0;SI5VY:$K#2K?,L#3HX]4-C4.K&`"+%,,5593EDT!W!BWZ-T M%"HL*2_$7-_3524]GPUXPM6%;A-O=)>+K!^5_JZ`T7"NP,J\'OL\\%;#0(EC M9^T??G9(<()8T=6,B+@3,;U/L'\J<"[GT]L&Z:PC1I'D[]]>.FX`T*0X3[JK M?X=90=_(\9Q7<@2V^RY%SZNJE*'U8R,OIX"F>$#7R% M@UH+AQSR%#3DD<]:SJ7GD?TN8[Z*4@\7K*@&R<*11"F/)`9MF6Z)#9F4<7TA M5P7H""L$>=(T`OO\D.J'9`5H_IV2X>*21I-AXY3"YV24OB^&?C!QBIEK'L^0 MA10=;`WH%^JP\&QZZ8D4WDS)+T6ROT5BEPA1K!>DKS?@2#/?-"+!Q$`"[F7' M3G:+JL=#P0O2QD$),^4D9@"??.E>(FM.DZ!R24FH`L81-]"4C$Z=#,4R>OSD M>QX<[#L6)U8R6\F\>>X&3S5EV:O],ER12[@RZCS9=E\3WIRH>;.Q/55RF MO)8"M(=OB7,8QI-R)N7N'70$8ZT6TS-%MS=CRD_&J!/0CK1DPH?",0DJ?$CZ MANG^F_0'5]N#UMEAR?Y>LO\#)7*(H7.@#F`]M9E(L^`>G3JG_(?#%(4;>N7B M5%[*ZFREN"KB>VBZ5#.*GH/N=+2F8_EQ#+E*(NZRAT1N@*! M_H5>R?/[R#$+^V1:B^4#3T!EWR5=%5"Z`T*(_IW_("/D*]&:BA.@53`IGT1R^SB<1%B959+@.L):5A9+$!^1VG:$=_B"8<*+3E61XP0BJ]\NJ00WGL MJ%,3G*4;5SM"`C*RL/P@?J+B=S!S^:')FKZPU.R:3-ZN>;!MK/PK-UT(V"C/ M\=<5?S'WJDK@+`1TRC,NA,`5HXF4^PP(P)58KH=8+7;?41;'(Z/O*T+LR\,. M=\XP@/#N5*H+0$!OE><;5?T4WF1.4*5Q`#*G"4)3^EM+=]F@'4BJH(J@*EAC MMGC;(8-%3`H[(/EJ$X1W)%X+#>\*32#BP\$6JXWMQ0@K1K":L8G%($V*!%.! ME+Z.FD-UP*A@H`NY/K@H4*,D.4>RTO^ M8N(!V5##0G@G&E!&H=GYZ)WL[CN+DHDR\I*KJ`A=T^F,%:6SR@NZWA_;1QT% M\OH8$O2Z.&U>76I^@3"O;"8@=!W?O'Y>90@K_PZ68)9M2:>1)PKBM2/ZG746 M07X%J<*K,#]`]X01>&F.]VD1^M^4ODC%.PRL.7;ODA6#.Q>#&.H+L,^5XC>H M?2?.5S_^9B6BQ9S5IZD4G.\S)FY6SY(UE"B<5 M+\#%9@59`@IER^KX_192[LPU2F,`B7$1"'XC1Y[SB,V)6QL2H^5VH!*R-JAHWW\[J5 MQC+"D>6N90I3RWG@<*L^^$<$!U28HXE=+G3F"&E$\X7Z#:T(@)?3FRU34Q\V M74]I,&\2=W,8VE[>O2L]T.Q3)UFC;)*S#ULUV#MEX5H MD$[WA^(@FD\K^VM^O,QT($*IK*KG+V0)H5'4S*VB@M_2+Q9%5?:A#`TH3^JI ML#F,0@3DBXQ5GI?LI(9<$B%'&;P5(RA(RA>P?J(NZ_<8>+3G=W@0R4J6C]2. MC[Q_2+G>QMQ]\2)O009@UIDRD@-,K#62DI?0HE[G\M6U,1A,AY*`U'6IUPW" MB%(_*0C(\,O@C6%8,DSFU"] M-^+F;*9:Q]U)O^Z7=Y^<7S'<5PF3D!L5]4E'S++P^>2^TGQ*0+(./ M+/*`>)_%YWWALS9SE.TSC]0L*3%J"IA.;_&D#./+$1Y?^)7#*D*SR$,))9B. M-H7]$N$KC!:,D%>[\5)^KX)@%)37(0]YGT]&^0BR4EO>NE-G,`PIV+L0KC&L MWE->B-*XMI$@^YX4RI5/=2T3=\R]-'?(GCR]2+WJKIXQ\S;_?GK_1IM`U\QY>VW,+NU'U#/#N@05! M]26`F<*>/9JEEF;#`ES_F08SYT0;GEGG"IV66GRYTR^^_,5-!'+T)-),&@>@#/;4H5738NSRFT M>435,L*,J=]SWV\`2\(.\[04BL7WXMC!\$5K[^W3 M@48PPSM=D.<#Y=8Y-RS^AH6(08*;X[[[;^!*GXD`]WDDC/M_2Y;-]YQ_QH:]*9%WKP#5J9'(_%?:.Q]SI]4P8 M;/K`C46AX[:; M%K$">]M/(S]PR-AN7Y1W3#!K$]ZQ**+$$$R+T,5'N^&PW@GTRE^BF[6.@@"X;Y0$@>:K3L%1F5 MD:T8>_'`()&+*2.P:[Q?A%]&67\*4*M;[7;S>?_B!/[5)D;6PDUU24RH+Y\\/KS(H\L,R>8HYA&Z$`BN5>19# M2F@JA9("JRZ:#U^_0/!5D2"\5.PYVBA'$./\F%FW(LT2[5]C6YGFM3L6&%N%"$,I6E3' M++/LAEDM96?2 MP!_2]YU61S*ZGXF[ZI]O!9X6P1,O(@79^V<7K&50#P M9R#A'\IA6.)<7`F&S[MMTY0'INPJQ*@%3-NM\UXY3$][*P.UL@QCS"?*X^-09-Q])C_7#JVP7)6)JM\31KQM!S M'1U'KH'%7/,"O6!7#K3=[CCY)Y22(BDFD+79%'F@6:L?9:HUI$I1G*!])ML+ MN72_3%XE(!Y#ZU46Y03H3Y"BF">&MD!F>>J2N?!80_D&9*]CQLL94`&!6 MSH88A1Q"420HM6BDQ8NI"[!7-N&(UY/I_P.5]_]U,D#_5[/Y[OT5Z.E<%D-O M-C/B9&L=!I9ZIM0)7-CR%70WOP*$P?*)>YN?."WJ(4SK(2NLIK_YU\<.J87Z,2_/5"^EL5#U`NL_,QK"HQ!E9(6:/ M264U%T2.-+PQ,BN'0P:&Q:U7+3AO?;RX<8!A]6N^N2DVP5)S6%T:BQ%AE3.9 M)B*K:TJ?B!%LGRF[GG0!2A%C.,XX5J;1;I6YQ6%^7SCRJ1BT'-%5'E-R9.?` M(&=D%-%+,M&E4D>>`R-+YCQ_TBO5:9SUVI5C*!A(G54U9"[Z/7#G^20Z+-X, M$I..B[*Y^R<;G[@L'C]+#*SRP?%FQ..M7.)R\J'B:^#N-,\72@8X=!\,A41F#0@M*0H`VRG!=`6 M:"U8-4:X%/+E21K-L+N_IOO3\N^YC55ARGLLXMTL22Z?:U(HV$+FIJIQLN9>O M;?YZR+Q/TXU[G82J(^=^U#2#R'FU'0/3WL3L?)KW2/Z_$^/])'G_@<5Q M=L\LTNSWZD4&W\6F#%?:@PS7D051C;L5&38O*^!PZ;-ERA:GPKX8N4\M&E@8 M#\G$S2-/I&>!JH-3L%6>4Z3M<255J=^NZT_IZENIB),J$P62/Q2AJDXT5SBD,C$D/X:Q#RH; MR'KI`H7UI=B$(W=#O>B\+-E<8>]YCY!,B51O`!8P1PP2V?6$4-)L61&#RH0N MKQ=B@`6.U.W;-$WBE[2_%]V7"P&3!>UO(-+D`:O#$QC("T.CJTA66UI?W9F5 ME)T7:;BX2NFY*H6FRCQ4RCU:_(-(,$!M7$[F01IA(6*:#?MB<5GN"Q/G*`@L M#;-+C3]3D<@*5UEE$PI%4RVTB(`P\":1_<]4.9:H0$DO/N+<3N=EYBC#!HH+ M!] M-(^>@9!`GOG+L_8SQP6F.\5PPG"4_1U/F:O_OO.]9/S+,RSC\:QP3;&RX,B$ M44(PIX4D8II_[>EQ:2[EA7E6LI>-7TIF`%R\U3'!^2KQ5E]L]4'O2P]YP)C7 MLPDH$@WJ/#8L`.N\MP8=%`!W#W'L=]/S;RG&\Y/S/P4V]B)G<"]+>)IL'DU= M4=!-XJLL[S)5PU0@BEQOF25:#MM7291_I((;UEC=F+%J&:EEI):1/H*1=G]R MWE)WJV`FFW5XV5\+NAO+5#39_I%J="''U)TKP(*B2ZLL-]O0WHHHPF)CV;NJ*9"R.`NU>O^=>B.2-EG&B@1PP=2@!L'*>I#3FE:=$7HO MU[X03(]F'2:CPXD(X(.ZDWR$M=:*ATN&E;QXUW4E%6!-@R`NU.4E-1U+"*`Y MGNGM)0ELM1*95B.W@L0*DBT)DMY/SF\E]G[&2%7G13'33>%W[.1I#=3N MT_\SY=FU]'?0SE3ZJ"+&$N40K\EAKODGRYR`22'<(>MPQ_`^.4"7HU'"6=9B MC9"\9H6F!EB[)XF-/(AB=,*Q=X2Q5+7_8ICE)1M*NVV4=*18/3GXXCPKTYY/ MKNM`Y?VTRI=3;$6\4*"*DD;12@&JT?$>*MNHK.^4KJ@6CWFQ)F&QL'QW[07? MNTA]7X6K@?56!GT:@4BH;`QAV:*LFF-[H3S(0S"F#$'N6/%&GLJ41M1I=74L M*&YJ+I8K+H'L_!DN6*[*:ZH8\/(B'6@C8^S9?$$!/PLOKIBBETWQ,/9;]5E_ M7,6&,U@H,D++/^O%/]TQYGAFC*88?YCEP/OD;Y*E"N+'7/59M_K#8\"4`Z3H M'%G1!7*Z"0^(X4?0OI"!2!(QR:;IG?ZP#11>[O`H.#DJ%M?9RMHJC[O('*M7 MZPH\,%CNZ;.JE7>[/SRK1HB]QP0^O/@]AIU^$E0AY!T&G*[AR0K%7<2FOSR3 M_U:"KO-#$3[TU$\.@F"G6UT-'0Q7PZKDIM>MF$!3/@(B=?I]*QO<&"WN>N&[ M(E2]7.FGSK8UP&)`N#F']/>?CY*@ETVCZC7F^O\#W;&;H'[G,!#O`2RASE2_ M_;6M2L7=:JQIUV"=-95OZVW"XH'%@R-4:@K^C&/4<.ZGB14U',=$1*G:J.\> M?K,\[T-8.OI1:$SH>-Z/IJ0!6X;"CSW+.F&^A8KE!_4XFQ7Y0=M:3FOI'_;?K;$4WRYVAV\TYFMU7ZB"[?/"UNH2 M2^9^KX%,"@BT]OM0:>]:=)VTYN2M M/511^(;"O"C,,X_PRJJLP->Z>O86Y..>G?F/9C;KN+7J0!HK,:-U-K5E9K62 MR^M%B1VZ5?ZV,R<7C?ER0[+;TEI=-G7(M-;K73Q=:MNT%5U%DOUCT"OF/,K8 M(&[;ON25X%DW;K",Q<'B'4^D@X#ODL<]WH.WUF;JP-NZRR[.ML[9ZH&GEMHL MM>V`VOJ6VE:K'W!_SL_>(\*//KFJ6NNR8-YMO[OR,HF.\XE)3$O.?=U M,<*2WHY(SU96V,XTCZI7DM%65B"`:K2!?$UD4GM(5;0]COGS9DG/O,T6MAR) MX1DC@2. M%?%;'W:-K3-PY50]F8H7^`O;*K2U]8=4KTVU,BE4B:9^L'*7JHE.5E$*70'<1%"J"B4[O[#4-:>NW>IQ;HR MLBR+*DB=C2\KU"&4[H/08$95$UC63$0UAL%2`P`)V0(&F[/S1)8^&`;B#E\6 MKD\[SCK=ZQ9:68WT4232J6I'0P5>51<<'VNB3YBLE1-0)6U&+=^3[%?=,VNA M'D,YR+*&*@T\9`!)`T^K4#=\2J@8](M:06E(\XE(V["EV4E,E1;#%\$(= MB1P$BX>B.[T@26:5"25<8Q9DO8/>?OWP#L_+2UVL&@$H#OA^?75SW:#M3G7O M,MR$;#<@QP44#E6I+E5C7=C:(C\'*8K>RC9& M6=*HI!B#5!I8F@(K4FF&#P@_%4C9FA1("@!>!5C%+@7RPR)G:)$M3`T'," M(47+)`T2?PJ+B/G$QQH^*58#I>(P4ZJ+`[!(D8^G$5;7HEK7HU'$1RA>=-6M MK+TY*Q3U>=YW`+:P]'"IC,3*/M1PBE9*4#$[@&050Z,X*6R'M@$/Y+#OZ2)( M*':*=?KT9&.6M]F=7W*O=;KA1WT+&J9*(_QG[`5=-&/Y+O MX\('V!E#G6]C85LHH&=8*\A8&CJ^\V65=_3Z^)8*J"#:D8Q)`R\.L/9%V]^?RN;0>`0 M`36MD"\UL#6$,:;#$NJK)M'>'.(2<+WRD'*ZR8002B?/;-4VLA`B.A02G MM$8MJ2(NRQ=/TP`(M0G+;3C`/N():_)PC'J,Y\`"))X!_.HM6>K(<6MJSEE( M[WR:7/E%BOL(1E+S(S'G];TFEK+V2EG;!;3M_%MG-9CH-I!*E:J2+YNU^OR. M2UW,Z.Z+2F].]MBEC*-X5OU-X5FC[%O1>V!X-]2=_FJNBH99,!:[MA4-W9;S M85CT%V!C;?(BJ-ZKF>]`[FR5IK\2$*@DF+O5/7EQ<:.0U+1-&/KWFOF%IJT( MW`B!2]9T%F2)1S3TO^<'.%QHOEK9T]RV7=TAQ[5ZS4%,<\7!/@::_C*`\R%# MP^HR-:&X;&>V:GH M!F8.G%\YMD.=5?HFLG%]U7DB%'<%7SDI(2&L#;:T4F%< M..5]=H?4S)884YQ=>*@*^X7E&]LOG?@?X@Y5M@:E;-Q['L4E8?B+H6_^ MG#N`YO.S=KL2[%6#ZCE\]^N*X^`+H94D@5<4O;B)PP--[W(B$;O2* M-J]-N(E,,*$Z6JRASN#8T!NLP&U6](8_U\50C6@`&J#K$%5^#MV8XX/-N MKVP-\N=(JLQ*/=9.\XHUZ+.4?M,_4T;WG5J95D7E#82UGKLCDP;I23P^I:4FKRM"VAXJ-_RR300,\YE6`[>UNEO'-G)4T1QR_D" M3\II=%`5MIX,*9Q%OQJ;R4;8%\<]'PQNOEMDJJI%"RE%[`PA`5&,>KKU&=4R?P1EM60%W7%I?+O M4VRVF?!0177)"]KL'1JEY;SA48)J2,6NR-U(Z]3K<,<^G)A6N#`0"!O1Z4`P M.J0$_6\5KKH_N&ZH0N!VWND3(F[K7*41Z$X`LRLX(>>%?.^\VVW__.[ZZBK[ ML_/S2Q7S1BTQ4!$*I&*5XP`@Q52/)G7_>`SV"+E'ST^RGCSD:%1=:)2_,=3; M@O$02@]NX&)9OF7Y]0;U3EC^#9F2Q%::\B[`-=0INHH(8V[:ZRMPW33$N"*3 M0WR]_BTN<(C5//R;`$/9KJ4=S&248;M8TYBLXTZO33\_[W5Z#2.H,JAVKDBC M?!GT4((AS^;S,@%G0RAEH32F\Z*DVQH:K<_[I^?UYG^K1!;:N]LGS'X66WQZ M*LH.M0=]KRG)R>QW"Z2D(\=+[B0U4>-O,2S<]:?<-9P7'*(VV9]M3K4%5ZN6Z^O/F7\^7JYL.7S]+\.:NG"T8VV<<$B%TBTM65JR30=LTX&-@Y+&?*<#/2E)]@7Y M@DL*<#U`S&]KQ1ODF@=9KVZ'561.6R4\YY+4VV3RXOOKQ MM^80[V8H3U^%`7$KR^JVZ/UP@W;K_)"[95E)5HM%[TD/:YV4N/R/`W>M%58$ MUEL?`W1#SYGY/%BGUKSE`$?,`8Y6C[6(:Q'W(!%WI0KH-E;3QFIN:)I'Q&IB MEH=./<$@0XJV])PTUN5O7V-`0//:'8L`YI@(CP>RQ&U6T.8V\PT[+@O<5(9% MRQ&8$_O?FS(@\%GPRSKA9%UXP*=SFFK>W;`C,#>\-5BT?O!WO/35IEU=QS(:VTR M&V9IN<%:&FV[>ZS,P.+NL>-NYVAQUUIA-LS2F^<<?J=P0-F!G[IAVQN3.%E<3XGM) MQ!`T3006=LST)8$;Y?QE?$$BJ!Y_R[G$QEY&?+`>WLN;:$;8>2`&L\F)>73K MNSRK/:M[:E(<3=9A M+3?4O5:3(;QL5H'6'"3BTXC'LBM)WB4-R0U@DG?U-0G7).T!_)0FV`T8H\`6 M.<[2^;->N]@0Q4AQP!*M]YY/HQUSU0B,9%G#0UP>FW,-&"3UZP8^LA&/5!W*TI%\7MY$YQ_ESQ(W M,7*>"GVWC?&G\`^/]0I=,9E@RQNY4-F%2+$M6&[`69Q@!R-X3S727.1!J=93 MY(ZLGF"9Q.$S";H]?H^WQQ_T[?%7;)GU4$:!U"BU\O)K:>`#>>>&HOFAB"O/ M#91YCXJR_/S:LS M`.H.$V*[0V?*?&P7C1G*\1@6H89&LBR(8U2^[T!?$+(Q=YCXKC]%7C%E,]GO M>V$(Q4"P%W',.66`#M,DC>89EZ5"2X6'1X7O133D/J+SP^D0Y*RI#8,RS@JM MGL"`S^Q@)<>&QK1HDV/?M$AU5[NOI1WFYCNR!Y2(M;M-=:Z:)[@LA,@$L0D#1)_"L*"FJ0JG`8I0XU>611A/WMJMGOXO0`M M6M8.+=^FD;YX,7K65;;(:\#+!<]*H2"+(#[JX.R35WRZ"#],&WJ MT5,70@T\HB-2E+]GQBX MWZDXSEKM_0KCSZSJ8E47J[K8B4IR..6DBDJMHF2GJ8<^=OS:PG%-\P`=T![Q MAJ;YJL.&GSS`W\#7$7.3E`6UVCYFOSDO_-#YWW5+55MUW*KC5AVW#K[:3G,Y M&D5\5%KIL2[<=T?3?`#9XX>Q[]9J\UCP8;O^']M78ZU+[$.MC/>:PTR4G&8D MS:^!6&K/M-15T&I/D0#;UDMVHW]M9%,7#]O4MJNBGW0:W?X.^B/LC(VM=UBK M,*,C(*,]'\?S1Y/,(DGL=@?=3NNT]V2IY%`)XY$68CTW9=&L;NNV:'8X:+;) M$MT[MU)D@L-N>P/Z4=G%DS5,K&&R5C^Y!YC9/M;>'AJW]X1IT[=.+:J@>Q_ MU75NA+(!?*GQT@X/GA:5GS0J/U!'V?NZ+5Y8O#A.O-B5A[Q_#'$\[RAP9T]! M//W]FRT/]Y7#XAU/I(.`'Y.SO&I7VP[CZ9\T>KW^QGG3(9['^I3)[K"L)_-N]=K=%SK4M7*LLJ25:UV55/Z.FEU-]\,_A"/S9*7E5H; MVTUS^S;JPA5*#6R1W:6@')/IBMT;N$?E4N>;.EA3MLX\ZTA5`C1ENZ>;ST@Y MQ).SIJQ5"C9IREJJLKKVX9S38=&7-64M>=7AG(Y+:EE3UM[!KFC(AV6Z>6JJQF?3CG=%CT==)J6[^0 M):^]G]-Q22UKN+ZB[GAE%IAMJ+UX"#=T")]YG3LQ;A"EBM/,]WEGN@PJC*[* M@"*!I!S;?II=/F.SS6=LAF$[+"EOZNFRP$T#1G?>,74"]?SAD$<\=+DSX,D= MYR%]K?P)W)EBTQ?=<#0%Y(B"&05]&TO`GP`/OO$D?URDD>.*R42$:LTP'WR] ML"K;[GNGT]C^PS6ZT-]P(N.!LR_+F3I?GS=VG-M]?"+_Z?N#Q MP*PA>:Q^,%OC>+OO@\+"$:HQQ\/D:G6*NKVA0RT%2]HA[Q>PE<;3PVO=KVS& MUJ`:2XF[H>+^KY[5^-=,H'ZX(#B21B6'R*WV+!^.:YK/*:KVZ\BZ*OY\/##9 MT31?[LN=?V(@OXR7:UP'KF15;3TSKQ=VO(/)P:1_,H!&U\6]FSTPM>[1FI+5 M]*RF9R>JT43'(\_M-/6=9K-=M8]?-[73/$2A?V0G;XM6AS7-@[J'VT/>T#2K M=RP_?I!CE_1:[1L[ML\VW;']\*W/>U,E=FR*/F+ENS%"C^+>^?@FVC@*'A4G M/JYI-FLV;4<$'2'8#\1>L>>YXC0Z_N.!P+6L_7[P4E1-WOK=EIZCO-1H.^+"K;:39T?V3QZH"G6>5&RQZP=0]9]]"3 M=@^MW@2M3IW)'U_[<9<%B5L7[27K/?PN\*L7\=[[.NL$W(-"Y--6^RDA\M+" MOGM?Z$%"MU8H?=(X[Y5H`Q:GZX8>]89NK7#Z?!L]Z&L(=*MO'+F^T;>(;!'Y MJ%CS2:/;WGQOFAI"W:+TT?/F\_.C1^15VRH>WL[JADZGK>[FFPK5$.B6+SX5 MC.YT6F?66V9Q^IAP^N2T<7K^E/BT1>KC1^K3UFGW":&T53V.'J-!]3BQ7@:+ MTD>$TOU^X^3B*5W469P^>IQ&-GW\%N)A!I@=*$:=M;K'CU&623XAE.Z>MGI/ M":6MQ^'XH8M2A\12H/F MT3L[M3AM*T*'U$*(V:1Z=G<=KB]/'@]--@ MTS86;:<^APL;A&Z9Y!&A=.?DB>&T=3D]IW0C;''Z^'&ZW3JU]IG% MZ"/"Z(MVJZQJM47IFF%'O8%;*Y0&Q:/SE)1IB])'C]+`I;O'KWC84+3=.1RZ MK2<5XV!YY-'C=/?\Y&D%.5B'P_$C]9-*?;,(??P(W6F='+\B:_6.IX319_U6 M^RFQ:8O31X_3_:=T<6?Q^>CQF7CT\=N&-@QME^Z&T];9\:<'6S;YA'"ZUVZW MNLD^A8+7%Z2>$TTV+SA:= M+3H?#L1M\-FN<&GE51\^4MV++S5>VN'!TZ*R1>4C@:=%98O*1P)/B\H6E8\$ MGA:5+2H?"3PM*EM4/A)X6E0^Y)`R9\H\SP]'3?G.3TYW^GW?&WX@KM5T*QM` MP)KN;/E.#G7=!WX"EDSJM+,5K^@.G68&(O)XE"U[$##W&R[>B47@>S\[=1.K M*Y'/.ILZ(HVGII1TO,1SX"=@!4Z==F;)I*8[L612IYU9OX%+=NIW5J]39+/E9O>Z3> MUNLV3OJ;U]L.\>36I2KK6;`"JEI`=5NG3]0<,IS)KQ(&@,_^\OQ;_1D^:H)S M>9CPJ+A'/_3@VY\73_SN- M$W\X*Y^_<_ZX!:QU"#=T")_A$+Z6'X+\XH[+608B\&H\S5*4*DX3BFC"`CG1 M9>R(H;.)ZKN$D8QYQYX[%SO-.%Q>2B(0%3AI& MW!6C$#;@.:Z83'D8L\07(?P1)T[$`Y;`+XEP1)K$"0N1+ATQQ4=B!_Z$(:.( MA4GLW(U]=XSS.&]@'!;.'/Y]REWX!=[.9G'$+2R2.5,>^<+#A;1;9Q?.C+,H M;BT28/4?AT=VCYR_CN103ZK+I_G*XR3R743AZP3@[?P6^DE\W&AFN?L^N/L- M\+VA"`)QAPR2-`0G3B<`9'@[-MGBCS%PW5M`3$#*K]>_.#Q^$M3H^**!V`RX-`Z9*_/&L_H[_C*7/UWTH7 M/6_GRNA#%$B<+P\UJ%3J3TYW'YU321>'%VCTZ*VX`@\?]M)]MK*5TEYBB.4! M<,]VCN/'-]$NL&7)-'5:RX:F^9RBZ%A'8%1)CQK`9)>`$\,#A]/UF$5\F;IK MK/MPPP*MG+-R[G`FJ@M_J,E:-C3-'_0-6$N;$'46%PX:%RYO1VMY$^LNR7>T MEE_1E>N\90D_<'B]9W[D_,Z"=-E&K/:S1K6;5:+4T M[(Z'TIBO6!SE:NU0J+-VVKK727>Z@B[W>* M*=R\O-OU!?BFN8][HGNZ@E?%NBTR]W(QX/73JV?,I;$,@[W8' MW59_![<#!U2`[1%6:14Q]8]!?JM;Q\9BM/_N9'H-,BT/+<7W2)/HN_U^H[,7 MSE4/''PBA'38IO5N<:?;ZCQ1>CBF['>;AKOS:7[3^8Y1GH\;4SXN2U;1=JK_ MJ'?$;MW/!:<91,ZK!P/:)B)O9YI'EYDH$-4FYBZ;"HFU48RV-\I,]$].'UMG MXNOU;W'CP84E>JWV^>,*2^C/?WN5QLT18].?7K/8C[\,KX"1`8[3#BY#[QJ( MP1_Z+@N32]<5:9C`ZJ]$X+L^CV^`)EXC[O_]/__#$FO-9A&X:1?"M?9W1=:[%Z4X4Z4BM)6<<&EC9>G@*Z2'=]J; MR`_/5,%$3$M<'ZI`EYJ%9E8<="^PJAU'K/LT%ZW[-.G5N$VE_6DQX`"F,3CR MXQ%@)8/+:K_[U7ZKO?7H?.]VNVVJI2!VG,?0G! M++B5EERW*]TCC8(IA+94P-%V8L[S7KL-2P),YB/?A<5H@00?Z:4A#(V6$4.+ M`,REQ$>->`K+\N-81#.8.X&GX.\BSC><#Z';:J!U%?FW,#Q-B],G8Y8X'K_E M@9C&SH1[8`0%^(7O2L8:/NKC:N62X"OX#0;D"8MF5*"037F:P,K3 M`#81@QT%%B%WQZ$(Q&AF*EC9IR)I^C%LT4UC@`9:EA%G:(CE2X#!`_\O_&I^ M]D#<`:HG8)5B):XXC8;,Y0X#6R[&!=VQ6^Z\N+[\XZ6Y(`>9@VM4]?+_3'G# MF0*`0CJ1*4S!P';E(8IP604L0?:!\$;C%\X"9QY&'-X,W5EC;B$&('`).$(D MTM$83N*6X=IG.$0LADG#&0;\.YWG!.:/?!:`Z>R';I"2*1U_`QS`\TA@:EPE MK0E_P1G1"&\X`P#8-SV#/D,`STCB5^($^+GAC`%1FZ-(W"5CI/=O8&N6'LXE M`&=**RR6/YN"]1RCS<]9+)T%0S_`&1!CP+@?^P,_0>.^^-I[Q-[SYK_4T\*D MC0M)&[1#P`+8MXBFR-/A071)P.8',YAR")]#EQ]YI4G+K/=5`C#'UB+W7>!3 M:W%D8IT#]&0YR!O0BX[DR!Q$<'R]T_X!'5_D[2*.A"P#*2H,4Q8$,Z(+X`LI MO%H@G,X)$4Z_E'ZO(J`C?PH,'5]GKANE,&:V`M*4:!>T2)8F`+$$!4`PT]O! MIX434QTB7.@U<";X]+K9<:X8[!:')Q[]QMC^%=%IE!7MA/>*\$NG0H(/MAOX MN`CA"-=-(WSTA?^29*$#!QH@DWTA(LFYHI<.\%DJM>B'+$0_#W*%XMCP\`N? MAHA9P!?F+@74!V"MGN>C2EB4SA.60V*Z%C3GX%99_0C]9;;]Y:1YYC+=CZ@_FP M+=AKU"\#YTK<`95:`]9B]`X-V'\RT$%`D^GTE?U:)FQN^(@%#2?F78FH(-5" M$#3.QX]OT.Q\`R<,JE+H,R?P)YC6!_^R`5ASR4Q;8`V2JP5,5V_#R@,JKSRA M4LH!NP,Q53V0\T*NZ[S;;?]LCI=]W?GY)1I0*+D]*:D962?R1A.7`8(XB?Q! M2E]A0,+,]N;]$QX]-]T+WHG MHL"[\STEM#)LQT`KS0U*!TAC./([AC,GTCU,P6?58I@T)VT'E)(,< M[EL6KT9MA.YPJ?BU(!#$Z10L,/RFH5=`GP>I']!P^)``M4&^I;8V%HFX%0&L MS76&;`!*A@0JV.-X2+[R*LBGARR:Q/+OXM6`1W5^_]2-8E(C*EW651G&*&*#LY%7PK^$0 MG=%],/T*"WO>S11EL$E`U1OCB$6D1*/<';-P1`8+;H1<&]]]=#4XW9,?'!`_ M(=@L;J[/PDOF(,OU9KDT\DX8725,6OQ#?6G2(2YVX80(0]27GUC(1M+E].MD M\`_D![]R`%5X'R>!0:=I!%N..>UV!!`<:5OK_*1Q=G9F*.?%\X-!)@#,++Z) M7!H\:W5.3)VYC"?"L'K+#G(L-0QA+IV#$>PP%>)+IH6#F^ M+]^&QV,W\E7K%X7VJW"=C#\7D/G/%&6Z3P(4?_4CE*C`\H`.35>=YF_#-`A( MUR41AB+*`T%)UZT-]#/ZDA9EL-`=1B%E3D7E48Q-5DF.Q(BCA,K]B5I5Z:I( MQ'J34AU1K*:AB!;2.Y_F*X_3(%%./T.9^#)5"EJ]V_`N=+1EFV[IQ"5UIVI]&_:&]@X;VSW@;(=*MT4DFHBTDJZ^2&9$DI M[^65.`N<#V&<1-*R=M[ZL0M02@%F]V6C9"\;[^:O'D(BRC$DAUAEO9;3G.PJ M-<2>?RVG*>6L#VW@6L^D_*,ZK^UZ2ZR^O*_["Y=%T8PNGB>8HKMX.[]SA;5B@Z-;;'#D>*F^)(&OY"W\+<>;YS%>;E#4 MIY_,6LX5Z-,4*OF>#R*ZYY!1T^UBS&(,IY.'S/LA19J+%.S<0`P`-CKBV[F, M,0*5W+S%$>[HSF4J8ADC(&^.:2A0\^%P0D?JHNXLOU=&`[K\HMO0WQU/(`*( MQ!GC(D%5PVP$V&WYT9%5$4^YFTJ8X)TNKJI\GO?S:TOR."EGQ&!<.I<7:#3P M^*5""WE_)0\+H\XGW'FASO%E0]Y#/>^>T9O/3T_7\D3@._)X`,B8\$['6KKV M+^'B^\4S&3,L3H/NFOP4,N!3/`!3&?4Q*+K.NS02L4-W_3.UN[FS\RO`N-I2 M^IW&6;^37_.;6?]W?C*NNC5OM]IMQ"T_HH`4GMQQV-`_4X`F3-13(4#:.81? M59WU(X^AN"6L0A#AZQAK0LQ!(@RN^50>?J_?-\L/AP,1F.! M+:U&HH$6C5FP!4UC%A."Y*^_M=O=9^CL!.8=Q+\\^_#Y_;._-]NM7M\TVA^X MCD,!3SL#3WM%\'3.GQ!XYETAR\#3:?5.GQ!XVAEX5L6>T[,M@P=9E1P)MF\" MZ#,GY?*&?7\$L,S1\\%AZ"]#&'A+/*G3.KVH@MJ#%G3H\%N3:0'/ZEGX/9RK M=5KG%GZ/8WMGE5+A<0!\QR*,%H\)(O138Q$P\R#1+\$[],K<#(]G5[V3?+=+ M)MOM3M;7=MIUW!;Z^#]A(K]GC_D_9 M+_C#\LNP(2R%_^W5PIO93&]4O;CW0-DL.BM M+..P9`G-9KO7['7D(JJ&R=;S5D7DXB'BW6W96O0S\I&5%X*?FIUNMI;287)L M`C:7S)P_>!`TOX7B#G,16"PP:>,#)AA$YHKDP_CLO_!1_:1\!0OKB=[0CZP[CKF7I^?7V/.5ZYR=)SKA"5IR3K4D]F# M\KGER_E?'IOK*1]F?EFT6.<-%C`1T6QQ,?2[_GGY&JZ!F''`?)?*Q6*NK##F M_(*NTD$`/.A](%BRN!SY*_U8LIC>/(?IF!RF_>SO)^W3TWZW8R[&&'%^*5_Y MR,?B+G!JG]F$+ZXF?P!_7PZ=FW>_7GYTWGSY>N6\>OONE;F,XE`+R,/178C7 M61[_[OR+EQR4>H2>@`>6+Z8-_[OH==HG%P6L*0ZSL!"9:D/Y[0TI-6+G2^Y* M+%D7O4$OR,>-IQ<6V6UW42J81]B;.\+.Z?GY>?NLL.9[IECDE";K?H^9?V6\ M,N>X],AJW++()^>&J%R(XMQ+EB*?6G$Q_],K6XHQQ.)B;F;34J&!WR^?L--N M_D]Q2GPOGX5/(SC#/&V%39`[_"6_:.+=7&X7Y/&->CW)B`4_F6.`"G!IC%"N M9J^G514X1;,'Y/&W5P^;MV:[OE<#6]CUR4D/V,*CMW[I_IGZL:^S0K'N$X\2 M610%+_%D9NQJ(##&PC+`YD-M!4%.0%1E M8'GX*@X",NLAS-E)>Z.0>9]?O#,/(SUT6GTA[U=?S15@@*_^CF]>9B]^&1KJ M0I8?^3A<:!H4LNJ4>]W>>@?:[/4N'K'!/R@Z!!#U\A;.=L2UVI@[&[RBLX&F MT6^IE^0[C_)F]>;W!:JDL:]5)MS'GN[U:Y7MZ;S^>[J7O`YT3_?2U";W]"&4 M*3P8*"`_?`@S]X)J9`"O.1^-2*;W][C?"UO7@^NQ/X1OS"AV&-<8MMK'_5B& MVNL9,F1#:SIL`*['LKN=_A8!"(J?R[FGH'*-5?N^#`&(8'./J!(>C;L2N/10 M.!(.]&68#Z/UA,WC5_>L=Y:#YX%KR)W";(J9IDZF!#M?5=B0A(.A-,N(-IRD MO-D(K4>-EPVG1J/!S+&P#PJ.9+,];+;'X<<:/WB:4YOM4<^#V=$TG]Y]NG86 M>7"T`@^V.2&U/56;$U+3:1Y7FS(/%>^<8G1S^[P8U\V03K'(H\LC+)'<^*3N+`;[]^>*>R,4I'H=]Q#"K83T7`_5@DD9B"L31Q5+\ MJ<[4P(X)6.B+3QL`?OBGB045/4RW4&DI"<;^CV4VQQT;PFX:*F"?8N,=TD8I M(KW;_JF#&00345'?CM:'N2*J.B064(#G5SO_L@.=^&XDFE3@&OZ=<,QNH'X4 M\0PV,RD6'"I4%D2F7:SN*>N(85\&.'\5K3_DLH)Z@RIA(F2#6&3`X]]=1KTQ M,A#A;JA7@J?:.;@,54HLZ4B_O?UZ^4E69@<0D:,U\#)=OHO"1U?U'H@I&M499'5?TK&EAG$X,%X@0FQ06\&`8Z MC0L/X"7VW!CY;L/Y^KYY[5_)$TLS:FS/>P(@%8 MHAP,B6#MX7[*5>*\@M(GL8XL7@)4W"E,=*+1YS-*AJ*]F.E*"3;:Q8`#-6 M5?;RBK:?6>RQ/S,=Z1,=L?YQB'E:+TY>4C%7[J:4MY5$C"[H/38#5)A@FQED MN%BX5:6TO4"*!`J4B7HO"VOTX%E;A,4J$!M7(#Y@]]HP5/T4[LJ%=D&=6%06 MBE6D0V*F`4JP%$@COY_-:FG"5T";B-99J1=,4QS*2L(H@W51S;)QZ.#CN=8Z M6!(7*8PCLW4"(.40R][FY3N#0-R9,^K"N2#Y-,V3+I0/4N1,#95S-LTZ4F!M M:&K<86S,J&>\V/'WS@^"O"2OED+YE34I9%BI=SCT`U]5ZDVH\CVI7.7UG'#1 M4BH2Q_P4M9Q?_6"`W3I>PWO`.F5"9`0\"`LX5]9L'NB:S5Y6LYE`\J.$.(Z2 MS;/6,"#4HXDOEY=U/6$#$$A3+01I%X0^U-2*153H^=+SO_/0^9VY:3IQ;C+5 M0)X%/AFG@YC:3B6RTPD,<#7D_A!12;V&!9.1,6\L!]!:GG7J\6&EQKY*$62< M3*8VH^:&7-8E.L=^:`)Y;NR\H)1YXHO+,T5B".PMNXS(-:[B$U_>2;_K3S,3KL&ZUYUK3\4\ZR1R!B,X"1']\NR_79?SX;#D>FSG%";%Y`Y)[$;KT24ELI==$ZG+PQJ3 M6IU0]/G#UGI1OE:"_?86V^^>/U5N``9APA_""_0.E$+0E(_\Y'2GWTMOTP^+ M45Q1I^%M<(F5X%9C%B)#.[)E#P+F?L/%8W4KWU--\VJ$]ROQFG4VM65>U&V< M]G?`C9P:XM_F%9:=,JE=VPLW(J%4P6(TGN59EF?MFF?U&NVS4\NS[E.K5K"J MMK?J0W__[/OAZ@,LWO%$"GK7+O6'QX>4K+69 M+;.F$\P'VH/>4`/$LZG4-0UHMYE0VYGF$3'MKSD`$Q,-=0^IH:PFFXS]R,L: M2E%2-K*V=7H[`Y,<@P"CA@$WS MK*=BNJNK$AKSK"29O2KSIN%QU4`O[U7G1K#OZLQ2.`0V4CE8:HC7.D/H;98A M5,PBHKQ)WZ.!U+2G=8H9:T$9&;C0]HL)@EATJT, M`%_,T7)%&E"3N4"$(SAN3/(247EN^I<0\SYA@$YI#T*=HW0W!HC/''$74M+8 M`';FLVC6<*[??VC(3H6^]@,WF]C)'3M@:4>%'$8US])4+KFKT=Z-Q(FN$ MB"`LSD)Y?W$LL&POGB!FIV&*6B)_PLPZS'\9I#$^7I(:?=%NTY.G)_`A1DJ/ M'6!A\83)"@8JLQ_`BTBG$9ICYP'.;JE_(:C-GZ[I`-7#DI4`!I5NJS2I,\=^ M8EB$/`T#">";=*(@D"]>5M MXD6QP8B8DZ50H,T,J$C\[#)+-J82&RJ)V%AKJKAPU1JN3`U!S$"NSII#&-.8 M[J-*G[Y<*WWZ!B8+%O.G=9I@A*P"ZQWXB\QIF&)-$E6((>?VY9*+F*XQU&2` MN<4%1F>`0Q]T)"5DMAKZ\B;"] MZL+9-99DI8^0O7.3AEB6/X_E=-2>RQ%?*C5S-3P0="FA)@6O0I%+6>)3A-B/\`."\,Y&LS3;) MC:F6$+"&G'+I]YBJZ$BRSVWH0TH2K^/)[8\0=Y$./S=5W6K>JG&KJMQNX327 MW[Q67JZ+0!XPYO5L`AC>(&-[N(E%&?"^.#V[6$8I*YU$E5#;%@BQ M:8@V#-A$I+)BVO/N25NR:NS_)JN-Z6K_*+CO1- M3R,_T-\T\-X)R^CZMSR8_8P/'*"PJ$LA*,M"+0NU+/2Q+%2Y^48&(\S*&P,_ M3*?(0579XPJ>.IAI-G>B.)^\[]0E?S-/QI1'2*VJSC##&J&NZM0BOE%W>/BZ MW+.-U4"_N^H.\?DI+2?K73CG9!61X5CQ9%EJ#+)BAJ+C#,_#&:*R^ M5K4P.RM70*L1B[;ZO!5&]PBC?KMU8'DEPL&#"P94?L* MO*9BH2,C6?!656AY@#7B`Q01],#S<_RRH4K6+\@XJC@]X,[)#UG81\FT)6+' M^G>L/+#RP,H#*P_J*P_.R^1!I[V20(#GV@M-BN32\#-L)H%]NP:74+NCY4Z# M=*X/4:>]AH0YMQ+&2A@K8:R$L1*FWA)&"I,%$=-=3<3T-BQBUC%BY,H/]?+! MRADK9ZR#W))?)7$`:B)]?]6NN=O&`3[0X2$5^;=]P5=]GY-;1. MKS':4;&Y^J7\Q\YYU*(`>T,@2HSC9!NX,DP=_IM MAP0AG&4DOOL3V8+X^8GN@1WQF-H8Z[BO,_EV9?(T'+4;^5.S[D&V.M7G%7,9 M!^*68[-Q%/FZMRLEQ\-C?H3-KP>X_B''MN-9[`5FP%&AF(6A92KZE'IFRUAE MQ)NA'\C6@^^^C_V!GP!VMSIZL/>`ULYY\U^JE;-Z6&B,ZNF-/IJ+WLO&+!M] MBFSTID"EF*"H&(-9(T27HP"\'3,O:TYH%@V9*Q!`0[J:5_7/NPL[6D4[KEYV M18TA3%9%11Y&289(5;JPQ^>/;X%<=9=>6?9![<;CMSP04Z2X6QXII@BL1I=O MF'%V3WMZ`I,L1`)0XI@JC'(EC3$'F&"0!TAYXBY,TBC4J0[%PA!J$)65BRXM M$?-L:."@V?*R8%HX&)A$XD!^DF`7CZWS*P% M/@!PM'E*D&':/ MEE503+B4-Z..L[(S#N'6A#A&505SFX@.G\&32)1;&\>-8!*DIDK,>YF8U'!D'R)P!"[]%Z321 MY570HH#?J]2O]WP04?SWA:F!Z6.6Q6ST22%\U!GEI1ADS1J`R_75#7`T]"UG M'!'?+`*T=!GYIVM>T-Z05>"P6,H@C!FAO5E'9@`LZ*[>=E(=!5]-JZ192%=/ MLSKCV["/E$[(`S$JD\!_+\RX"*H6K`99Z5><_,XB,%%\W]-6Y(+U$ZA]:MR#88 MLTA6')(P>@],R>4-Y_JR6*'Q1UW%K[E8Q0\WMU@P3M>A>6`Y/]+0YNOY24U= MG94Y25:'R#A2N=-89&7=^'16G]ISVMHL$/;6J[T1$%8L\C97.BTSCQ]5 MW$V:E`Q=1,#%\-_(3P"B""-5X2TS/;7I3=02:V>1KNQ&'BUC'O2\Z+*?F?"` MC5C68UG/=MS%ICQ$48E\90)"T)B42&=UV=3`@`V59]O(KVJ>=_.OL^". M,:)XD[XCSHC$2_\&I*`[HI87OQ$#DR<@\@7ND%E0`J:BXF`R<3M0I\ MEL`M@6^%P(V;T[B:?+.[E?OD]=P]*PJJPD4KO.]':URUQBEFIV>*"W*!J2_M M)$G!8P;3##A(UODKUUC>N>*JX4.W6`RDL6C3X(5L=A.;F:X=\](:MU,P-$$7 MXK`KI4C-*>CQ9`CUX`K4*P[X4!N4?E$Z# M7-4&H>R9]"'+?P.:=*B['>/?C M2BMKF",4-01=H-)5/F;R+@I$/C1"T([!OJ.D!PQ8@.Y:)QYS`DSBO.4NGV#8 M6L\L3U8L=2,]I[(2\4(=8EMX^'#8U"[R@G::_9-]6FRPIX;>4V?:=1N[[GBU ME1BV:F]&5^"AP@:ZSY8V`E1+7M(6^5F-&KQFC"<&] M=&Y^-,99BK$4HRDF4T\LN2QOMUP?&K(RTE+\`RD>S1!+[)92+*582MFV6*R= MY-O^@C9'GWM?ZT-Q>/\KKQLD[:EO?>55'*E09*("UBL5HVA>+!5L%_L7;+G[ MO.)>;.5BZY:,GB(9V5-_BJ?^$.:IKQ_.3G_8.".5][R[X:22;;HNE@>)51D+ M698MBWW.OXP;,%2BPG?%'=X`RM!J'5B,R=_RFM03Z2`9I@'=)J:Z^9%J=W36 M6?7&L!C$M`;S+M9VJCB\S@_[IYGJI=657*H7?5&^:#J$[:VZWSYY)%\Z")A; MC'XR&'UR4>)Y.3*,?O)"][-(N"EQK7"K`UK6C15T3X^>$UB$?DH(?=(]/WJ, M?JQL6^G>[6`%WU7$*0LN*X.5FYK4\QPS;\B/MP6)N.=(A4=SER6WE4[=*&$E M[K/.IK;,G3K=[3.GG5UR;D<&6Q*JRZ9J2D+MITE"!:'O#$:N"$3TR[/_=EW. MA\-GBY3V8#6@?Q1JP`TFO^O,FGL27G:G!/3WCT0/YV"P>'*Z!WR7+.SY=CA7 MU6:V[4GN]_;`N^J!=I9X+/$\3NXW.MV+ITD^%:+_;NPG_-GR`S7=V=O;P+I1 M\M;K=D1>MXV%!,/:7=@\VXXPZ4 M!1LO2OF]@;)&-=HMB$D;ZE>73=4SU*]W_D1C_2P-61K:T*[.3G:0#U-'&K+Q ML@^)EUVM_/P.=8$:A%_9N+]]QOWM1PFH!]I9XK'$\\B@V?Y>\F5J@'B&_']% M'1_*9-5NJJ[:5GX'V9GG@^Q7$\*@S@0>&L<.#[$7WT)EJ6+7X(B[8A3"#)[C MS=TU4)6J3J^-+3.'V!Z=.MW)?KFNF$S\.,:.ELHC4VAX:XYP?N$,83NRP8T? M`@K]QH5@O2W^FUN(J#4JV^!,NN7=T_T``0!HE8^PK&&$S3O7>-/)%!*/' M+JB%V*NS9>!Q]DG!*&83>(/#*]X"++A_"W,][_?;F=M%0[>@S(#\_[>.`0Q'!(8;*=P6/&RU$X]+%2Y57`Y86 M5Z'P.G=P`L\[C5[_1)88ZS?.^V=.UO9YC'V7\8?ER-(N7PJ.(C5P$MW=,UD:3?:,YK+O)(`PP/;)>2/5H9XF'.5>P;DS`2)*AP#5-`+\]#AV M7VX@X_G&Z37J\LRC6]\UFKD2#AH[R%M7ZT/CW]TQ"T<`1`\YX21KU8SM(0&W M$O9=K\AY,>`A'_K))KK#UYGK=\\LU]]//[:L_WL0BP*GZ35.3MHY[\WHK=M3 M)09-SOOYXUO==;R4YB^Q^SB/L_9O=YS:H0(^`D"0`3.(;ZFTIKV0NN!C-Z?S8W!2PS@I.`YPV$#!'UI\]%U6Q MJKAXWH&=2[&B>`OPF[/3,T>V>)\3:*6K>YM&N)$N=\/= M,7PM1C/G!4#I)4QWQR+)))&M9XWD4I2-V)76`R8MV\U/TB#QI["(F$]\[&67 MN@G,P_],_2E)-H-;1I)SL]$H`G&6S'?N7FS"W7<`F6'I8>6A:CQ5.H#BZP05 MLW^VWH$?F7WQ8#NT#7A@`8\W-&/,$28XC6KTO:`YE4[TQ]C'\4BP^I%\?PPX M0&V)U>$4U0S\-82G9J!2F4MCB;FLTLFNJ;8H+-@@5U(G4CPTI=3$LIDY\8,! M7YEZM/86!!GI9&(5L$>O-(-A.9_`A?E(^8`=+@?M(,DQEK8XB'QOQ(F;.",V MA14F=PBJ,7`W1&*1CL;3-&D`B,(F+'5([,YQQXBT\.&6`9D`N\E(XL6;W]^^ M)/&+0P`N9B\UX##NC#$=!O:>[SJ2JLPA+H&4*M$H)\M,(Q&WB!8GSF_72NX3 M'\2QD)[SO[(`I:(AJ]ZK;;O5?X M\RM\\)EZ/IE-X7D8F[2^9S3X_/#JT8`->/#+L_?JV^:'A$^:G6=K3*P'+$X. M$@@8B(O?3@*8!9LF\K#YV_6SO[\%BD&-/Y.2>4MP!DI?,M_K$ZD@='TX93`( M$MF7_&^O"ILI[!#@J98"['GXR[/_+NY)[5A^^?^"05!<.+P-*`L:WZM2L%U& MKD/^FU^>=5IM_2J+W"6@4D^\0E[?G`<90J)T1:+R9.1B8=3YA9;OOENV^V[M M=M_=SNY[9;OOU6[WO>WLOE^V^W[M=M_?SNY/RG9_4KO=GVQG]Z=ENS^MW>Y/ MM[/[L[+=G]5N]V?;V?UYV>[/:[?[\^WL_J)L]Q>UV_W%=G;?:9=MO].NW?[G MEK0Y`)3K>S54^+:D\75*5;Y._72^SI:4ODZIUM>IG]K7V9+>URE5_#KUT_PZ M6U+].J6Z7Z=^RE]G2]I?IU3]Z]1/_^ML20'LE&J`G?JI@)TMZ8"=4B6P4S\M ML+,E-;!3J@=VZJ<(=K:D"79+-<%N_33![I8TP6ZI)MBMGR;8?;`F..<-_0A_ MP/=_>X7K@`__'U!+`P04````"`!H,$]`X_\662P,``!`DP``%0`<`'1G86PM M,C`Q,3$R,S%?8V%L+GAM;%54"0`#\Y`[3_.0.T]U>`L``00E#@``!#D!``#= M7=USV[@1?^],_P>/[]E1G+37)G/NC6S9&76<2&,GU[[=0"1HH4<"*D#:5O_Z M+DA0$DF0!$$JA/+B#VJQ7_AAL0"6T"^_OD;AV3/F@C!Z=7[YYNWY&:8>\PE] MNCI/Q`42'B'GO_[CSW_Z)23TCX_RQPH)?`;MJ/CX*LC5^3J.-Q\GDY>7ES3?G^\?O36.T`6A(D;4P^=G0/]1I`_OF8?B5.A!\]<5#W,& M[R<[6;44\K^+G.Q"/KJX?'?Q_O+-J_#/E8KR8P,A.?EKA5[9=/GAPX=)^NF. M%!B1!M8[L\%[9V>9_S@+\0,.SN3O;P_S7>L8/Z'PC<>BB?QD,F->$F$:3ZE_ M2V,2;^*G9GZ3 M[@K.Z3,6L60I;/0I-+<0_X`]:8WGL03,H4]+SBC\Z6%KC=HX6BCY";,GCC9K MXJ&P9__5LK)0ZS..Q`W:D!B%M_]-R$8:^(!#%&-_*@0&'\!3021_`7AY1"&V M\JB='`N#[@B%84:D9T3,$VL(Z/E8*/0%QW,(HA&^9T(L,;]A4<3HXQIQ?+NQ M4JV-HX62`'`_\>)_(CY1$89F%H$=P@L;X+V8OX1E'B$_C41ETK,<

W1RAG*H&L4RFG^<8UQ+)8P)&F\QK$,U<,;923K*(8=V98:]<$P M+PG3KKN'_PNB\6N,@>U.(6G($/:EXG,%0N85A(8R;V6\:+"2F:9_`1*K-`>$ M[/D)H7^L6>A#]`3B7LX>_BP,HNJ:1E%,1!)E*>@%#)DH M;Q]P%C7V%K,P]D#UCV=5WFUK'Z9S2<'&BY@"@ND[H- MQVL(4^09[],]R/T6P5?T6@*-96OEU,ZM7853/S<88*NS``6T=PX!S??3918* MEXCXKP]^YTN%H>2C-^0V&"2SU=]['R M1?5C5_NVQ1"#3JUR4+WY%W=Z$U:5`>8<^[4=VD"A7*&E<+5;V\TQZ%DM$]6Y M?VWIW._I"N,TGAGDP06_M'&67M)Q="]3.K#D)N%RT5N_%BH15%<_.P(7S%D$ M,R(V3*#P$V?)!O*),)&'+_#48W(C.H&T(]^\^,*HUV9^3X95=UDS=&)(E='` MCN"LND&G9,MA-H1,]X8EI,8YELC5WC8RRFQ\ M:_D8+CA/1Q-U8-JBSF=!@$X%\58/"8K M07R"Y.$IZ,B\]"ETRS\9H?%O0)YP7+9P$%[*,3UYC3<^2MW,AG5+8ENIZ.)U"7,=#"J!A+-'%R-F36Y M@^ZS0@0=?^'>8>66G15D&FNGBD%X*?_TY#7VH-`D74-Z1S-X#M*RGI)<#*MX M@XA_^[J1!0\0%5*UFX9>AQ;[[>3V%@["JKNES>`QXN=>''Z`1((3+\:^+/0" MM>4O.7D\H_"P>G)7GV!&OJM.:"-W$!D=;6R&13LS]Q;X>DVG\0WB?`L147N0 MV*5-?KIHUL9!B-A8VXP30XX.[A!4L]F.033=$='&28?&Q!>6+:7N&:)"OB$` M7;0*,:0*0M0>QG1KI#QDVLBE'KI)38ISCZI- M6_WS:(/J\%V&\MC1?98/D>)G(^ZFY4K:T0IPK2L[VXP:2ZMX`L&G>3608: M[TUK1&Y3`RTD]0T<-O\:!XRKVD_H8"QN7V..H",)17P[!_"FW/9CM,>K/"P7`F^@%3B?;Y['LF M#EIM#/?&W>J<^G3MF&O=CGU5S=4&5L[5I0J8H0+Y-6M]!:JPG)$0W5: MP&PSTQI4&L:Z0*N;-!W<7S78V^NR<:IGUS(1C7O&TW)+CENG]TO,B5QO>APC M@6@3?H`N7%"CTA>;ILHYW9J. M-_2M^I_U"42BZ^TW"#%SFNT*02B<>K#6 M3-]^J!Z.=FRX/SDU;CA>V2+:IF'U*TLO!N2XMKBY7+W8N6%>Q-BAX:@S<]=> M9SV<4IZ^#66GQ9`=9`ZZ<5"];TP^^?W@@DEY-5^FRZ$:^G/;$KQZJ#06@'3M+P/)$$?#V,_37[E!LPB@'4B3&)D%>*T&,H(DCVY[%^4 ML>-R:I`8A#B-5+6[;2#-O2TIK=Z'EY68P$M'WX2M(OT/`:P& M%PR-JJ(H]V)Y56GUKNQ,7V%6==F-2"SXS)Z2/2PEF#PM1,OFZ1.W(- MD5'M9OI^QXQ(UU!?+/A,UHG)%SU:WY#HP[!+%7`+PQ,$^+!.[`?VWKKH%L\C M`_\3(E0:M:`'B__]-FJYNM2,.J\N;:,^-3QV,[\'V%H%F2Z<1T%2MN-9/\D; M4%80I*$\7?2TF3T((W2:L1(KJ-TL;"9*$=>#=')0&OP/'!G9AVE!LUW`=`DVD]^KW$ M-M^M?7O$0_@[1'@:DZ;^?Y)L\;@(#KZ:1GW#:KEONS93OC%O=FJ(L'1(#["8 M2\QQ-,BV?PV.#I.R4BYF5,-AW5Z36!NV/S6(]7710"FWH>@<=`X=#-1L9I0J MHNHW"8Q:-6\Y55N=&@KMW#'\%E158(XXAV[Q2TT4H.\=XS.6K.(@"?,3M&IE M92OIOGRR@?34`-7!\!XH:I:20\>A:K+JF5;A:LY%D,$^KYV;"OFJ&#@B"\!S MFE\NO0BN$T$HKJ3GQQ-0>_K97\"I@?OH3A[TU+2_;OE`:ON:PSZIID;OPXO1 MY56>^YJ7^DORVH=#'Z[U8\".ZP\`_`'<.2S:[13*(?YS"\1/N%2TO7KQ&*6B M6JD.WLRLU_Z.4$0]BU+1AH;-I:+:AC\,!MO=<@P,:J6Z`L``00E#@``!#D!``#M M76ESW#AZ_IZJ_`>4DZJUJV3+K1[H(GG`5Y<+_[\[Y\>$_`!9GF,TA^>+5Z] M?@9@&J(H3N]_>%;F+X,\C.-G_[[\QW_XFG^W:<\_N'9 M0U'LOSL]_?CQXZN/W[Q"V?WIV>O7B]/_>O=V&S[`Q^!EG.9%D(;P&<#RW^7T MX5L4!@5UVE'_=)-K#'Y[E\>,^@? M#I9/38IW'Q0PND5%D-@I)[4W+NO(C7FAKVU]6E&1KVU^9(2OW'%C7N@; MF,4H6J>1^X(/7=DJ_+8(LB-`9>S,_`>X+S6CJ`EY]!;_U?,+/Q4PC6#4>":V M!6TG=4T;6VJYM8W"GM6$]"(H8_X<:G`7Y'?4*N[+[H-@CZTO%JM\I@SDJLQ`.2CGQM_X]N4NTZK$' MP^HGFKE^3/!/("$*3%_^M'T&XLC,XK*C!!#1`F%7#218X\^GAV\W_MZKK`_- M(`N;GXS_E'RF6N(T1#A>V!U]LEZ''Z8A"5JJYKC5:KN^`IB%0(&!4AE-O MC4`4Q21*#9*;((ZNTO-@'^,@9$AVL51#:IZ4*7G9=JV25.A"2$:!YO+P$NSQ M6SQ.`&'UWC/5)/6)M#[^@#ILA1Y%1#:]4>''($X),S?I-DC@9D?9N\IS6.0# M8"I(UM]$*&E("X%M96J(HJD^0^3>1"R1:2_)2X!2$,7Y'N48+F@']AG:PZQX M`D$:`?A_9;Q_A&D!7N*>*RWBM,1#>$`DZ##;<^>E`@FD77=]9@F4NNR2VG:+ MNX6M-EG!CP'D%L^61`(\)S(O"/2(&($=%025Y)<$JH5+5"T\-MQX2%E`TC1L M=I=Q&J1AC#L6E-,N9G67%UD0%@,LZZC4GTM-Q9!;*DYLQCT:_D1<4S:S/-]< M7ZROM^L+@/_:;MY>7:QN\7^\6;U=79^OP?8OZ_7M%OQWH_0_?@FH!1,TO1K[ MC%31[E)3W9LWBIX'^<,JC<@_:]R1?\!-2%KDJ^(\R+(GW(__'"3ED!-:.O47 M5-0Q9*F2%YLTU7$HXJFZG261H8%72/Z`!VF_C-0#!3*HLSXGE=2[I-3P=RPT M:D5F>][4\$1DRL(U#4-\;(*@`'?P/DY3.C;`0PCZ*[YTR'(B.W>8'4=[SD![ MI@_:T6+,1,B>V8+LF02R$#__:L!Z=FRPGGF,>Z[2,(-!#B]@]>]5>I-!,A5X M`7%E+0E@)9+3 M%J):G0EF,/]@"#QD$P;]UF*:O6[S85(B;YRP-K=F5@0W=,"!7:,,GC?J+T"< M@H8FM2IER7QFZ>;`$DX$Z),F/F<$QZ7>5.L$Z7V]UL29%]17Y':O?$7KS0?/ MEHV$T-CR_`%;PMTC;@M0(UCWD+0Q2.+@+D[B(H;Y=W-K#*0`$C8` M*E4KXSS/AICG8L\SHO8J#%&)0_^;X"FX2X:L49;G$GDD;YV_`P^ZM/T`LSLT MW#DI8R_;IQYI63:6S4.PKY[.C8^\ZA?24%!#,O8-5,6D8_HY!MX<1I8<;\90 MX\>++01OOFP(*D=]IAB<5RR'"YB5>+1_Z/15VGR.BJC9'ZFX8.+`R;$:?[9; M;5*RS"SKYZQIC;#$@X:TZ$9L,V0G#RLR@@KJ4H&B`VTI2YG>C@11M_T%QZ$- M=`I[#8K:MU\+-'6Z#PO8]-F)G*/'1Y1N"Q3^NGT(,`=69?&`LOBWPWF-9M>! M7++9:R"2-%T>X]NVNJ]`ZD:X_B717E8"("<2)R"G,B!HAPP,57ZBUKR6S/AT-7>5[*^=.7XG&GD;+-F\JN4\[T7&CQI:/)YDI, M!6;,DT'EBC@RK@D)/RH%(3>Z-N?#BTU9D'/1Y(BYC!P,41Y#>J*V:=(Q[I0K M8S]:A!FJLUF##E(SI@ZKZD7\X521A$0=+2&31M;G0"?FKE#.ZS%M+.WU'!AT M1`_E'9PLE1X-O@?__/K5ZP78!QGX0$2^!W]\??+Z-?W?.`C['BQ._O5/?SKY MT^M_H\/TZK^^_9=O!GT0'<)WP!04``?\\/$.#^J_69P`4IM4Z!TFPT/[Z`1@ M&WL8%O$'F#R]F@T'^?N8!/7-Y=IX M'PJ+9\O.BQ-0O_I\8<"9")J"`Y^3/.,2<79YR`6YK9ZU71Q\TS8C#*D7/?0/ M=F6,FT+/NR\4*E9(!OGN"KZ.F!OSV3U1YY^XQ!^,[)LNGMY!'`M&5^D'F!?D M%!EC-4U=Y["-T*; ME'U29T"1*:KU)]53-:2PCC.;D=P$OR(Z:YM;5AJDNX&U#LBP$LW:$L[SL/`D M3"'SNNY37<=*E_'ZWOUEX"!3A6^"'$8DVQE,A'YLDDC/I5KV)[FEY34LP#U) M!D764.HL4'$K61TTF4LF*#6D,+-"*5HD`L="L4@+,1_A(Q)TT9:`-T/BK)5 MH3[5/.P"U*2;+D`F;6*0(`3:JE M`0DUM[?X MGW?KZ]LMV%R"SKV"@N`YS^E01G%.-A[,9LTF[*Z'\V["RN*-=$^4AA/ MK7-LSF2I]KP-NN42HTN*K'8CZ/2+?K@!?I:MF]T>^+>_R.(J#+(;Y*L]12)_B M*/$_4)P6/V/Q,F.X_+-82_N9G=1S^7^F*%RCYO3I"1'2"[:R5L8M6WI-:Y_ MV0D%0X/CO;V3#=K;`SRQ"([V"IN51G%/L8F3[@9\,@D;=71F$WM;A"Q[U[(% MT'!W-T^TS=D%;532.31BN'FEFS$>4!+!+*_VW_&;**'XN`'BB-MK7I@.7!ZW M$CE4;!_X)NJC6)US!W3*..](_X&N$_I>E5%&!)O?TEKCLI>IR>&FP,L1`.CB MA)?0F2GZ^J>_*/#67S#4Y&?#K&!M)N?&F.63GR)34E-L]EV<,!,Z3MU>K-U=NKVZOU%JRNR?K'YORO?]F\O5B_W_X!K/_SIZO;O\V;H(HG MU92K4H^ODE-L"EZ]T?<:%F0W]$V&/L01C-X\_93#Z"JMKT)+[UHK1#,GICP& MG'W&F>HEY42 MLUHDG3#,$RB*>TNFHIN6@N'J6,,\ONL)C0//V&&8M^^T"7$C/?L.480A.>\E MM:M$=X8-!9IS/1\5QJX[.H%;>QB6=VRMXMS'>D[0K-=[687SY]%;Z8WU%`QH M]UZNQWH"ES;7'B9[M],8B`=YGW6?-B&F5:SSJ8V"1D@K+:DO'8P=:U;SX`NJ9'^HH5O0X8#&NZ3.+O>O8LE85GU55W#^'/I>9:7L_,J:MS;9,<6P3T(MZ=$40 M3/_H:)V`2J^]G[MS??G7A6Y.,'(L>'N=>T%I.]RNNEEVID*I7#/>XLN9AFL\ MR\J=D'IJ6IDO82PGU%UNB@>8M;%[G87PQ0E(?6>$EMV*[ M+B%D;X9=YF4R>LC`K_.^'1[4(KX'@=8`Q!L<&B/(;TM;)55YBX(T?P]#B#L& M/)#[,._Q["/ M\QQE3R!%OI,9:2(%F=3CD)8J^GV.JGOTQM=-OQ5AS#L+).HOQ)0PI!W#IO5A M.-^'B%4\K>5A59?,5?KEB:C2D/)7[C.`(=R%.]>6&R18"V0$]B?`8-'%06]B M\W,&!"=4F88(G^')#;8%<;M;')A M5B2[RO-2B6!]00&Y&D$'Q*I,NR95SXLNH3K*7#+%5&;>1!I4MX1$XXJ1$ZC2 MD9&G:WE6Q-F415X$*AK2`0CUI!SSJV'=-IK$K748-+7!IA0Z"\^86 M"PP2@G%J3,ZRCJ*,:B,?,^';39!M,GJ=1?1SD)3P!F:TP$+:R928[.,K624A MSXT[+DH\JE-2:&C,S'V0@0]$CA(R0DD29#G`PX^*G+/BIA0Q7(JJU*>(J3Q] M/F'%'CWR%D5E6/P29%F0%D\D&VZ"\C*#M_!3\08[_G7$656%EJ]R!6.NREPX MR.BB[%1,524CRUH.-(*^6:B,`32UEH;LD^GVF:?FZ2BPLS:[IN[.''&+,>3` M013\-Q$&5-IS6A274.1,U;G`HM^)O&X)8Y@?RL@[/Z.CPNP&>"I6&2`L17";*:TQ$1;8VGXPB;S[92.^EO<%H*59IM&XNF[Z& M#!9*10_L$XB:LXYKW#+;9'XD+!.K+V^8MWS/8*N54DTC_1H9L8FK-6"1Q+I/ M]GR(\QBEERB[0.5=L2N351BB,BV&B_$JH@?V"$3-V<,U;ID],C\2]HC5EZT$ MV*$,1+4,"&JAZH*,(($YR&!19BE^DB3H8X!1GX.7\[Q`1PDD2+\R1\3C:@V( M)['NCWC!$[TF[!:M0MP<9)!NV3ELU1F23U&\(:!4W)2$$@<.M@PKNA1R4L7$ MDJS'$)*16ZK(MC-,OT;`,[E408"F5=2`9!+-'M&4O!P!<_8F#Q2=F<*-3!S4 M8N2#UH+5EC_P_@L''F_"P#+RO$X6#,O'#09E+;Y4D=?V"Q1M,Y+KZAC]@+SX!6"):*U6YA-]<&T*F2SP?%=ON^AVI M6WNPYO1%CP".(41NL@2W$[EN,!5/E8 M)J1YOH"[.(R'/9>Z0OTA510,V2QW87/J0-F;B+N*1I:=YR"J7OCEI$;]HZDU MU*>@7+=+/55/WABW)9,^[^$'F)9P/(O->5M_D=%;0^(,[-ED"=NTB!(LC67] MWSC8RF#%@GV0^5[QYU424OJR?70/!+M09MKPAEMRD"_%MA5VQ:B(UE]!+&H( M;Y%Q!WM@%-R)\"]57S82WK-Z*E4PTJ^(/C5$6EV>R*T[QI&U\8&*(Q,(+0X8 MFND.%MO(XH3UMJ#E,W3?PGLR@G@/]R@CA^'D[;*&1A-PJ&B8!B%R'PX::W6O MPIA%TD.W:^=`]M:30FYV))'6)4D/S=F^J"+: M=`="45,&"HQ;'9G*_0@9)U-?GF^N+];7V_4%P']M-V^O+E:W^#^VM_B?=^OK MVRW87(+SU?8OX/+MYI/Y3&I11C`>W+V:S@U$)%$B_\@:\$VCU"">U[I%H MF.T/*(E@EI-9W>*)2S.98$LROJ`QQ7BF7418,F=BE@F5E]WW?Z"+>3I\L8LM.,60O/I*ZF0Z?Q1>/'UZ<8P%`/J.:59[#(C]GYGIC MOJM__N"=(0-ZUJPGCV)9%T%]++^\)3Y`DSDLH`)^L>Z/Q37(`[<\BF.*<[%N-7;C6G;3MNE$;`+%85LWFT&R.4)4 MFD$MB/AL%B_B?(_R(/DQ0^7^*@V3,JHGQYJ3+)MFER1-X]T4G_Z6`6*MV*H_ MJJ$M0\X9>;3O+4U!VH(D<(*3?B!B9[38V%LKG M.51CQF;,8,Q2%^MH5*@<777'@?,9__&[1EFT-.[[+,9##@(@]8BG%^+,OY*$ M`0N[EGR&)+0]>AL'=W%"K^-D3QU)I)ILY#PITSS4;+LVNWZQ"V$V:H'F\AP] M/J*TRI4&/E9I)$!2"WO>HRFK4Z15`8/TU&R%7HIJD4V/>SB;?-F7^"-5<[OO M8/%`+E9JKFG(KV&QV5W$Y&;;-,HW&>[HJXL32>@UP+`]@^U^4'.#QKO]3(O@ MX#RZ/U_5>Y$',F7V'2:HR2.Z";N8+?#Q`A\W_IA$;[( M%8"&&Q=-;?>W-]HIZ2P89W$7KJWBN"<;W=';O>667@%?60.5.="Q=T(NBB5\ M;&T"E(&>U=\9*078_"GI?W5$N"PB7`^QO!#B?`5$>^FCO^:QVF[7M]LYC/SD M,]BJBQO\*6L'RQD.US'T%S"8*QR4DJ*ASO6!\V&1)CJ02=V-CRW)]8<'F%0] M'@V85L_+J;NT@\E%#Y0G`(M7$T+@:\6JX(R=*[!ZG5-N;I^K;\;E=2)2N>$M MEV,Y6S<<#BU;G5N6.%&ZZY"IV[GPL+[HV_>6('F5LJX\%'U]SKV'0Q7F[8=L MN_/AA8P/,A[8Q[_U95F>!RW0=Q=KT0CR,T.\$M(U$"Y$MI6XA&G5_BVO0^O: M$.C=\+K^S&M?=K&KJ M+LFT=$RG/D^?)W0BN[UDRW.?+ZU=I%<3?4+P-+J\$%MU"!YKC:3,R53<+"K@ MU"L@])IH+`;J?0G5'63/US?;^9RKM84F3OMJ"B>?K6U5:SHW)FIHU)])2<.0 M40H^;(Z_U-V)6*9JI;?G9^[W(^K@`TVNP#X#%92[9%3V-:,#[@/<\P6X!]H= M'$*V/K3CNM`[=]P=W.6,0\=S.W/,(H3X:\N.&(N/%CLZD^[X+/JT,^C,L^?U M1UH5U0I^DP(?MP;>CW6:H$/Y!+H<'GZ7#\,,!CF\@-6_5^EYD&5/.'ZB;?1F M5ZUV5E<2P&B5GZ,TCZ/Z.,15VIR=V.S>E'FDDN\%<.%W^&."X#,=K^PR%$$9Y?=T-C*J-8M4)GGNR>7G?)(>?Z>53 M#HF"C@7-T<8QR[X&&\F<_!+/F]=O@T_U].`;F,+=*#^]1*JWS9PA964GZ\BN MY>9)X$*^XY2MV>PB+8)/S+W2$.YAE M,**!$N7Q`(@"B?;Z1H:$\:V-(YLV(<\W+[ZCD:VU;%]4`[+OP3^_?O5Z<9C+ M^![\\>3UZ]?D?]4T1@Z"LGA`6?P;C+X'*4HAB/.<=([DLA14%GF!_\`MJ^_K M&?EUCY0K:W@9XTBX?P`&C@!C8FJ]D%CA-X3]K731#2[Y84G<]HFP;M^0"K'V2AA[ZH!KN4C;)70 MN59`K*NXYCVOA6YA]G:E>A&O=#,3M4OLND23L[T36M<#2)27S7L*H0H[\[D* MP!Z$%'=+Z&/(9[/["XSO'W`8P*.7L6INJ7G]" M?75#MNDZM#D!,=&WB)F33"X;+1!4:LW\1)GC9W%ZV'D!<.^P+PLZE^MY`]UD MH"$[E=_GO*ZE;E,PK10SR?;"S-=6G22_#3YUEY]O47NSR1HKC#9\6+?+S/UB M9-=J0@J#DC@YAFFW;.HY*DQ]M9DJDD.F"LY2XPE(JSP51?#)]R9X^W#G9J:P MA#11?@H#%_PT%<;EGA-?'>61L5"JHU&5G56F:Q1L.ERM<\I@RR>SW,?T^3!8 M*<7,'"GL->\TW&@%::`[8I_V<#D]$FND.FS)WD/21ZU$`_QR36#N'#D M'[(1^4.0D+V1`RZHBM4:1]-J MI4\QF6:77FI>_"4%C/ZWK/.XD/B1?.(X@3B\/$2AMX@4^29#)*UA].;IIQQ& M5VE[*'P5%O$'FDN9EUK0H8LF0:$3%Z99\!P4RF9+X;!\PGQ\KMPN.Y8)`[/& M-IVSZA]BQZ_)0])P@>?U)/V+TWWM$=P]=1)^!*T[WQ=?N202.AYP!PD+'7CK MI3UT]FO\-=IAB$K\>VZ")S+PY]R[*11J&DZ.D&G3QS3K8(`L="1LA?B*R^8= M.7I#7GIFO;@>D#EE M#8#B->-U&&8EC*3WS$CE#JTE3\Z<#6S+;MI,H2\),02ZR_IUFR.M.H=!DW`V MMQXG!U7O?)%4.M*LGQ%IV"H#WHCLND25S696[&4RH!8'1'4$YM/>6L(/O]4U M!)#G`_J=5:SS=MW@L(;U!NY0!ML#?3!??\+!-&2I%J_)6G?+7Z1W\MGFW"(ZVXS@II\?F@+UEY^"FLV&G:3-J M>>KJ!/2<`>KM!/3]@<;A[VV+`WQ_B8V+S\CP)H/[(([J!`ZK-*(7"E193]CC MC=W6ODAP,2E:6M:!H1#^'>ZQU$((F5^$H!8-,>9"2 M0B;S`VXAR>F=W[R;2/,SB/>GR M-KMK^+&>:29'L#.4XC]#6%V]B(J_P6(5H7T!H]&N4@,;[3;323:,=_--\.ID M(^KT; M'0X0K:\-O(6($BL@^)?HMC8K7;\)B7SC-CK'7<-@KBDBP+#EOH MV+9CIM>SUX9FU(?/C5Z<'GTN_)K+]=OUL)_,%E=C_FH"@->?3U%E7,4M5[5X M[[',F9-\$-KN52]"5C+7O0W9][K0!,!P;CS6J4C^M<1$2%!>8Y+[D9&4I'VLA&@H>9,;FM4J5^D71%C1G&4A@02VO9&E\LX M#=(P#I*K%)>GI!P_%)(7W6EJU=],6IY%C-.QM&R%04?:+_ET M$8*,JJ]/2D4#78)J^3P>/*U%;9H^+2%SP8$F.,C/*$@[#F0YH9E;S/H,R+;P MGA2M33O%B<9D8LW-'%PQTZL&.(9M!F$2'\+K`D2JRQ\ANL^"_4,<4J+M4/98 M30W.)1:3UB[2JXE!YGZ.1B\YO]#JC$_`W,",S"&&>.1U$2=E`2/6;=K&=I1/ MKW#M.-^)SO'L/$VK?EG,MI*+;-,E@)!.>T35.]^#+%/<:6W65H"`[DYLCDF] M?=;"?%(9G/?G)J6RE<7Y\^WCS9`Z,?>R8;\_R?C4=,O'BP4FE\-+ MEG1K\8&!F\F9T3^3N&%NY+20$OUX[)S3-7R#,@Z:`T5ISI5\(VG+5ZD-[#OH MS]4\ZMRMQK(PMWY8M=8%%ZL)JD9\N]I`473'&M.'>X@YN[./X\L07FNH1I1":7+Y/@?@!@ MYKLF4US_W42*C$I@8\6"9Y0%>K;LLGT$R#//:;B8M8`D'V^0::LK1K#(T3T2 MZ.J3MYD.*GWEP)),EWB!:8.M(<%[3V[>XMZVS MWS8#NN%;`_`.;-F"+=LL#[`LZ67U<$8;A'B5@J1?TAE2MKC%N.9;LH%CL18UJDVR"LS0VC[J#SY&25E6@39TV6+D8PQ M'P86[?*`;5R,?Y9.@_OV':A>S@'MO&I#BE^9A>Z!>!_53%M'17,=W;<[X[9% M4)1L4(M%>]CFB1I#G&W8+M*%/L2`%Z@VN&^&F*T,J(3F@'])#2.]FF"Q@:W5 M)X7(\E&Y04EYCL<&]RA[8E*"*=%CPD#"F``]>W9QSS(MAOM8HT$Y?0.:5W/` M-KNJD-*W92&Y)]P',,/.47%[4]XE<7B9H&"XSY[[OH?9WGMCQ':LV<7KV+`8 MK4/Y!JO5A[>!^3'?AI<1T\#J$C$NGA M="AB#-6^0;MH9=H6`Y:ATF#V\`J0=W.`+:?"D-H'9H&W+]W'+\O2<0-G'*)D MY/A5!#_]%;+#`XY,/U0>RIC'R'V+EH-CIG%)5,S0:GQ$Z;9`X:]T33W?E$5>!&F$`W`VMA44^D`7*IBC M7F#>,@7DGB1\D!EHR4$%`94\J3:)Y*`C/`NNJ.``3:DI)HL$N@-*2;T<>>GR ML(!ZB9\,IU@D4D5_^7(D96$!:V#N+&X9&E^3XT?.$GE.J+XC$@B"GAU_H MP:7P<,09M3:^FTW.#S,0(EN8Z+-YDCE">]/">.&%UIF(`F;L4S?F9;!/CT7% M#T(/-5I\U5S@'+CP1(9I)S-TNTOV,4#=#E/-BJS+E%EQTCB(G;KO-I7\Z[<, M"F;E76?4/?/[676>BH"4-AGJZ%!L,\0&Y:V&2H$\\>1,ARB"XZLVRN&",&<5 M8RJJG$XBSE?/EK/9T>7,9C=[`?<9#./F_HK5(]F8]1O]3W9)AO,@4_6;R1)] M?9/&0MN=M>YTJF=NNS#-X+*K1L\C!QU%\)+7$/B^'VXJRI"-BA],'.F::DD_ ML1!'![S6\#*JY\RHNC7D"T>7$RTN;Q\@".[O,WA/CHS5MUH#;`K=I_%O&.]Q M"@HLT]PWL:\FXXN'H`!!0IM5F%<2**^6N`#$SD,C_SL%V5#TRD&K(]M5^']EG,?$.+D_BE1P\82+LL:/ M]X1)2AVOH97ZX M>*CZTSZE$I3>OTSB#S`Z`?N'IYSF5*_[W!W*.F2J.WP\-`X3+!#O8FPVR'O< M>_75,X[3,WNDW+B7/A;GU":2OJTXE]+P,^).)!F6PP7ESG[OH*Q!9#9TL3J/ M=`V+<]P@OX):\+(YHU`V`XY3&OW0NB02]>9#`;O^,8]V$'"7K=]//PV`?%SC^I7-@ M45R4N%)>G(`<[8J/-%\ED4?T_M71C!8Q_UD%R[.A+'^[AE_.6IW>N@SB[.<@ M*>$J^M^RNEUVL^L5J>5W.Z"8!UW/'=)1L,N[D-(E>`UG8'1<6=V[H^O8"GC/=!M< ML+ZZO02O_^WEZS^"Y[=H'X?@3XL_OO@*L,R9/'&*9:O3(R2/>4XF:&#>-**< M':L*DO5'$$J:T%!@V%J`(_?!Y9A,E5[O0$#=$-UC=; MSR,#IQ#GC`B<8-QP)*#JQNHH0,>I,<;/9G<-E5/L<2)X)]BS&KE?I6$&@QQ> MP.K?J[1.8DJG5W/L^6T".R^]7V5I%>S('=+ZK9,E!VT#9K7` M,^&HW3#3-RR("ZZ( M=C]6^X>#A$P1USTW.0Z$RN)PY&>',G+LM@R2Y`D$69R3H+Q-,$56P$IB(*NW M/R80EQ=D9.8IQU%\$M0S4O,,S&=`14[@[9&+AH&U@6>K@;1A.5QPL4XPLV\Z MKW97/^53LQ=YN(-XKEO[9T`>3FCLD3Q60]_+.`W2,";7(>1%1KL>7N8V%=%F M#[!0U&A#FL"RO;V^7=)&]NIOY.!'1-N379KC7BF)>"RTLSP MLE8'K3ZH#=2#P*X).C-%C#G=G@ M>8[_9L(\SAC0,_4,QX%&OJV.!(U+XH9Z>#3X;OUN"\;]5Z;0?_U.'/[XSS-Q MK(X!=4O"&1^:FID8_-H95T[UZBWT51V/&MF='/C.9#!K#,FI38A\$#S5XN3V MPUY^;Q//7GM=Y0S?9H9-^MS?J:.0ZMLK=ZQVO20]1(I=AJ@D(Y?[FPRE^,\0 MBB9B]93J3Z>J9-(PJ/FPUF5JN>-R7S4A@B978)^8:OHM M#77<5;CL?M6W^"_\L'F$_^\NR"%^\O]02P,$%`````@`:#!/0%_*"G/0%``` MN#D!`!4`'`!T9V%L+3(P,3$Q,C,Q7W!R92YX;6Q55`D``_.0.T_SD#M/=7@+ M``$$)0X```0Y`0``[5WK<]LV$O]^,_<_>-S/CN/T7LDTUU'\R/B:6!H[;:^? M.C`)6;A2A`J2CM6__@`^))$$B`5(B8#=+XTK+A:[BQ\6B\7KN^^?EM'1(V8) MH?'[X[-7KX^/+-%V].SW]^O7KJZ_?OJ+LX?3-Z]=GI__]_.DN6.`E.B%QDJ(XP,=' MG/Y=DO_XB08HS2O=*?YTSZ**P;>GF[J4%.+_3BJR$_'3R=F;DV_/7CTEX7$I MHO@,J*0B?VK1ESJ=O7W[]C3_NB'EC$@'ZXW:W'I'1X7]&(WP+9X?B7]_O+U6 MEGY[*BA.8YQ^0O'JMP7#2_%![#R3C7] MA9YA1FAX&8?[%[Q9U5#"WZ6('0`J[)F< MHQ7AX\7E[QE9"05O<20`.TD2S&W`?TV(X)]PO-RA"%M9U*X>"X6N2,PC"2(L MDZ0LLX:`G(^%0'Q@N^9QXA)_HDG"7=@M?-A+"S(,Y1=C$@K2JMY(Q);OCTV*\+A/ MV`=6Y'0L(^2Q0:)05_ZQ5*SY<605SC,FNF>G)@J:FD(MFM'T$J,"C]3$/R*B M>^01&_>ND_2<\QYQ1 M,1_MT#Q7.]J=M(X`LEL^,60DX'Y8KFH#7U#RTLIZN3Z5X;*S=#`WB"\ MRD;JRU998OQO_KG/+D?9Y2&\<7X#N#FY0_N[>6.GK06\409, MRJ&%+LXEN#YAW^>8F<]YSJ> MS.Y3:A0?XKU_L_E,3I3YP\8[@Y#`["JVR6GKS:0 M1@)BMV>5);C_Z1^X;VBAT">*XD2L$_*IT7V$>3B0)#9=(^Y=_2)-."Z2AJ_N!>I^(NQ$ZOQTRFCJXC;2!IR+[*[.5,O+< M\K#/_'5-J0]H-:,E#:I9$Z@;$<)Z:]I]V_2`CN430?=\O$Y)[D#O4AK\MJ`1 M5RH1$6BZ5BQ2F!8KC0XOYH)!NM=I](1MI=U9L2GW,R4SM!9#I6(JWTE4#3@* MHM'K]8LJ/4=&Z055=.LH=CV![$K1DZ M#MK!;6:"[B$J]W<]1>LRM9[$0R4*K.7?KIJIF M;BHJQZ$!T\X$(4J.]G.VT8$2!-DRRX_K%;N:Z)(KL,!Q0A[Q]C#:#4ZG\R_H MJ3WYMRF]30F8E78=<+VL801$TYK\G4W=XA21&(>7B,5\WICLJ'Z!YR0@S9@. M7F"S65Q?P''D&>ML`C8(<_O9V=CX:NNNG2-HYP;.XT6KDPD^9,SL][AY.UL' MSR7M9^M=5=C'JNZEC:6&,%RT-ERL]@QLAMH/DB!25&0?^SK1U4WWH5ANEK#; MH0*O;*"IZG>G+?M_XC^,*IMA MEM]2TYE^UA629J35A1P/L:UTM\];JROP-Y5=US!7)YEDZ8(R\L=VC)%B344L MQ5B;V"ML:72UQU2;L;\)<9EFUTF2@7!4)^S`4$7H(7ZD.O;%3L74W_RX3*MI MEHI;;<4V%@!X)-0="*I1>P@CM;9]L53C[&\^>V>5$1A%&91HK^)Z&S^9:VVY MUJN-G#Q,:N^HIPF;`)1M4'D7,,&UM`21,E3R\)1W2RUIG*2A4H'&DP@)IETO ML#1B(P]/3+=44@=&$%(59'P*B0ST[`4>63`TU$EHQY<^W%AG&RJ=\N=*A^5* M1]\&&'NE0W=O\7AWO(C=0QOI%,EL#=7F7A8%U7C9>G']_"U^Q'&&VY<=*;Y6 M>?GFU]%ZLL[Z5*=*O8\JV.6>L,G&WVQRV@=15B"ZB);Q,^HR MNJZBZR*N@T2GD`$L)*SL5T^((J:("A#I86*R(`W+@U7&5`]=QF\KX@.>4E8>1OJ`GG%P^<:VYQB1&;'W-[91?Y\A+F-%0U"TFH1N[0^T4'A9I'YA+V M(MIVJ)>(Y&^&&N"=#^<-P/Y]KR(]J[F!S#;&WM[8:?L.Z/WALL\^*@?A);U3 M:G,(>I*FC-QGJ;C/\0N]Q2O*\J`L?RBY$X4#\)6"M1=??S`]G/DLH=]+`/M- M8(Z7\=:E!A@S#2;[.,$,:O7VLZKB%]&,0K!"Q&J/ MHLJQ*Y:V>O'8PL*&AR-#A$Q(KH1XV#F8Q.$%B3*Q-B_9A=N;#SA>4?(9K0OV MPPTHR($9K]Z9K<2"149*<;R_=Q_F3GN["1.W:U.9_:Y)/K/J,RB;NF=Y\&'J MH&%<="Y:Q\41)]T=K]FXZUX<+6)WCUPX$%F&4?V@[KQ;1--X_T_7WMO!]'?N MNNKLMS0[,NNJ+LNJE%8X?!U9:7`UF3,*-OJ41D\%M4+=%O5H74S;7M14UWI? M4O$7G4G+]R4X,&"'`7LH-3_[5\D<<4$_8_*PX,"8<'G0`[[)EO>83>>M`R0* MUV1;O&P!\^+#!>.-NHLZNQV421&YAHHBHW4FZ_:C5M:H]SC3RD57A%7Z$IQ< MSZX'=G[F]536?_V,3M^7K_Q,V(,M<\SF18K&P=>[-EBW-)RAX$U M7#CO7VV]P%SL@.0&Y7]'.,=6'$Z68C_<'[)(Q:1(V6RP(L\6[!86.PS088+9 M[Q;N#7*%N]Z5NR&N?(FQ`\)&Y25X!I9_$>"VL>7AD0Z4TM][(#\B$@M+3>/B M%>;\VJ7I_)I;.7X@]Q&>)`EN!3.&I:K[0:"EGFT'L+/;86`/ELW?>RMSBR1< MK2O*+FAVG\ZS:!($-&N'ZQ#2S27-7:3/%LL&%CH,@+L%\O<2S6W'%'=M3>?Y M>XX:MZRD;+EB">6SA2SR4<@O+W$`,HP1?X.)?\;(S8VMND3SY,YT7O9;;%)-''$X2 ML96`6["8(5R7=D'1=/XA2TB,6^NS^ZM@NSE]\`J>;2?;>VL, M?H9$2&QJ.HQN75/9,X5$_[ M^C%1F@O&9,Q=LJ;`D([L%K9J;9\%"B(?DV$"6.P=<=T#5,F9&5J+JS6TJ%;0 M*P'J]T6&!:6K;J\?S]>JB/+N!+;IR4@(%04Z<)AJ\AS@&*W'09'8ZNZ M$7=4*!:;)1.NC(F6*+PX]^D["JA/N>IS`WVXJA,"=ER]A_(0UAP6[982[6?W MQ?.:0MI-)L;*UZC%J^+!H6X&]N:=L7K&TST($H<.7[N*3V@*T$.DIIU!ZF3^.UJC5K@;V]3CB^!RFRJ#U.@P(8 M='N43@;C;79"ZW+TF02_9X3A:CE6'*Q(>5`I4M$K0=+<^F17ZM2H+1=/83N,U8;` ML+4D[AT$X]('&(?YC+S8O]78*PL"=$\NVSVH=EP\!?0P5AO$*=M*XE[VLC1` MM1UD&D_QLE*AVM4%PG1_1O6`RXJ1I\@>S'9#@+N/,/;)R+$G&JTXZX:FN-PE M)5FHA)*KHN06N:?(-;3#7B+B5I7[>8_.R5FO]6S7>I;K+52M;3.@4P55OH\W M)OS)F\$S,X/DS3JK>W:9]RL2HSCHD3<#,.CV*)T,/#"7M9FLS>.>PX6`0-W! M];8!.=P.(3JZN[1R^_2X$\^=7<[G..!N[_(I6/!)*+[ECG`:"^TG<2C^$7F6 M1SY-;9]XM2E:W<9M5-13"/>PSQ`@-JO>W]%*KE%Q651S?T0#P39%RQ8R*^HI M@GO89P@$FU7_LE>,X;'5()%O9W7>7UPE!]XDK1V&`_D219E.)](JXSPF;70W M@R&P!OL4XBKW*EP,ECY;]/WZYB7CKZ7]/A%H<;%3@<#+N)Y`/."M]N)=A$2L ML6[Y6=Q:KU@JDC!7)`\`E&4#=E*.UGUE4L7A'7F(R9P$8M]%<4Y&W&A*(Q+P MH?,+;Z8/7*3?`*8P9=5A*SBKT3P`!`QT4$/5O4)'_<(I]*MWV!OA#^@I1-XS MYMU')$#&.YM5R+`6RXD133+E@V@`RLT)EP[*$4^AM:12.0P(J5I7%SH\I+&H MD:+-@S9*_L6!BBZ^WG98/GT+LR`M[Q9>C]9IZW)P][$ULVHMP:3(=F\3H,B8 MEPKN-H:^5\,+2`W@6`\W:E!JH7V]PT.J*[=E::OQMO_73A'-,"OO&Q>O3ERN MQAO#7]R+IJH>KJ53J.A"?[9YOQ36=4U>+GT.O;1,JJ+H.N:*9OE&I>%FX#+N MB@X'(:V>F^@D':WCR<32#[2&I3I,X-:0"VI/:JM_O=-VU96_?P&MP]MN_!DO MD_+T]>:0PBV.Q-[`?"OLSHD&<51?[`$?L)N;UJQP`7W9;#+,MFR&VZ5N*H/* M._3F8VD3%SQ(;SC0X>Q7]S>VDA4Y?6N)O/5.'S%]8&BU((%PP7/*EK:9_H$> MBL,/A>E7XM4,Y=/A.K+JN3UMAQ:'%VH+#8S&_,\`#SQ_Z*Y'T6W-"I4M"RTTXL-F2<#(JCB3>H._ MJD2]H>DO?"0)Z6KG&R>BK+B,9HC,$0#'<9*=4]FDO8*HK[I:3(17Z:W?N*!!GL81ES)P]YBNAYM6)#AX M]4`?3T-,BH[#_VCV%_[3KT6]RNRZ_&N54V]^[=GCS62^Q0_BYG84IS=HV=S5 MUT52D[Y),MYB@,+4%*1,(_U?YY5G_:4\QKZARJS%S[F&3,R]0_ST`VZ^:M1) M4VOS%HV[C=ZM#K#56TS&/K(";?;R;M8K/NM$T2\8L8?HWO,$IHC,/\@7LF=0(:VIHS4-*Z"`H3 M]8#.0,N#+K5`39_B\G8[RL; MA@2%=]LD*,59A$S>^MVD]0!!0>HN%D#*0<,%!:^Q'R,V0T:.YW,^T#U0)@\5 MI10U'#0HW&W^+E6`K=Y@,?8;OF:-/2^WM`@;K7[RS@+BH,%(6.`)T< M+5Z8'04W579M._6YXK\T@P,-5;5>I*)R$18PE;184+(9_5U2.P04UQ_H,2"A MDZ*@1N<^#M1J&2*AQLCFN MFG+"90YS/$:H.?9+OY7V:'QSL36[Q-(.N#NVV!2M7O?S)UZ(;3\(OYSCQ+,?_D_4$L#!!0````(`&@P3T![ M`*&UZ08``,\S```1`!P`=&=A;"TR,#$Q,3(S,2YX.L(6H*LMN9*"C!R(D MY>RBT3YJ-1!A+OH?FF04/6+AAA".DQAAGC"BL8CZ8JK@Q#RJ8\KH$Z'=NS MA(\[,D4FVF?:BHN&I$'HZU":NKD@TXN&'C;-9)!\#04Y`OL2$<%]4D".;G9` M1<)`-I8-EQTG$%BX&R@;HP%`>$B$HC#ZEH/)>3&W7/@8*KH%*F[D[[57/IY4 M]0I4B/]C_=$X]^`!TH7/=X.<.I<1F#IB'TQY_2.)M6.1 M(LVU<;B]XM*RY_7BVH2R'\;D+1;@_9PH"NY4IO49[3*.VS4Y7NGN]8'S[3E/ M@RU'TQ',%,:#K3[C,LUBKH^W_I[']_"X[M\`SZ,K-+KMWW7N!R!P8+D>RUTL MYU<^?ZQ,GZ7$:"P(M!07R*LCB'\*?A'\"?"%-61;LDXU@QP@H@3A$/(WX#5$#!F]DR*6\):++@X"S\1SV M5OTP'NDE,F5\O-G@`P"1140:$@$FLJ#(H*)7_=OQ8>Y?LG1%&6RS*?8'3"H1 MF;79% M6FE,D1WFC;&?+!.U-,L(?+=!X'7_>HSB?E#:$1*V)V2Z0MF^$&8>,KT=:$YI M_IWPF<#A7/]1#MB4BR"SSWJNL8RLWS;(RB*A#-2!B92).^*";QW7Y1%3E,U@ M"6=0=$EF[BN1*>/E_08O%A`M$=$JY(&?E>VP5!DRLA5ED3_-W0['VH<@IT'N M<=>LQ+`N]&$\JJ>-.:E0HIB&UJFE(4;(%@$-6;C_R>QT[JSE:&S%:B9'YW%H M$'*A$-M('6:S65;4B53VMD&AJDK*QNQU++%G-F^]WN=JC*-J@Z_:\&586B.A.)DBF]!!?9"P[;Q,"H MZ+=FHJ=I M_G6,;?K/:MY8Q9V_@,T+)=4LJ6]&\8V?^IL*@U7P5<17GHQ%YO1/']+9\[I; M(LP)W97@09?K?Z0(?I.6F<#.1"J!765WI_H:Q->:^O9RA;EV=`9U(#50)-![ M-G`]`C&J(JWRN^!1F`A2$&D@1GT?3_0M"24B$,A$\#@I7^;UWQ/,C&HH9OU/N"P MI&#Q]`+^3[$O2P)@VR;VA@,TD`E5SX1*ID,%UA*O[`?D0Z MWE^1/1<93>.TB^+NMSB1E0W+]BK_E2#DY+5SIM5"J3V;.K\0.IOK@_\'&)(S M8E8`J1UPX3/O43]*[V48U[837_'1B/P[9#[G)"QP@F!)>L0^!ZQK?E"5^4AU MCF-(\83Z5-]/?'[]R\3AQ1#W9N27390P^[N$>,89G:,930Q.CLBDR)_&9,ST4B^W9_%`U3WA/%NK2A\D]X_`.:]J+\F4KJ?^YL M4M6=G"%0'V+/AD=QOBO'\VT5?J*?YJ#=_LK"VS]02P$"'@,4````"`!H,$]` MB\6,>Q.-``"[E`<`$0`8```````!````I($`````=&=A;"TR,#$Q,3(S,2YX M;6Q55`4``_.0.T]U>`L``00E#@``!#D!``!02P$"'@,4````"`!H,$]`X_\6 M62P,``!`DP``%0`8```````!````I(%>C0``=&=A;"TR,#$Q,3(S,5]C86PN M>&UL550%``/SD#M/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`:#!/0!L_ MM9SK+```/6<"`!4`&````````0```*2!V9D``'1G86PM,C`Q,3$R,S%?;&%B M+GAM;%54!0`#\Y`[3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`&@P3T!? MR@IST!0``+@Y`0`5`!@```````$```"D@1/'``!T9V%L+3(P,3$Q,C,Q7W!R M92YX;6Q55`4``_.0.T]U>`L``00E#@``!#D!``!02P$"'@,4````"`!H,$]` M>P"AM>D&``#/,P``$0`8```````!````I($RW```=&=A;"TR,#$Q,3(S,2YX M`L``00E#@``!#D!``!02P4&``````4`!0"_`0``9N,` #```` ` end XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Income Loss Per Common Share (EPS)
9 Months Ended
Dec. 31, 2011
Net Income Loss Per Common Share (EPS) [Abstract]  
Net Income Loss Per Common Share (EPS)
4. 
Net Income (Loss) Per Common Share (EPS):

Basic EPS is computed by dividing net income (loss) available to common stockholders (numerator) by the weighted average number of common shares outstanding (denominator) for the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted EPS uses the average market prices during the period. All amounts in the following table are in thousands except per share data.
 
Basic net loss per common share is computed using the weighted-average number of shares of common stock outstanding.
 
The following table represents the calculation of basic and diluted net loss per common share (in thousands, except per share data):
 
   
Three Months Ended
  
Nine Months Ended
 
   
December 31,
  
December 31,
 
   
2011
  
2010
  
2011
  
2010
 
              
Net loss from continuing operations
 $(583) $(303) $(2,293) $(1,149)
                  
Income income/(loss) from discontinued operations, net of taxes
  2,852   211  $3,091  $(1,277)
                  
Net income/(loss) income applicable to common stockholders
 $2,269  $(92) $798  $(2,426)
Basic and diluted:
                
Weighted-average common shares outstanding
  1,689   1,688   1,689   1,688 
Weighted-average common shares used in diluted net gain/(loss) income per common share
  1,689   1,688   1,689   1,688 
                  
Net loss per share from continuing operations:
                
Basic and diluted
 $(0.34)  (0.18) $(1.36) $(0.67)
                  
Net income/(loss) income per share from discontinued operations:
                
Basic and diluted
 $1.69  $0.13  $1.83  $(0.76)
                  
Net income/(loss) per share:
                
Basic and diluted
 $1.35   (0.05) $0.47  $(1.43)
 
Outstanding options, RSUs and ESPP's of 408,006 and 296,260 shares of common stock at a weighted-average exercise price per share of $9.82 and $15.05 on December 31, 2011 and 2010, respectively, were not included in the computation of diluted net (loss) income per common share for the three and nine month periods presented as a result of their anti-dilutive effect.  Such securities could potentially dilute earnings per share in future periods.

EXCEL 13 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]A,3!E,6%C8U]F,C@Y7S1D,#5?.68U8E]B968Y M,39D.#@V8V4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!R;V1U8W1?5V%R#I7;W)K#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K M#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE M#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T M#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\ M8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@ M36EC'1087)T7V$Q,&4Q86-C7V8R.#E?-&0P M-5\Y9C5B7V)E9CDQ-F0X.#9C90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO M+R]#.B]A,3!E,6%C8U]F,C@Y7S1D,#5?.68U8E]B968Y,39D.#@V8V4O5V]R M:W-H965T'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^3F\\2!#=7)R96YT(%)E<&]R=&EN M9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,3`M43QS M<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'!E;G-E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'!E;G-E2!I;B`H96%R;FEN9W,I(&QO M'!E M;G-E*2P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XR+#@U,CQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N("T@9&ES8V]N=&EN=65D(&]P M97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA6UE;G1S("T@9&ES8V]N=&EN=65D M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]A,3!E,6%C8U]F,C@Y7S1D,#5?.68U8E]B968Y,39D.#@V8V4-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83$P93%A8V-?9C(X.5\T9#`U7SEF M-6)?8F5F.3$V9#@X-F-E+U=O'0O:'1M;#L@8VAA'0^/&1I=CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I3H@8FQO8VL[(&UA3H@8FQO M8VL[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V1I6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M/&)R("\^/"]F;VYT/CPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF M>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,3AP=#L@9&ES<&QA>3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SY);B!T:&4@;W!I;FEO;B!O9B!M86YA M9V5M96YT+"!T:&4@=6YA=61I=&5D(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@ M:6YT97)I;2!F:6YA;F-I86P@2!T;R!F86ER M;'D@65A6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B!4:6UE65A3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N M/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!4:6UE6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[ M)SY4:')O=6=H;W5T(&UO2P@=VAI8V@@ M:&%D(&)E96X@96YG86=E9"!I;B!S979E2!S=7!P;W)T960@8GD@8W5S=&]M97)S(&%N M9"!T:&4@9V]V97)N;65N="!O9B!&6QE/3-$)W1E>'0M:6YD96YT.B`Q M.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!4:6UE&EM871E;'D@-#2P@=VAI;&4@=V4@9F]C=7-E9"!O=7(@969F;W)T2!A;&P@;V8@ M;W5R(')E;6%I;FEN9R!A2!P6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T M97AT+6EN9&5N=#H@,3AP=#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!N;W)M86P[)SY/;B!*86YU87)Y(#$T+"`R,#$Q+"!T:&4@0V]M<&%N>2P@ M&-H86YG92!F;W(@86X@87!P2!P M2!S97)V:6-E'!E8W0@=&\@96UP;&]Y(&]U2!T M:&4@=&%X(&)E;F5F:71S(&]F(&]U6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$ M)V1I2`Y M+"`R,#$Q+"!T:&4@0V]M<&%N>2!A;F0@4U!0(%!R;V-E2!3>7-T96US($QI;6ET960@*"8C.#(R,#M34%13)B,X,C(Q.RD@96YT97)E M9"!I;G1O(&%N($%S2!A;F0@<')O9'5C="!L:6YE2!A M;F0@;W1H97(@87-S971S(')E;&%T:6YG('1O('1H92!$4DE%($5T8V@@<&QA M7-I M8V%L('9A<&]R(&1E<&]S:71I;VX@*"8C.#(R,#M05D0F(S@R,C$[*2!B=7-I M;F5S65R M($1E<&]S:71I;VX@*"8C.#(R,#M.3$0F(S@R,C$[*2!I;G1E;&QE8W1U86P@ M<')O<&5R='D@<&]R=&9O;&EO+B8C,38P.R8C,38P.TAA=FEN9R!D:7-C;VYT M:6YU960@=&AE(&EM<&QE;65N=&%T:6]N(&]F($Y,1"!D=7)I;F<@9FES8V%L M(#(P,3`L('=E(&EN2P@=V4@8F5G86X@=&AE('!R;V-E2!C;VUP86YI97,L(&EN8VQU9&EN9R!31DD@86YD(%1E9V%L($=M M8D@L(&%L;VYG('=I=&@@8G)A;F-H97,@:6X@5&%I=V%N+"!+;W)E82!A;F0@ M271A;'DN)B,Q-C`[)B,Q-C`[)B,Q-C`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`[345-4R8C.#(R,3LI)B,Q M-C`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`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V1I"P@ M26YC+B!W87,@8V]M<&QE=&5D(&]N($YO=F5M8F5R(#(R+"`R,#$Q+"!I;B!T M:&4@9F]R;2!O9B!A(&-O;G9E2!B92!U=&EL:7IE9"!F;W(@82!V M87)I971Y(&]F(&UE9&EC86P@87!P;&EC871I;VYS(')E<75IFEN9R!I=',@=6YI<75E+"!P871E;G1E9"!A<'!R;V%C:"!W:&EC:"!E;F%B M;&5S('1H92!T2P@;&]W+6EN M=&5N2!U;'1R87-O=6YD('-U&EB;&4@;6%T97)I86QS+"!I;F-L=61I;F<@3H@8FQO8VL[(&UA6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I M2!O;F4M=&AI"<@9FER6QE/3-$)V1I M2!O9B!D:7-P;W-A8FQE('5L=')A6QE/3-$)V1I2!# M12!M87)K(&-E6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE'!L M;VET(&]U2X\+V9O;G0^/"]F;VYT/CPO9F]N M=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I2!S96-U2!B92!F;W)C960@=&\@8V]N2!O2!P6]U('1H870@=V4@=VEL;"!B92!S M=6-C97-S9G5L(&EN('!U2!O9B!T:&5S92!S=')A=&5G:6,@ M86QT97)N871I=F5S+B8C,38P.R8C,38P.TEF('=E('=E6]U(&-O=6QD(&QO6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I M6QE/3-$)W1E>'0M:6YD M96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE2!A8V-E<'1E9"!A8V-O=6YT:6YG M('!R:6YC:7!L97,L('1H92!$4DE%(&)U7-T96US(&%N9"!P87)T6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`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`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`E+"`Q."4@86YD(#$W)2P@6QE/3-$)W1E>'0M:6YD96YT.B`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`R,#$P+CPO M9F]N=#X\+V9O;G0^/"]F;VYT/CPO9&EV/CQD:78@3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,3AP=#L@ M9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SY4:&4@8F%L M86YC92!O9B!T:&4@;F]T92!R96-E:79A8FQE(&%T($1E8V5M8F5R(#,Q+"`R M,#$Q(&-O;G-I6UE;G0@ M;W=E9"!B>2!/14T@1W)O=7`@:6X@=&AE($=E6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE2=S(&YO=&4@2`U+"`R,#$Q+"!A;F0@ M=&AE('-E8V]N9"!I;G-T86QL;65N="!O9B`D,30P('=A6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I65A2!T2!P=7)S=6%N="!T;R!T:&4@9&5R:79A=&EV92!T2!T2!S=&%T=7,@87,@:68@=&AE2!R96-L87-S:69I960@)#,T-B!F2!F86-T;W(@;V8@-SDN,24[(&%N9"!A(&1I=FED96YD('EI96QD(&]F M(#`N,"4N)B,Q-C`[)B,Q-C`[070@1&5C96UB97(@,S$L(#(P,3$L('1H92!F M86ER('9A;'5E(&]F('1H92!W87)R86YT65A2!R96-O2!R96-O6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^26YV97-T;65N="!I;B!5;F-O;G-O;&ED M871E9"!!9F9I;&EA=&4\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+V1I=CX\9&EV M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P M=#L@;6%R9VEN+7)I9VAT.B`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`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`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`P<'0[(&1I3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&)R("\^/"]F;VYT/CPO9F]N M=#X\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`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`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`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`P<'0[(&1I6QE/3-$)W1E>'0M M:6YD96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE&EM871E;'D@,B4@;V8@=&AE($-O;7!A;GDG6EN9R!A;6]U;G1S(&]F('1H92!#;VUP86YY)W,@8V%S M:"!E<75I=F%L96YT6QE/3-$)V1I M6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&)R("\^/"]F;VYT/CPO9F]N M=#X\+V1I=CX\9&EV(&%L:6=N/3-$8V5N=&5R/CQT86)L92!C96QL<&%D9&EN M9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$-C`E('-T>6QE/3-$)V9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I M;F#LG/CQF M;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`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`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$P)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@ M'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL M:6YE.R<^,C`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`P M<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^26YT86YG:6)L M92!!6QE/3-$)W1E>'0M:6YD M96YT.B`R-W!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`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`Q,2P@=&AE($-O;7!A M;GDL(&%S('!A&EM871E;'D@)#0@;6EL;&EO;BXF(S$V,#LF(S$V M,#M4:&4@0V]M<&%N>2!F:6YA;&EZ960@=&AE('-A;&4@=')A;G-A8W1I;VX@ M;V8@=&AE(&9I&EM871E;'D@)#,N-B!M:6QL:6]N+B8C,38P.R8C,38P.U1H92!# M;VUP86YY(&9I;F%L:7IE9"!T:&4@2!T:&%T M(&)R:61G97,@=&AE(&=A<"!B971W965N(&AI9V@@=&AR;W5G:'!U="P@;F]N M+6-O;F9O6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M26UP86ER;65N="!O9B!,;VYG+4QI=F5D($%S6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`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`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`P<'0[(&1I6QE/3-$)V1I6QE M/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^(#(P,3$@86YD(#(P,3`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`P M<'0[(&1I6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$ M)V1I6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`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`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`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN M+6QE9G0Z(#EP=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$ M)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE'!E8W1E9"!V;VQA=&EL:71Y M(&-A;&-U;&%T960@=7-I;F<@82!S:7@M;6]N=&@@:&ES=&]R:6-A;"!V;VQA M=&EL:71Y+B8C,38P.R8C,38P.R8C,38P.TYO($534%`@87=A2X\+V9O;G0^/"]F M;VYT/CPO9F]N=#X\+V1I=CX\+V1I=CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE M/3-$)V1IF4Z(#$P<'0[)SX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0S-B4@#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT M.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#EP=#L@;6%R M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q,"4@#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q,"4@#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#EP M=#L@;6%R9VEN+7)I9VAT.B`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`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`P<'0[(&1I6QE/3-$)W1E M>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`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`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`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`P<'0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE6QE.B!I=&%L:6,[ M(&1I6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I M6QE/3-$)V1I2!D=7)I;F<@=&AE M('%U87)T97(@96YD960@1&5C96UB97(@,S$L(#(P,3$@:7,@87,@9F]L;&]W M3H@8FQO8VL[(&UA#LG/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF M;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I M6QE M/3-$)V1I6QE/3-$)V1I&5R8VES93PO9F]N=#X\+V9O;G0^ M/"]D:78^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^4')I8V4\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]W M6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&UA M6QE/3-$)W1E>'0M:6YD96YT.B`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`H:6X@665A'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B!T:6UE3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q,"4@6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^06=G3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^26YT#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W!A9&1I;F3H@8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SY"96=I;FYI;F<@;W5T3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@8V]LF4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@8V]LF4Z(#$P M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;FF4Z(#$P M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$.24@6QE M/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]F;VYT M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@#LG/CQF;VYT('-T>6QE M/3-$)V1I6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR,"XT-SPO9F]N=#X\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`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`M.7!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#EP=#L@;6%R9VEN+7)I9VAT M.B`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`T<'@@9&]U8FQE.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)V)O M"!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+C(R M/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T M<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I#LG/CQD:78@86QI M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#EP=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)V)O M"!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-#4L M,C8U/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`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`],T1N;W=R87`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`P<'0[(&1I6QE/3-$ M)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1IF5S(&EN9F]R;6%T:6]N('=I=&@@6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I M6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^17AE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I#LG/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$ M)W1E>'0M:6YD96YT.B`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`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&UA6QE M/3-$)W1E>'0M:6YD96YT.B`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`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`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`P<'0[(&1I3H@8FQO8VL[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`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`Q,3PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)V1I3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#DE('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXV+C`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M.24@6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M.24@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT6QE/3-$)V1I M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-RXR M,#PO9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`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`],T1N;W=R87`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`],T1N;W=R87`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`],T1N;W=R87`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`],T1N;W=R87`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`],T1N;W=R87`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`],T1N;W=R87`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`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L M969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T M<'@@9&]U8FQE.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@6QE/3-$)V1I6QE/3-$)V1I M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`Q M.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)V1I2!E>'!E8W1S('1O(')E8V]G;FEZ92!O=F5R(&$@<&5R:6]D(&]F(#`N M-SD@>65A2!S='EL93TS1"=T M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`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`P<'0[(&1I6QE/3-$)V9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W!A M9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F#LG/CQF;VYT('-T>6QE M/3-$)V1I6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT M97(@3H@8FQO8VL[ M(&UA6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R<^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^1W)A;G0@1&%T93PO9F]N=#X\+V9O;G0^/"]F;VYT/CPO9&EV M/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^)B,Q-C`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`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#EP=#L@ M;6%R9VEN+7)I9VAT.B`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`Q M,2P@/"]F;VYT/G1H97)E('=A'1087)T7V$Q,&4Q86-C7V8R.#E?-&0P-5\Y9C5B7V)E9CDQ-F0X.#9C M90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A,3!E,6%C8U]F,C@Y M7S1D,#5?.68U8E]B968Y,39D.#@V8V4O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B!4:6UE2!S='EL93TS1"=T97AT+6EN9&5N=#H@ M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE M/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[ M(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V1I65AF5D(&%N>2!S>7-T96US('1H870@=V5R92!I;B!F:6YI2=S('!O;&EC>2!W M87,@=&AA="P@:68@869T97(@87!P2`Q."!M;VYT:',L(&ET M(&1E=&5R;6EN97,@=&AA="!A('-A;&4@=VEL;"!N;W0@=&%K92!P;&%C92!W M:71H:6X@=&AE(&YE>'0@='=E;'9E(&UO;G1H7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2!; M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\3H@8FQO8VL[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`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`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`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`U7SEF-6)?8F5F.3$V9#@X-F-E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\=&%B;&4@8F]R9&5R M/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$ M,3`P)2!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SX\='(@=F%L:6=N/3-$=&]P/CQT9"!A;&EG;CTS M1')I9VAT('-T>6QE/3-$)W=I9'1H.B`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`H3&]S M6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!N;W)M86P[)SY"87-I8R!%4%,@:7,@8V]M<'5T960@8GD@9&EV:61I M;F<@;F5T(&EN8V]M92`H;&]S6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD M96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`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`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`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O M;3X\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`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`[/"]F;VYT/CPO M=&0^/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE M/3-$)V)O"!S;VQI9#LG/CQD:78@86QI M9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R<^ M,C`Q,3PO9F]N=#X\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]WF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`R<'@@6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE M/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I#LG/CQF M;VYT('-T>6QE/3-$)V1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O"!S;VQI9#LG/CQD:78@ M86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE M.R<^,C`Q,#PO9F]N=#X\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]WF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`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`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R M9VEN+6QE9G0Z(#EP=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I M'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[)SXH-3@S/"]F;VYT/CPO9F]N=#X\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@#LG/CQF;VYT('-T>6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXS+#`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`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@ M;6%R9VEN+6QE9G0Z(#EP=#L@;6%R9VEN+7)I9VAT.B`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`],T1N;W=R87`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`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@#LG/CQF;VYT('-T>6QE/3-$)V1I M#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$ M)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT#LG/CQD:78@86QI9VX],T1L969T M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@ M;6%R9VEN+6QE9G0Z(#EP=#L@;6%R9VEN+7)I9VAT.B`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`M.7!T.R!D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#EP=#L@;6%R9VEN+7)I9VAT.B`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`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`],T1N;W=R87`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`M.7!T.R!D:7-P;&%Y.B!B;&]C M:SL@;6%R9VEN+6QE9G0Z(#EP=#L@;6%R9VEN+7)I9VAT.B`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`],T1N;W=R87`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`],T1N;W=R87`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`@ M("`\=&%B;&4@8VQA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V9O;G0M9F%M:6QY.B!T M:6UE2!S='EL93TS1"=T97AT+6EN9&5N=#H@ M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!4:6UE2!S='EL93TS1"=T97AT+6EN M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B!4:6UE6EN9R!A;6]U;G0@;V8@=&AE($-O;7!A;GDG2!S:&]R="!M871U2X@4')I;W(@=&\@1F5B2!H860@;F\@;W!E;B!F;W)E:6=N(&5X8VAA;F=E M(&-O;G1R86-T2!O=&AE&5R8VES92!P2P@=&AE($-O;7!A;GD@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A,3!E,6%C8U]F,C@Y M7S1D,#5?.68U8E]B968Y,39D.#@V8V4-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO83$P93%A8V-?9C(X.5\T9#`U7SEF-6)?8F5F.3$V9#@X-F-E M+U=O'0O M:'1M;#L@8VAA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE M/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$)W1E M>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE2!A;F0@06QC871E;"!,=6-E;G0@96YT97)E9"!I;G1O M(&%N(&EN=&5L;&5C='5A;"!P2!A9W)E96UE;G0@<')O=FED:6YG M(&9O2!R:6=H=',@=&\@=&AE($-O;7!A;GDL(&$@=')A9&5M87)K(&QI M8V5N2=S(&)O87)D(&]F(&1I2P@86YD(&ET6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V9O;G0M9F%M:6QY.B!T M:6UE3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY!6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)W1E>'0M:6YD96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE M9G0Z(#$X<'0[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SY43H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R M/CQT#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT M.B`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`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@#LG/CQF;VYT('-T>6QE M/3-$)V1I#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD M96YT.B`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#EP=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T M:6UE'0M86QI9VXZ M(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ M+#DR-#PO9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`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`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`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`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@ M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&)R("\^/"]F;VYT/CPO9F]N=#X\+V1I M=CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W=I M9'1H.B`Q.'!T.R<^/&1I=CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!3>6UB;VPL('-E3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M5&EM97,@3F5W(%)O;6%N.R<^)B,Y-C6QE M/3-$)V1I6QE/3-$)V1I M6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY!;B!A9V=R96=A M=&4@;V8@)#$L-S4P(&-A2!I;B!F M;W5R(&EN6UE;G1S(&]F("0R-3`L("0U,#`L("0U,#`@ M86YD("0U,#`@;VX@2G5L>2`Q+"`R,#$P+"!/8W1O8F5R(#$L(#(P,3`L($IA M;G5A6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W=I9'1H.B`Q.'!T.R<^/&1I=CX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!3>6UB;VPL('-E3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<^)B,Y-C6QE/3-$)V1I6UE;G0@:6X@8V%S:"!O9B!U<"!T;R`D,2PP,#`@<&%Y M86)L92!T;R!T:&4@0V]M<&%N>2!B>2!!<')I;"`Q-2P@,C`Q,2!B87-E9"!O M;B!T:&4@9F]L;&]W:6YG('!E2!T:&4@0V]M<&%N>2!O3H@8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&)R("\^ M/"]F;VYT/CPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W=I9'1H.B`T,"XU<'0[)SX\9&EV/CQF;VYT('-T M>6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6UE;G0@=VEL;"!B92`U)2!O9B!T:&4@87!P;&EC86)L92!B M;V]K:6YG&-E6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(@ M=F%L:6=N/3-$=&]P/CQT9"!S='EL93TS1"=W:61T:#H@-#`N-7!T.R<^/&1I M=CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!4:6UE3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SYI9B!A<'!L:6-A8FQE(&)O;VMI;F=S(&%R92!G3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`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`P<'0[(&1I6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W=I9'1H.B`T,"XU<'0[)SX\9&EV/CQF;VYT('-T M>6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE.B!I=&%L:6,[(&1I M&-E6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I2!S='EL93TS1"=T97AT M+6EN9&5N=#H@,3AP=#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!N M;W)M86P[)SY"87-E9"!O;B!T:&4@87!P;&EC86)L92!B;V]K:6YG6UE;G0@2!R96-E:79E9"`D,S`P(&]N($IU;'D@-2P@,C`Q,2!A;F0@)#$T M,"!P;'5S(&%P<')O>&EM871E;'D@)#4@;V8@:6YT97)E'0@;V8@=&AE M($%M96YD;65N="P@82!C;W!Y(&]F('=H:6-H('=A&AI M8FET(#$P+C$@=&\@=&AE($9O6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE65A2!I;7!A8W1E9"!B>2!T:&4@9&]W;G1U'!E;G-E2!E=F%L=6%T960@=F%R:6]U6QE.B!I=&%L:6,[(&1I2`Y+"`R,#$Q+"!T:&4@0V]M<&%N>2!S;VQD(&ET6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[('1E>'0M9&5C;W)A=&EO;CH@=6YD97)L:6YE.R<^5&AE(%-05%,@ M5')A;G-A8W1I;VX\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+V9O;G0^/"]D:78^ M/&1I=B!A;&EG;CTS1&-E;G1E6QE/3-$)W1E>'0M M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE2!I;F-O2=S('=H;VQL>2UO=VYE9"!S=6)S:61I87)Y M+"!A;F0@<')O9'5C="!L:6YE2!A;F0@;W1H97(@87-S971S(')E;&%T:6YG M('1O('1H92!#;VUP86YY)W,@1%))12!S>7-T96US(&%N9"!C97)T86EN(')E M;&%T960@=&5C:&YO;&]G>2!34%13(&%L&ES=&EN9R!C M=7-T;VUE2!O8FQI9V%T:6]N&ES=&EN9R!C=7-T;VUE M3H@8FQO8VL[(&UA6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I2!A;F0@4U!44R!E;G1E2UF6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B!4:6UE&EM871E;'D@)#(L,3`P+"!C;VUP M2`D-3`P(&]F($%S2!U M;F1E6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!4:6UE&AI8FET2!R M969E6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V9O;G0M3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[('1E>'0M9&5C;W)A=&EO;CH@ M=6YD97)L:6YE.R<^1&ES8V]N=&EN=65D($]P97)A=&EO;G,\+V9O;G0^/"]F M;VYT/CPO9F]N=#X\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&-E;G1E6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!4:6UE2P@:6X@=&AE(&%C8V]M<&%N>6EN9R!C M;VYD96YS960@8V]N3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&)R("\^/"]F;VYT/CPO9F]N M=#X\+V1I=CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\='(^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X M.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@ M/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D M:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@#LG/CQF;VYT M('-T>6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I M6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R<^36%R8V@@,S$L/"]F;VYT/CPO9F]N=#X\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1I6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I M#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#LG/CQD M:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL M:6YE.R<^,C`Q,3PO9F]N=#X\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]WF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`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`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`M.7!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#$X<'0[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY. M;W1E3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR-CPO9F]N=#X\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`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`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@#LG/CQF;VYT('-T>6QE/3-$ M)V1I#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT M.B`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`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`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE M2!R96-E:79E9"`D-#0P(&9R;VT@ M3T5-(&EN(&EN6UE;G1S(')E;&%T960@=&\@=&AE('-A M;&4@;V8@;&5G86-Y(&%S'!E;G-E6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1IF5D("0S+#4U,"!FF5D('1H92!S86QE('1R86YS86-T M:6]N(&]F('1H92!F:7)S="!O9B!T:&4@9F]U65T M(&9I;F%L:7IE9"!T:&%T('1R86YS86-T:6]N+B8C,38P.R8C,38P.U-A;&5S M(&]F($Y,1"!P871E;G1S(&EN(&9U='5R92!P97)I;V1S('=I;&P@86QS;R!B M92!R96-O9VYI>F5D(&EN(&1I65R(&1E<&]S:71I;VX@*$%,1"DN)B,Q-C`[)B,Q-C`[5&AE('!O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A M,3!E,6%C8U]F,C@Y7S1D,#5?.68U8E]B968Y,39D.#@V8V4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83$P93%A8V-?9C(X.5\T9#`U7SEF-6)? M8F5F.3$V9#@X-F-E+U=O'0O:'1M;#L@8VAA'0^/&1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\=&%B;&4@8F]R9&5R/3-$,"!C M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S M='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\='(@=F%L:6=N/3-$=&]P/CQT9"!A;&EG;CTS1')I9VAT M('-T>6QE/3-$)W=I9'1H.B`Q.'!T.R<^/&1I=B!A;&EG;CTS1&IU3H@8FQO8VL[(&UA M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^-RXF(S$V,#L\+V9O;G0^/"]F;VYT/CPO9F]N M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0^/&1I=B!A;&EG;CTS1&IU M3H@8FQO M8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM M97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^1V5O9W)A<&AI8V%L($EN9F]R;6%T M:6]N.CPO9F]N=#X\+V9O;G0^/"]F;VYT/CPO9&EV/CPO=&0^/"]T3H@8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&)R("\^ M/"]F;VYT/CPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL M93TS1"=T97AT+6EN9&5N=#H@,3AP=#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM M97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!N;W)M86P[)SY02`Y+"`R,#$Q+"!T M:&4@0V]M<&%N>2!O<&5R871E9"!I;B!O;F4@2P@=&AE($-O;7!A;GDG2X\+V9O;G0^ M/"]F;VYT/CPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B!4:6UE2!G96]G M3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F;VYT M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T M>6QE/3-$)V1I3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R<^4F5V96YU92!F;W(@=&AE/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)V1I3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^4F5V96YU92!F;W(@=&AE/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/"]T3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0V M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,B4^ M/&1I=B!A;&EG;CTS1&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE M3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P M86X],T0V(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0R,B4^/&1I=B!A;&EG;CTS1&-E;G1E6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0V(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,B4@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@ M3H@:6YL:6YE.R<^,C`Q,3PO9F]N=#X\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R<^,C`Q,#PO9F]N=#X\+V9O;G0^/"]D:78^/"]T M9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#LG M/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@ M:6YL:6YE.R<^,C`Q,3PO9F]N=#X\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]W M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#LG/CQF M;VYT('-T>6QE/3-$)V1I6QE M/3-$)V)O"!S;VQI9#LG/CQD:78@86QI M9VX],T1C96YT97(@3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R<^ M,C`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`M.7!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#EP=#L@;6%R9VEN+7)I9VAT.B`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`],T1N;W=R87`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M#LG/CQF;VYT('-T>6QE/3-$)V1I#LG/CQF M;VYT('-T>6QE/3-$)V1I6QE/3-$ M)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE M2P@:&%V92!B965N(')E8VQA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)V1I6QE/3-$)V1IF4Z(#$P<'0[)SX\='(^/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4V)2!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I#LG/CQF;VYT M('-T>6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F3H@8FQO8VL[(&UA M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,;VYG+6QI=F5D(&%S6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE M3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q,"4^/&1I=B!A;&EG;CTS1&-E;G1EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q M-C`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`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`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]A,3!E,6%C8U]F,C@Y7S1D,#5?.68U8E]B968Y,39D M.#@V8V4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83$P93%A8V-? M9C(X.5\T9#`U7SEF-6)?8F5F.3$V9#@X-F-E+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\=&%B;&4@8F]R9&5R/3-$,"!C96QL<&%D M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS M1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SX\='(@=F%L:6=N/3-$=&]P/CQT9"!A;&EG;CTS1')I9VAT('-T>6QE M/3-$)W=I9'1H.B`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`Q.'!T.R!D:7-P;&%Y.B!B M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4 M:6UE6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[)SY) M;B!$96-E;6)E6QE.B!I M=&%L:6,[(&1I6QE.B!I=&%L:6,[(&1I2!T:&]S92!A;65N9&UE;G1S(&%R92!E>'!E8W1E9"!T;R!B M92!P3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]A,3!E,6%C8U]F,C@Y7S1D,#5?.68U8E]B968Y,39D.#@V8V4-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83$P93%A8V-?9C(X.5\T9#`U7SEF M-6)?8F5F.3$V9#@X-F-E+U=O'0O:'1M;#L@8VAA6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!4:6UE3H@8FQO8VL[(&UA3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&)R("\^/"]F M;VYT/CPO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`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`X M+4L@9FEL960@;VX@3F]V96UB97(@,CDL(#(P,3$@86YD(&ES(&EN8V]R<&]R M871E9"!H97)E:6X@8GD@3H@8FQO8VL[(&UA6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I2!F:6YA M;F-I;F<@8GD@3F%N;R!6:6)R;VYI>"!O2!M87D@8V]N=F5R="!P"!3 M97)I97,@0BTQ(%!A6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@8FQO8VL[(&UA6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I2`Q-"P@,C`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`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`Q.'!T.R!D:7-P;&%Y.B!B;&]C M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE M2`D,B!F3H@8FQO8VL[(&UA6QE/3-$)V1I M6QE/3-$)V1I2=S('-H87)E(&]F(&YE="!L;W-S(&ES("0S-S,N M/"]F;VYT/CPO9F]N=#X\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&IU7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC'1087)T7V$Q,&4Q86-C7V8R.#E?-&0P-5\Y9C5B 17V)E9CDQ-F0X.#9C92TM#0H` ` end XML 14 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Product Warranty
9 Months Ended
Dec. 31, 2011
Product Warranty [Abstract]  
Product Warranty
2. 
Inventories:

Inventories are stated at the lower of cost or market. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis and includes material, labor and manufacturing overhead costs. Any excess and obsolete provision is only released if and when the related inventory is sold or scrapped.  The Company did not sell or scrap previously reserved inventory during the nine months ended December 31, 2011 and 2010.  The inventory provision balance for the periods ended December 31, 2011 and 2010 was $0 and $547, respectively.  The inventory provision for the nine month period ended December 31, 2010 was related to the DRIE products, which were sold in the prior fiscal year.
 
Net inventories for the periods presented were zero.  All remaining inventory was included in the sale of the DRIE related assets in the prior fiscal year.

Prior to the sale of the DRIE assets in the prior fiscal year, the Company periodically analyzed any systems that were in finished goods inventory to determine if they were suitable for current customer requirements.  At that time, the Company's policy was that, if after approximately 18 months, it determines that a sale will not take place within the next twelve months and the system would be useable for customer demonstrations or training, it is transferred to fixed assets.  Otherwise, it was expensed.
XML 15 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2011
Mar. 31, 2011
Current assets:    
Cash and cash equivalents $ 8,264 $ 7,575 [1]
Restricted cash 200 200 [1]
Prepaid expenses and other current assets 92 139 [1]
Other assets of discontinued operations 443 1,129 [1]
Total current assets 8,999 9,043 [1]
Property and equipment, net 58 112 [1]
Investment in unconsolidated affiliate 1,545 2,046 [1]
Investment in convertible promissory note 300 0 [1]
Total assets 10,902 11,201 [1]
Current liabilities:    
Accounts payable 81 262 [1]
Common stock warrant liability 20 26 [1]
Accrued expenses and other current liabilities 57 94 [1]
Liabilities of discontinued operations 380 1,410 [1]
Total current liabilities 538 1,792 [1]
Stockholders' equity:    
Preferred stock; $0.01 par value; 5,000,000 shares authorized; none issued and outstanding 0 0 [1]
Common stock; $0.01 par value; 50,000,000 shares authorized; 1,688,807 and 1,688,943 shares issued and outstanding at December 31, 2011 and March 31, 2011, respectively. 17 17 [1]
Additional paid-in capital 129,107 128,977 [1]
Accumulated other comprehensive loss (140) (167) [1]
Accumulated deficit (118,620) (119,418) [1]
Total stockholders' equity 10,364 9,409 [1]
Total liabilities and stockholders' equity $ 10,902 $ 11,201 [1]
[1] Derived from the Company's audited consolidated financial statements
XML 16 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Basis of Presentation
9 Months Ended
Dec. 31, 2011
Basis of Presentation [Abstract]  
Basis of Presentation
1. 
Basis of Presentation:

In the opinion of management, the unaudited condensed consolidated interim financial statements have been prepared on the same basis as the March 31, 2011 audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary to fairly state the information set forth herein.  The statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (“SEC”), but omit certain information and footnote disclosures necessary to present the statements in accordance with generally accepted accounting principles (“GAAP”).  These interim financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2011.  The results of operations for the three and nine months ended December 31, 2011 are not necessarily indicative of results to be expected for the entire year.
 
Tegal Corporation and its subsidiaries' (“Tegal”, “the Company”, “we”, “us” or “our”) consolidated financial statements contemplate the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future.  We incurred net income/(loss) of $798 and ($2,426) for the nine months ended December 31, 2011 and 2010, respectively. We (used)/generated ($2,273) and $314 of cash in operating activities for the nine months ended December 31, 2011 and 2010, respectively.  We believe that our existing balances of cash and cash equivalents, combined with continued cost containment, will be adequate to fund operations through fiscal year 2012.
 
Throughout most of fiscal 2011, our operations consisted mainly of the sale and support of the Deep Reactive Ionic Etch (“DRIE”) product lines which we had acquired from Alcatel Micro Machining Systems (“AMMS”) in fiscal 2009, including the operation of our Tegal France subsidiary, which had been engaged in several joint development projects partially supported by customers and the government of France.  Tegal France had also been the center for the majority of our product and process development efforts and engineering activities related to the improvement of our DRIE product lines.
 
DRIE systems sales and the associated spares and service revenue represented the sole source of the Company's revenue in fiscal 2011.  For all of fiscal 2010, DRIE sales represented approximately 47% of our total revenues.  Since the DRIE markets were seriously impacted by the downturn in the semiconductor markets and the lack of available capital for new product development globally, DRIE sales alone were not enough to continue supporting the Company, even with significant reductions in our operating expenses resulting from the sale of our legacy etch and PVD business, as well as the implementation of further cost containment measures.  Accordingly, while we focused our efforts on the operation of the DRIE business in the first half of fiscal 2011, we continued to seek and evaluate strategic alternatives, which included the continued operation of the Company as a stand-alone business with a different business plan, a merger with or into another company, a sale of all or substantially all of our remaining assets, and the liquidation or dissolution of the Company, including through a voluntary dissolution or a bankruptcy proceeding.
 
On January 14, 2011, the Company, se2quel Partners and Sequel Power entered into a Formation and Contribution Agreement. The Company contributed $2 million in cash to Sequel Power in exchange for an approximate 25% economic interest in Sequel Power.  Sequel Power is focused on the promotion of solar power plant development projects worldwide, the development of self-sustaining businesses from such projects, including but not limited to activities relating to and supporting, developing, building and operating solar photovoltaic (“PV”) fabrication facilities and solar farms, the consideration of other non-photovoltaic renewable energy projects and engagement in ancillary activities, such as advisory services.  The Sequel Power model for large scale PV-based solar projects is unique in the industry and has won significant acclaim from governments, industrial companies and industry advocates for its innovation and prospect for success.  By investing in this new company, we expect to employ our capital equipment know-how, a portion of our cash and potentially the tax benefits of our NOLs.  We intend to support the activities of Sequel Power through our direct efforts and through related operations and investments that we may make in the future, should the circumstances be favorable.
 
Following our investment in Sequel Power, and as a result of our continuing efforts to reduce our operating losses, on February 9, 2011, the Company and SPP Process Technology Systems Limited (“SPTS”) entered into an Asset Purchase Agreement.  That agreement included the sale of all of the shares of Tegal France, SAS, the Company's wholly-owned subsidiary and product lines and certain equipment, intellectual property and other assets relating to the DRIE Etch plasma etch systems and certain related technology.  The other major asset remaining after the sale of our legacy etch and physical vapor deposition (“PVD”) business and our DRIE business was our Nano-Layer Deposition (“NLD”) intellectual property portfolio.  Having discontinued the implementation of NLD during fiscal 2010, we instead began to offer this asset for sale to third parties.  Concurrently, we began the process of closing and/or liquidating all of our other wholly-owned subsidiary companies, including SFI and Tegal GmbH, along with branches in Taiwan, Korea and Italy.   As a result, all of our activities related to our legacy etch and PVD business, our DRIE business, our NLD development activities and our subsidiaries and branches are now included in discontinued operations.
 
The process of consolidation and transition, driven by the financial crisis and worsened by our relatively weak strategic and financial position in the semiconductor and micro-electro-mechanical systems (“MEMS”) capital equipment sectors, continues.   Our main objective has been to preserve as much value for stockholders as possible as we transitioned to a business model that avoids high fixed costs, but retains our capabilities to attract and exploit emerging technologies. So far, we have invested in two opportunities.
 
The first investment was made in Sequel Power, and was motivated by a desire to exploit its proprietary model for large scale PV-based solar projects, which is unique in the industry, and has won significant acclaim from governments, industrial companies and industry advocates for its innovation and prospect for success.  Providing a window for us into this market, our investment in Sequel Power has allowed us to evaluate several different aspects of the solar market for the purpose of determining if further investment or business activities would be fruitful.
 
The second investment of $300 in Nano Vibronix, Inc. was completed on November 22, 2011, in the form of a convertible promissory note.  Nano Vibronix is a private company that develops medical devices and products that implement its proprietary therapeutic ultrasound technology which may be utilized for a variety of medical applications requiring low cost therapeutic ultrasound qualities. Nano Vibronix is focused on creating products utilizing its unique, patented approach which enables the transmission of low-frequency, low-intensity ultrasound surface acoustic waves (“SAWs”) through a variety of soft, flexible materials, including skin and tissue, enabling low-cost, breakthrough devices targeted at large, high-growth markets.
 
NanoVibronix is developing a series of products directed at the treatment of chronic, non-healing wounds. The global wound care market is estimated to reach $22.8 billion by 2017, of which approximately one-third is addressed by advanced wound care products, according to a report recently published by Global Industry Analysts, Inc., a research group. The growth of the market is being fueled by an aging population and the rapidly increasing incidence of diabetes world-wide.  Nano Vibronix' first product, PainShieldTM MD, has gained FDA clearance and CE Mark certification in Europe, and is marketed for the treatment of tendonitis, muscle pain and trigeminal neuralgia. Additionally, Nano Vibronix has developed a family of disposable ultrasound devices to treat catheter-associated infection and injury, accomplished by preventing biofilm formation and decreasing the friction between the catheter and body tissues. The UroShieldTM product is currently CE mark certified, and is the subject of several independent clinical trials being conducted by leading researchers in Europe and the Middle East.
 
At the present time we are engaged primarily in supporting the activities of Sequel Power through our direct efforts and through related operations and investments we may make in the future.  In addition to our investments in Sequel Power and Nano Vibronix, we are actively evaluating opportunities for partnerships with other diversified technology-based companies in order to exploit our shared experience and to enhance our value as a public company.
 
We cannot assure you that we will be successful in pursuing any of these strategic alternatives.   If our efforts do not succeed, we may need to raise additional capital which may include capital raises through the issuance of debt or equity securities.  If additional funds are raised through the issuance of preferred stock or debt, these securities could have rights, privileges or preferences senior to those of our common stock, and debt covenants could impose restrictions on our operations. Moreover, such financing may not be available to us on acceptable terms, if at all.  Failure to raise any needed funds would materially adversely affect us.  It is not possible to predict when our business and results of operations will improve.  In consideration of these circumstances, the Company may be forced to consider a merger with or into another company or the liquidation or dissolution of the Company, including through a bankruptcy proceeding.  We cannot assure you that we will be successful in pursuing any of these strategic alternatives.  If we were to liquidate or dissolve the Company through or outside of a bankruptcy proceeding, you could lose all of your investment in Tegal common stock.
 
Reclassifications
 
As a result of the sale of the Company's DRIE assets in the prior fiscal year, and in accordance with generally accepted accounting principles, the DRIE business operations related to the designing, manufacturing, marketing and servicing of systems and parts within the semiconductor industry has been reclassified to discontinued operations in our condensed consolidated financial statements.   Amounts for the prior periods have been reclassified to conform to this presentation.  The exit from the DRIE operation was essentially completed by the end of the fourth quarter of our 2011 fiscal year.
 
Concentration of Credit Risk
 
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash investments.  Prior to the sale of the DRIE assets, the Company's accounts receivable balance was also subject to credit risk. Substantially all of the Company's liquid investments are invested in money market funds. The Company's accounts receivable are derived primarily from sales to customers located in the United States, Europe and Asia. The Company performs ongoing credit evaluations of its customers and generally requires no collateral. The Company no longer maintains reserves for potential credit losses. Write-offs during the periods presented have been insignificant.
 
As of December 31, 2011 and 2010, two customers accounted for 100% and 73%, respectively of the total accounts receivable balance. Approximately 12% of the total balance in accounts receivable for the period ended December 31, 2011 is related to our semi-conductor business and is included in assets of discontinued operations.  The Company considers this amount collectible.  The total amount of balances in accounts receivable for the period ended December 31, 2010 is included in discontinued operations.
 
For the three and nine months ended December 31, 2011, Sequel Power accounted for 100% of total revenue, which is included in continuing operations.  For the nine months ended December 31, 2010, a leading precision timing device manufacturer, Ulsan National Institute of Science and Technology, STMicroelectronics SA, and Uppsala University accounted for 28%, 20%, 18% and 17%, respectively, of total revenue.  Total revenue for the three and nine months ended December 31, 2010 is included in discontinued operations.
 
Note Receivable
 
The Company's note receivable consisted of outstanding payments owed by OEM Group in connection with our sale to them of our legacy etch and PVD assets completed in March 2010.
 
The balance of the note receivable at December 31, 2011 consisted of the net outstanding payment owed by OEM Group in the German subsidiary in connection with the sale of legacy assets.  This balance due is included in discontinued assets and will be offset in a non-cash transaction at the final liquidation of the German subsidiary in the first quarter of the next fiscal year per the schedule of the German tax authorities.
 
The outstanding balance of cash owed on the Company's note receivable from OEM was paid in full during the first quarter of the current fiscal year.  The Company was entitled to receive an additional contingent payment of $440 related to the terms of the sale, which was paid in full in two installments.  The first installment of $300 was paid on July 5, 2011, and the second installment of $140 was paid on October 7, 2011.  In connection with the installment plan, the Company received an additional $5 in interest payment.  Both the first and second installments were classified as a gain on sale of discontinued operations in the second and third quarters of the current fiscal year.
 
Derivative Instruments
 
In June 2008, the Financial Accounting Standards Board (“FASB“)  ratified the Emerging Issues Task Force (“EITF”) consensus on EITF Issue No. 07-05, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock (“EITF Issue 07-05”) (Topic 815) which applies to the determination of whether any freestanding financial instruments or embedded features that have the characteristics of a derivative, as defined by Statement of Financial Accounting Standards (“SFAS”) No. 133 (Topic 815), Accounting for Derivative Instruments and Hedging Activities, and to any freestanding financial instruments are potentially indexed to an entity's own common stock.  EITF Issue No. 07-05 (Topic 815) became effective for fiscal years beginning after December 15, 2008.  The Company adopted Topic 815 as of April 1, 2009.  As a result, warrants to purchase 285,454 shares of our common stock previously treated as equity pursuant to the derivative treatment exemption were no longer afforded equity treatment. The warrants had exercise prices ranging from $30.00-$495.00 and expired or will expire between February 2010 and September 2013. As such, effective April 1, 2009, the Company reclassified the fair value of these warrants, which had exercise price reset features, from equity to liability status as if these warrants were treated as a derivative liability since their date of issue between February 2000 and January 2006.  On April 1, 2009, the Company reclassified $346 from additional paid-in capital, as a cumulative effect adjustment, to beginning accumulated deficit, and $502 to common stock warrant liability to recognize the fair value of such warrants on such date.  As of March 31, 2011, the fair value of the warrants was estimated using the Black-Scholes pricing model with the following weighted average assumptions:  risk-free interest rate of 2.24%; expected life of 1.1 years; an expected volatility factor of 79.1%; and a dividend yield of 0.0%.  At December 31, 2011, the fair value of the warrants was $20, which was calculated using the Black-Scholes pricing model with the following weighted average assumptions:  risk-free interest rate of 0.83%; expected life of 1.63 years; an expected volatility factor of 155%; and a dividend yield of 0.0%.  For the nine months ended December 31, 2011 and 2010, respectively, the Company recorded non-cash gains of $6 and $344 related to these warrants. The Company recorded a non-cash loss related to the warrants of $8 in the quarter ended December 31, 2011 and a non-cash gain of $3 in the quarter ended December 31, 2010.
 
Investment in Unconsolidated Affiliate
 
The Company evaluates its joint venture arrangements to determine whether they should be recorded on a consolidated basis.  The percentage of economic interest in the joint venture, an evaluation of control and whether a variable interest entity (“VIE”) exists are all considered in the consolidation assessment.
 
We account for our investment in joint ventures where we own a non-controlling interest or where we are not the primary beneficiary of a VIE using the equity method of accounting. Under the equity method, our cost of investment is adjusted for our share of equity in the earnings or losses of the unconsolidated affiliate and reduced by distributions received.
 
Any differences between the cost of our investment in an unconsolidated affiliate and our underlying equity as reflected in the unconsolidated affiliate's financial statements generally result from a different basis in assets contributed to the joint venture. The net difference between our investment in unconsolidated affiliates and the underlying equity of unconsolidated affiliates is generally amortized over a period of ten years, which is determined to be the estimated useful life of the underlying intangibles which created the difference in carrying amount.  The net difference at March 31, 2011 was $1,730.  The amortization expense related to this difference for the fiscal year ended March 31, 2011 was $45.  The amortization expense related to this difference for the three and nine month periods ended December 31, 2011 was $43 and $129, respectively.  There was no amortization expense related to this investment for the three and nine month periods ended December 31, 2010, respectively.
 
 On a periodic basis, we assess whether there are any indicators that the fair value of our investments in unconsolidated affiliates may be impaired. An investment is impaired only if our estimate of the fair value of the investment is less than the carrying value of the investment, and such decline in value is deemed to be other than temporary. To the extent impairment has occurred, the loss is measured as the excess of the carrying amount of the investment over the fair value of the investment. Our estimates of fair value for each investment are based on a number of assumptions such as future revenue projections, operating forecasts, discount rates and capitalization rates, among others.  These assumptions are subject to economic and market uncertainties. As these factors are difficult to predict and are subject to future events that may alter our assumptions, the fair values estimated in the impairment analyses may not be realized.  No impairments of investments in unconsolidated affiliates were incurred during the year ended March 31, 2011 or the nine month period ended December 31, 2011.

Fair Value Measurements
 
The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and we consider what assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.   The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
 
 
·
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.

 
·
Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.
 
 
·
Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management's estimates of market participant assumptions.
 
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.
 
The Company's financial instruments consist primarily of money market funds.  At December 31, 2011, 98% of the Company's current assets in financial instruments investments were classified as cash equivalents in the condensed consolidated balance sheets. Approximately 2% of the Company's current assets in financial investments were classified as restricted cash.  The investment portfolio at December 31, 2010 was comprised of money market funds.   The carrying amounts of the Company's cash equivalents are valued using Level 1 inputs.  The Company also has warrant liabilities which are valued using Level 3 inputs.
 
The changes in the fair value of warrants is as follows:

   
Nine Months Ended
 
   
December 31,
 
        
   
2011
  
2010
 
Balance at the beginning of the period
 $26  $363 
Issuance of warrants
  -   - 
Change in fair value recorded in earnings
  (6)  (339)
Balance at the end of the period
 $20  $24 

Intangible Assets

Intangible assets include patents and trademarks that are amortized on a straight-line basis over periods ranging from 5 years to 7 years.  The Company performs an ongoing review of its identified intangible assets to determine if facts and circumstances exist that indicate the useful life is shorter than originally estimated or the carrying amount may not be recoverable.  If such facts and circumstances exist, the Company assesses the recoverability of identified intangible assets by comparing the projected undiscounted net cash flow associated with the related asset or group of assets over their remaining lives against their respective carrying amounts.  Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets.   As of fiscal year end 2011, all of the Company's remaining intangible assets were included in the asset sale of the DRIE product line to SPTS, except for those that were internally developed, which have a carrying value of zero.
 
During December 2011, the Company, as part of its proposed sale of its intellectual property portfolio for Nanolayer Deposition Technology (NLD), awarded three of the four offered lots to multiple semiconductor equipment manufacturers for aggregate consideration of approximately $4 million.  The Company finalized the sale transaction of the first of the four lots on December 23, 2011, and for which the Company has received approximately $3.6 million.  The Company finalized the sale transaction of the second lot after December 31, 2011.  While the third lot has been awarded, the Company has not yet finalized that transaction.  NLD is a process technology that bridges the gap between high throughput, non-conformal chemical vapor deposition (CVD) and highly conformal, low throughput atomic layer deposition (ALD).  The portfolio included over 35 US and international patents in the areas of pulsed-CVD, plasma-enhanced ALD, and NLD.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, as well as at fiscal year end. If undiscounted expected future cash flows are less than the carrying value of the assets, an impairment loss is recognized based on the excess of the carrying amount over the fair value of the assets.  No impairment charges were recorded for fixed assets for the nine months ended December 31, 2011.

Pension Obligations

Prior to fiscal year 2011, the Company began the process of closing and/or liquidating all of our wholly-owned subsidiary companies, not already sold, including Tegal Germany.  The subsidiaries are now included in discontinued operations.  The Company has recognized an ongoing liability for pensions related to the Tegal Germany subsidiary.  However, in fiscal year 2011, the Company recognized an additional liability for the independent third-party administration of the pension program.   The total pension liability in the prior period was $700.  The total pension liability for the period ended December 31, 2011 was $0.  The pension liability was settled on October 6, 2011.  The settlement of the pension obligation is classified as a reduction of liabilities of discontinued operations.  The related foreign exchange gain of $23 is classified as a gain or loss on the sale of discontinued operations in the third quarter of the current fiscal year.

Stock-Based Compensation

We have adopted several stock plans that provide for issuance of equity instruments to our employees and non-employee directors. Our plans include incentive and non-statutory stock options and restricted stock awards.  These equity awards generally vest ratably over a four-year period on the anniversary date of the grant, and stock options expire ten years after the grant date. Certain restricted stock awards may vest on the achievement of specific performance targets.  We also have an Employee Stock Purchase Plan (“ESPP”) that allows qualified employees to purchase Tegal shares at 85% of the fair market value on specified dates.

Total stock-based compensation expense related to stock options and restricted stock units (“RSUs”) for the nine months ended December 31, 2011 and 2010 was $130 and $313, respectively.  The total compensation expense related to non-vested stock options and RSUs not yet recognized at December 31, 2011 is $468.
 
The Company utilized the following valuation assumptions to estimate the fair value of options that would have been granted for the three month periods ended December 31, 2011 and 2010, respectively.  No options were granted in the three month period ended December 31, 2011.  The valuation assumptions are included for comparison only.

STOCK OPTIONS:
 
2011
  
2010
 
Expected life (years)
  6.0   6.0 
Volatility
  155.08%  74.30%
Risk-free interest rate
  0.83%  1.51%
Dividend yield
  0%  0%
 
ESPP awards are valued using the Black-Scholes model with expected volatility calculated using a six-month historical volatility.   No ESPP awards were made in the nine month period ended December 31, 2011.  The valuation assumptions are included for comparison only.

ESPP:
 
2011
  
2010
 
Expected life (years)
  0.5   0.5 
Volatility
  116.27%  86.10%
Risk-free interest rate
  0.02%  0.12%
Dividend yield
  0%  0%
 
Valuation and Other Assumptions for Stock Options
 
Valuation and Amortization Method.    We estimate the fair value of stock options granted using the Black-Scholes model. We estimate the fair value using a single option approach and amortize the fair value on a straight-line basis for options expected to vest. All options are amortized over the requisite service periods of the awards, which are generally the vesting periods.
 
Expected Term.   The expected term of options granted represents the period of time that the options are expected to be outstanding. We estimate the expected term of options granted based on our historical experience of exercises including post-vesting exercises and termination.
 
Expected Volatility.    We estimate the volatility of our stock options at the date of grant using historical volatilities.  Historical volatilities are calculated based on the historical prices of our common stock over a period at least equal to the expected term of our option grants.
 
Risk-Free Interest Rate.    We base the risk-free interest rate used in the Black-Scholes option valuation model on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with remaining terms equivalent to the expected term of our option grants.
 
Dividends.    We have never paid any cash dividends on common stock and we do not anticipate paying any cash dividends in the foreseeable future.
 
Forfeitures.    We use historical data to estimate pre-vesting option forfeitures. We record stock-based compensation expense only for those awards that are expected to vest.
 
The Company does not use multiple share-based payment arrangements.
 
During the three months ended December 31, 2011, no stock option awards were granted.

Stock Options & Warrants

A summary of the stock option and warrant activity during the quarter ended December 31, 2011 is as follows:

   
Shares
  
Weighted
Average
Exercise
Price
  
Weighted
Average
Remaining
Contractual
Term (in Years)
  
Aggregate
Intrinsic
Value
 
Beginning outstanding
  151,245  $21.63       
Expired
  (5,911)  20.47       
                
Ending outstanding
  145,334  $21.67   5.22  $- 
Ending vested and expected to vest
  145,265  $21.65   5.22  $- 
Ending exercisable
  132,544  $22.64   5.05  $- 
 
The aggregate intrinsic value of stock options and warrants outstanding at December 31, 2011 is calculated as the difference between the exercise price of the underlying options and the market price of our common stock as of December 31, 2011.

The following table summarizes information with respect to stock options and warrants outstanding as of December 31, 2011:

Range of
Exercise Prices
 
  
Number
Outstanding
As of
December 31,
2011
  
Weighted
Average
Remaining
Contractual
Term
(in years)
  
Weighted
Average
Exercise
Price
 
  
Number
Exercisable
As of
December 31,
2011
  
Weighted
Average
Exercise
Price
As of
December 31,
2011
 
$2.90  $6.00   5,831   8.67  $4.67   5,204  $4.88 
 6.25   11.70   56,685   6.62   11.54   44,591   11.50 
 17.20   26.30   59,401   4.58   21.52   59,376   21.52 
 28.10   61.80   19,421   3.00   42.47   19,413   42.47 
 61.94   151.94   3,936   0.63   90.11   3,914   90.23 
 152.21   285.00   58   1.53   174.08   46   174.00 
 286.72   300.27   2   0.00   293.50   -   - 
                           
                           
$2.90  $300.27   145,334   5.22  $21.67   132,544  $22.64 
 
As of December 31, 2011, there was $12 of total unrecognized compensation cost related to outstanding options and warrants which the Company expects to recognize over a period of 0.79 years.
 
Restricted Stock Units
 
The following table summarizes the Company's unvested RSU activity for the three months ended December 31, 2011:
 
  
Number
of
Shares
  
Weighted
Avg.
Grant Date
Fair Value
 
Balance October 1, 2011
  272,405  $2.18 
Granted
  -  $- 
Forfeited
  -  $- 
Vested
  (28,260) $2.45 
Balance, December 31, 2011
  244,145  $2.15 
 
Unvested restricted stock at December 31, 2011

As of December 31, 2011, there was $456 of total unrecognized compensation cost related to outstanding RSUs, which the Company expects to recognize over a period of 3.08 years.
XML 17 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 18 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Inventories
9 Months Ended
Dec. 31, 2011
Inventories [Abstract]  
Inventories
2. 
Inventories:

Inventories are stated at the lower of cost or market. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis and includes material, labor and manufacturing overhead costs. Any excess and obsolete provision is only released if and when the related inventory is sold or scrapped.  The Company did not sell or scrap previously reserved inventory during the nine months ended December 31, 2011 and 2010.  The inventory provision balance for the periods ended December 31, 2011 and 2010 was $0 and $547, respectively.  The inventory provision for the nine month period ended December 31, 2010 was related to the DRIE products, which were sold in the prior fiscal year.
 
Net inventories for the periods presented were zero.  All remaining inventory was included in the sale of the DRIE related assets in the prior fiscal year.

Prior to the sale of the DRIE assets in the prior fiscal year, the Company periodically analyzed any systems that were in finished goods inventory to determine if they were suitable for current customer requirements.  At that time, the Company's policy was that, if after approximately 18 months, it determines that a sale will not take place within the next twelve months and the system would be useable for customer demonstrations or training, it is transferred to fixed assets.  Otherwise, it was expensed.
XML 19 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited) (USD $)
Dec. 31, 2011
Mar. 31, 2011
Stockholders' equity:    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, shares issued (in shares) 1,688,807 1,688,943
Common stock, shares outstanding (in shares) 1,688,807 1,688,943
XML 20 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document And Entity Information (USD $)
9 Months Ended
Dec. 31, 2011
Feb. 02, 2012
Mar. 31, 2011
Entity Registrant Name TEGAL CORP /DE/    
Entity Central Index Key 0000931059    
Current Fiscal Year End Date --03-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Smaller Reporting Company    
Entity Public Float     $ 5,066,421
Entity Common Stock, Shares Outstanding   1,688,807  
Document Fiscal Year Focus 2011    
Document Fiscal Period Focus Q3    
Document Type 10-Q    
Amendment Flag false    
Document Period End Date Dec. 31, 2011    
XML 21 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2011
Dec. 31, 2010
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) [Abstract]        
Revenue - related party $ 38 $ 0 $ 75 $ 0
Operating expenses:        
General and administrative expenses 432 306 1,873 1,493
Total operating expenses 432 306 1,873 1,493
Operating loss (394) (306) (1,798) (1,493)
Equity in (earnings) loss of unconsolidated affiliate 181 0 501 0
Other income/(expense), net 8 (3) (6) (344)
Loss before income tax expense (583) (303) (2,293) (1,149)
Income tax expense 0 0 0 0
Net loss from continuing operations (583) (303) (2,293) (1,149)
Income (loss) from discontinued operations, net of taxes 2,852 211 3,091 (1,277)
Net income/(loss) $ 2,269 $ (92) $ 798 $ (2,426)
Net loss per share from continuing operations:        
Basic and diluted $ (0.34) $ (0.18) $ (1.36) $ (0.67)
Net income/(loss) income per share from discontinued operations:        
Basic and diluted $ 1.69 $ 0.13 $ 1.83 $ (0.76)
Net income/(loss) per share:        
Basic and diluted $ 1.35 $ (0.05) $ 0.47 $ (1.43)
Weighted average shares used in per share computation:        
Basic and diluted 1,689 1,688 1,688 1,688
XML 22 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Geographical Information
9 Months Ended
Dec. 31, 2011
Geographical Information [Abstract]  
Geographical Information
7. 
Geographical Information:

Prior to February 9, 2011, the Company operated in one segment for the manufacture, marketing and servicing of integrated circuit fabrication equipment.  Currently, the Company's sole potential source of revenue is from the project activities of Sequel Power.  The Company's chief operating decision-maker has been identified as the President and Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.
 
For geographical reporting, revenues are attributed to the geographic location in which the customers' facilities are located.  Long-lived assets consist of property, plant and equipment and are attributed to the geographic location in which they are located.  Net sales and long-lived assets by geographic region were as follows:

   
Revenue for the
  
Revenue for the
 
   
Three Months Ended
  
Nine Months Ended
 
   
December 31,
  
December 31,
 
   
2011
  
2010
  
2011
  
2010
 
Sales to customers located in:
            
United States
 $38  $-  $75  $- 
Total sales
 $38  $-  $75  $- 
 
Revenues for the three and nine months ended December 31, 2011 are all part of continuing operations.  Revenues of $1,345 and $4,847 for the three and nine months ended December 31, 2010, respectively, have been reclassified to discontinued operations.

   
December 31
  
March 31
 
Long-lived assets at period-end:
 
2011
  
2011
 
Discontinued Operations:
      
United States
 $-  $- 
Europe
  -   - 
Continuing Operations:
        
United States
  58   112 
Total Long-lived assets
 $58  $112 
XML 23 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
MEMS Capital Equipment related Asset Acquisitions and Sales
9 Months Ended
Dec. 31, 2011
Capital Equipment Related Asset Acquisitions and Sales [Abstract]  
MEMS Capital Equipment related Asset Acquisitions and Sales
6. 
MEMS Capital Equipment related Asset Acquisitions and Sales:

On September 16, 2008, the Company acquired certain assets from AMMS and Alcatel Lucent (together, the “Sellers”).  With this acquisition, we entered the DRIE market.  DRIE is a highly anisotropic etch process used to create deep, steep-sided holes and trenches in wafers, with aspect ratios of 20:1 or more.  DRIE was developed for micro-electro-mechanical systems (“MEMS”), which require these features, but is also used to excavate trenches for high-density capacitors for DRAM and more recently for creating TSVs in advanced 3-D wafer level packaging technology. The acquisition was designed to enable us to pursue the high-growth markets in MEMS and certain segments of integrated semiconductor device manufacturing and packaging.  Current end-markets include production of a variety of MEMS and power devices, memory stacking (flash and DRAM), logic, RF-SiP, and CMOS image sensors.  The Company paid $1,000 in cash and $4,000 in shares of the Company's common stock. The 208,877 shares of common stock issued by the Company was calculated by obtaining  the quotient of (a) $4,000 divided by (b) the average of the closing sales prices of the common stock as reported on the Nasdaq Capital Market on the five (5) consecutive trading days immediately prior to (but excluding) the closing date.
 
In connection with this acquisition, the Company and Alcatel Lucent entered into an intellectual property agreement providing for the transfer of specified intellectual property rights to the Company, a trademark license agreement allowing for the limited use of the AMMS trademark by the Company, and a preferred supplier agreement pursuant to which the Company will purchase certain equipment from an affiliate of the Sellers.  AMMS designated Mr. Gilbert Bellini to serve as a member of the Company's board of directors. AMMS' right to designate a member of the Company's board of directors terminated upon the absorption of AMMS into its parent, Adixen Vacuum Technology, and its subsequent sale to Pfeiffer Vacuum GmbH on December 31, 2010.

The purchase price was allocated as follows (in thousands):
 
Assets acquired:
   
Trademarks
 $428 
Patents
  2,648 
Total Intangible Assets
  3,076 
      
Fixed Assets
  24 
Inventory
  1,900 
Total Tangible Assets
  1,924 
      
Total Acquired Assets
 $5,000 

Beginning in the fiscal third quarter of 2009, following the acquisition of the DRIE product lines from AMMS, the Company experienced a sharp decline in revenues related to its legacy Etch and PVD products, a result of the overall collapse of the semiconductor capital equipment market and the global financial crisis.  The management and the Board of Directors of the Company considered several alternatives for dealing with this decline in revenues, including the sale of assets which the Company could no longer support.  On March 19, 2010, the Company and its wholly owned subsidiary, SFI, sold inventory, equipment, intellectual property and other assets related to the Company's legacy Etch and PVD products to OEM Group Inc. (“OEM Group”), a company  based in Phoenix, Arizona that specializes in “life cycle management” of legacy product lines for several semiconductor equipment companies.  The sale included the product lines and associated spare parts and service business of the Company's 900 and 6500 series plasma etch systems, along with the Endeavor and AMS PVD systems from SFI.  In connection with the sale of the assets, OEM Group assumed the Company's warranty liability for recently sold legacy Etch and PVD systems.
 
The Company and OEM Group entered into related agreements for the transfer and licensing of patents, trademarks and other intellectual property associated with the legacy Etch and PVD products.  These included a Trademark Assignment Agreement for certain trademarks used in the legacy Etch and PVD Products, a royalty-free Trademark License Agreement allowing for the limited use of the Tegal trademark by the purchaser solely in connection with future sales of legacy Etch and PVD products and solely in combination with the trademarks transferred to purchaser, a Patent Assignment Agreement for the transfer of certain patents related to the Etch and PVD products, and a perpetual, irrevocable, non-exclusive, worldwide, fully-paid, royalty-free, Intellectual Property Cross License Agreement, pursuant to which the Company granted OEM Group a license to certain intellectual property owned by the Company for use in OEM Group's manufacture and sale of the legacy Etch and PVD products, and OEM Group licensed back to the Company certain intellectual property for the Company's continued use.

The consideration paid by OEM Group consisted of the following (in thousands):

 
Cash in the amount of $250 paid at closing, which occurred on March 19, 2010;

 
An aggregate of $1,750 cash payable to the Company in four installment payments of $250, $500, $500 and $500 on July 1, 2010, October 1, 2010, January 1, 2011 and April 1, 2011, respectively; and
 
 
A contingent payment in cash of up to $1,000 payable to the Company by April 15, 2011 based on the following percentage of applicable bookings of Etch and PVD products in excess of $6,000 received by the Company or OEM Group during the period beginning March 19, 2010 through March 31, 2011:

 
if applicable bookings are greater than or equal to $6,000 but less than $8,000, the contingent payment will be 5% of the applicable bookings in excess of $6,000;

 
if applicable bookings are greater than or equal to $8,000 but less than $10,000, the contingent payment will be $100 plus 10% of the applicable bookings in excess of $8,000;

 
if applicable bookings are greater than or equal to $10,000 but less than $12,000, the contingent payment will be $300 plus 15% of the applicable bookings in excess of $10,000; and

 
if applicable bookings are greater than or equal to $12,000, the contingent payment will be $600 plus 20% of the applicable bookings in excess of $12,000.
 
In no case will the contingent payment exceed $1,000.
 
Based on the applicable bookings of OEM Group for the designated period, the amount of the contingent payment due was $440.  On June 21, 2011, the Sellers, OEM Group and Purchaser entered into an amendment (the “Amendment”) to the Purchase Agreement which, among other things, revised the payment schedule of the Contingent Payment.  Pursuant to the Amendment, the Company received $300 on July 5, 2011 and $140 plus approximately $5 of interest on October 7, 2011.  The description of the Amendment provided above is qualified in its entirety by reference to the full text of the Amendment, a copy of which was filed as Exhibit 10.1 to the Form 8-K report filed on June 23, 2011.
 
The Company retained the DRIE products which it had acquired from AMMS, along with the Compact™ cluster platform and the NLD technology that it had developed over the past several years.  The DRIE markets were seriously impacted by the downturn in the semiconductor markets, and as those markets recover the Company is not in a position to make the needed investments to improve its competitive position.  In addition, it was not clear that even with additional investment and significant reductions in operating expenses DRIE sales alone would be enough to support the Company.  As a result, the Company evaluated various other alternative strategies, including sale of its DRIE products, Compact™ platform and NLD technology, the transition to a new business model, a sale of all or substantially all of our assets, or  the liquidation or dissolution of the Company, including through a bankruptcy proceeding.  On February 9, 2011, the Company sold its DRIE and Compact related assets to SPTS, but retained its NLD technology.   See “The SPTS Transaction” below.

The SPTS Transaction

On February 9, 2011, Tegal and SPP Process Technology Systems Limited, (“SPTS”), a company incorporated and registered in England and Wales, entered into an Asset Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company sold to SPTS all of the shares of Tegal France, SAS, the Company's wholly-owned subsidiary, and product lines and certain equipment, intellectual property and other assets relating to the Company's DRIE systems and certain related technology SPTS also assumed existing customer contracts, including all installation and warranty obligations of existing customers, and other liabilities arising after the closing of the transaction (the “Assumed Liabilities”).
 
In connection with the sale, the Company and SPTS entered into related agreements for the transfer and licensing of patents, trademarks and other intellectual property associated with the business, including a royalty-free Trademark License Agreement allowing for the limited use of the Tegal trademark by SPTS solely in connection with future sales related to the business and solely in combination with the trademarks transferred to SPTS, as well as written assignments to SPTS of all rights in the patents and trademarks that are part of the sale.
 
The transaction closed immediately after execution of the Purchase Agreement. The consideration paid by SPTS totaled approximately $2,100, comprised of approximately $500 of Assumed Liabilities and $1,600 in cash, of which $200 in cash will be held in escrow for one year after the closing of the transaction to satisfy any indemnification obligations of the Company under the Purchase Agreement.
 
The descriptions of the Purchase Agreement and the Trademark License Agreement provided above are qualified in their entirety by reference to the full text of such agreements, copies of which have been filed as Exhibits 10.1 and 10.2, respectively, to the Company's 8-K filed on February 15, 2011 and are incorporated herein by reference.

Discontinued Operations

The assets and liabilities of discontinued operations are presented separately under the captions “Assets of discontinued operations” and “Liabilities of discontinued operations,” respectively, in the accompanying condensed consolidated balance sheets at December 31, 2011 and March 31, 2011 and consist of the following:

   
December 31,
  
March 31,
 
   
2011
  
2011
 
        
Assets of Discontinued Operations:
      
Accounts receivable and other receivables, net of allowances for sales returns and doubtful accounts of $0 and $71 at December 31, 2011 and March 31, 2011, respectively
  405   591 
Notes receivable
  26   528 
Prepaid expenses and other current assets
  12   10 
Total assets of discontinued operations
 $443  $1,129 
          
Liabilities of Discontinued Operations:
        
Accounts payable
 $-  $522 
Deferred revenue
  --   130 
Accrued expenses and other current liabilities
  380   758 
Total liabilities of discontinued operations
 $380  $1,410 
 
In the nine months ended December 31, 2011, the Company recognized deferred revenue of $130, offset by related commission expense, as well as revenue of $89 from the finalization of the sale of the DRIE assets which occurred in the fourth quarter of the prior fiscal year.  In the same period, the Company received $440 from OEM in installment payments related to the sale of legacy assets, and recognized $64 in foreign currency transactions.  Total revenue from discontinued operations was $1,345 and $4,847 for the three and nine months ended December 31, 2010.  The total loss from discontinued operations for the nine months ended December 31, 2010 was $1,270 and included the reclassification of operating expenses related to the manufacture, design, marketing and servicing of the DRIE operations including foreign exchange adjustments and income tax expense (benefit).
 
The Company also recognized $3,550 from the December 23, 2011 sale of the NLD patents.  As these assets were internally developed, there was a corresponding zero book value.  The NLD revenue is recognized in discontinued operations, along with the related costs of $813, which includes $767 in commission expense.  During December 2011, the Company, as part of its proposed sale of its intellectual property portfolio for Nanolayer Deposition Technology (NLD), awarded three of the four offered lots to multiple semiconductor equipment manufacturers for aggregate consideration of approximately $4 million.  The Company finalized the sale transaction of the first of the four lots on December 23, 2011.  The Company finalized the sale transaction of the second lot after December 31, 2011.  While the third lot has been awarded, the Company has not yet finalized that transaction.  Sales of NLD patents in future periods will also be recognized in discontinued operations, as well all related expenses to finalize the sales.  NLD is a process technology that bridges the gap between high throughput, non-conformal chemical vapor deposition (CVD) and highly conformal, low throughput atomic layer deposition (ALD).  The portfolio included over 35 US and international patents in the areas of pulsed-CVD, plasma-enhanced ALD, and NLD.
XML 24 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Recent Accounting Pronouncements
9 Months Ended
Dec. 31, 2011
Recent Accounting Pronouncements [Abstract]  
Recent Accounting Pronouncements
8. 
Recent Accounting Pronouncements:

In May 2011, the FASB issued ASU 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs, which amends ASC Topic 820, Fair Value Measurement. The purpose of ASU 2011-04 is to clarify the intent about the application of existing fair value measurement and disclosure requirements and to change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements.  This pronouncement is effective for interim or annual periods beginning after December 15, 2011.  We do not expect the provisions of ASU 2011-04 to have a material impact to our consolidated financial statements.
 
In June 2011, the FASB issued ASU 2011-05, Presentation of Comprehensive Income, which amends ASC Topic 220, Comprehensive Income. The objective of ASU 2011-05 is to improve the comparability, consistency and transparency of financial reporting and to increase the prominence of items reported in other comprehensive income. The update will require entities to present items of net income, items of other comprehensive income and total comprehensive income in one continuous statement or two separate consecutive statements, and entities will no longer be allowed to present items of other comprehensive income in the statement of stockholders' equity. Reclassification adjustments between other comprehensive income and net income will be presented separately on the face of the financial statements. This pronouncement is effective for interim or annual periods beginning after December 15, 2011.  We do not expect the provisions of ASU 2011-05 to have a material impact to our consolidated financial statements.
 
In September 2011, the FASB issued ASU 2011-08, Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment, which permits an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. This pronouncement is effective for interim or annual periods beginning after December 15, 2011.  We do not expect the provisions of ASU 2011-05 to have a material impact to our consolidated financial statements.

In December 2011, the FASB issued ASU 2011-11, Balance Sheet - Disclosures about Offsetting Assets and Liabilities(Topic 210), which requires entities to disclose both gross information and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting arrangement. This scope would include derivatives, sale and repurchase agreements and reverse sale and repurchase agreements, and securities borrowing and securities lending arrangements. The objective of this disclosure is to facilitate comparison between those entities that prepare their financial statements on the basis of U.S. GAAP and those entities that prepare their financial statements on the basis of IFRS.   Even though this pronouncement is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods, disclosures required by those amendments are expected to be provided retrospectively for all comparative periods presented.  We do not expect the provisions of ASU 2011-11 to have a material impact on our consolidated financial statements.
XML 25 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Investments
9 Months Ended
Dec. 31, 2011
Investments, All Other Investments [Abstract]  
Investments
9. 
Investments

The Nano Vibronix Transaction
 
On November 22, 2011, the Company completed a $300 strategic investment in the form of a convertible promissory note from Nano Vibronix, Inc., a private company that develops medical devices and products that implement its proprietary therapeutic ultrasound technology.  Nano Vibronix is focused on creating products utilizing its proprietary low-intensity surface acoustic wave (SAW) technology. The company's unique, patented approach enables the transmission of low-frequency, low-intensity ultrasound waves through a variety of soft, flexible materials, including skin and tissue, enabling low-cost, breakthrough devices targeted at large, high-growth markets.  A copy of the Company's press release was filed as an exhibit to the Company's Form 8-K filed on November 29, 2011 and is incorporated herein by reference.
 
The Company's investment in Nano Vibronix is in the form of a convertible promissory note that bears interest at a rate of 10% per year compounded annually and matures on November 15, 2014.  Principal and accrued interest under the note automatically convert into shares of Series B-1 Participating Convertible Preferred Stock of Nano Vibronix upon the earlier to occur of (i) a $3 million (or larger) equity financing by Nano Vibronix or (ii) a sale of Nano Vibronix.  In addition, the Company may convert principal and accrued interest under the note into shares of Nano Vibronix Series B-1 Participating Convertible Preferred Stock at its election at any time.  In either case, the conversion price is $0.284 per share.

The Sequel Power Transaction
 
On January 14, 2011,  Tegal, se2quel Partners LLC, a California limited liability company, and Sequel Power LLC, a newly formed Delaware limited liability company (“Sequel Power”), entered into a Formation and Contribution Agreement.  Sequel Power is focused on the promotion of solar power plant development projects worldwide, the development of self-sustaining businesses from such projects, including but not limited to activities relating to and supporting, developing, building and operating solar photovoltaic fabrication facilities and solar farms, and the consideration of other non-photovoltaic renewable energy projects.  se2quel Partners is owned by Ferdinand Seemann, who previously served as an independent member of the Company's Board of Directors.  Pursuant to the Formation and Contribution Agreement, Tegal contributed $2 million in cash to Sequel Power in exchange for an approximate 25% economic interest in Sequel Power.  In addition, Tegal issued warrants (“Warrants”) to se2quel Partners and se2quel Management GmbH, a German limited liability company, to purchase an aggregate of 185,777 shares of the Company's common stock at an exercise price of $3.15 per share.  The Warrants are exercisable for a period of four years.
 
The descriptions of the Formation and Contribution Agreement and the Warrants are qualified in their entirety by reference to the full text of such documents, copies of which were filed as exhibits to the Form 8-K report filed on January 21, 2011.

Results of Sequel Power Operations

Revenue
 
Revenue for Sequel Power operations of $0 for the three months ended December 31, 2011 decreased by $2 from revenue for the three months ended September 30, 2011.  Revenue for the nine months ended December 31, 2011 was $4.  All Sequel revenue was generated from project services.
 
Sequel Power's net loss for the three month period ended December 31, 2011 was $553.   The Company's share of net loss is $138.   Sequel Power's net loss for the nine month period ended December 31, 2011 was $1,490.   The Company's share of net loss is $373.
 
XML 26 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Cash flows from operating activities:    
Net income/(loss) $ 798 $ (2,426)
Adjustments to reconcile net income/(loss) to net cash (used in)/provided by operating activities:    
Stock compensation expense 130 313
Stock issued under stock purchase plan 0 1
Fair value adjustment of common stock warrants EITF 07-05 (Topic 815) (6) (339)
Depreciation and amortization - continuing operations 7 0
Depreciation and amortization - discontinued operations 0 553
Net gain on sale of intangible asset (2,737) 0
Provision for doubtful accounts and sales returns allowances - discontinued operations (71) (144)
Loss on disposal of property and equipment - continuing operations 51 0
Loss on disposal of property and equipment - discontinuing operations 0 185
Gain on proceeds received from contingent payments - discontinued operations (445) 0
Change in value of unconsolidated affiliate 501 0
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 47 31
Accounts payable (181) 0
Accrued expenses and other current liabilities (37) 0
Current assets and liabilities from discontinued operations (330) 2,140
Net cash (used in)/provided by operating activities (2,273) 314
Cash flows from investing activities:    
Acquisition of property and equipment - continuing operations (4) 0
Acquisition of property and equipment - discontinued operations 0 (406)
Net proceeds received from sale of intangible asset - discontinued operations 2,737  
Net cash received on OEM asset disposition - discontinued operations 502 750
Issuance of note receivable (300) 0
Net cash provided by investing activities: 2,935 344
Cash flows from financing activities:    
Net cash used in financing activities 0 0
Effect of exchange rates on cash and cash equivalents 27 (66)
Net increase in cash and cash equivalents 689 592
Cash and cash equivalents at beginning of period 7,575 [1] 7,298
Cash and cash equivalents at end of period $ 8,264 $ 7,890
[1] Derived from the Company's audited consolidated financial statements
XML 27 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Financial Instruments
9 Months Ended
Dec. 31, 2011
Financial Instruments [Abstract]  
Financial Instruments
5. 
Financial Instruments:

The carrying amount of the Company's financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, notes receivable, accrued expenses and other liabilities approximates fair value due to their relatively short maturity. Prior to February 9, 2010, the Company sold products in various global markets. As a result, the Company was exposed to changes in foreign currency exchange rates.  The Company does not hold derivative financial instruments for speculative purposes.  Foreign currency transaction gains and (losses) included in other income (expense), were $27 and $66 for the nine months ended December 31, 2011 and 2010, respectively.  On December 31, 2011, the Company had no open foreign exchange contracts to sell Euros or any other foreign currencies.  On December 31, 2011, the Company had 41,741 warrants outstanding with an exercise price of $30.00 expiring between June 2013 and September 2013.  For the nine months ended December 31, 2011 and 2010, respectively, the Company recorded non-cash gains of $6 and $344 related to these warrants. The Company recorded a non-cash loss related to the warrants of $8 in the quarter ended December 31, 2011 and a non-cash gain of $3 in the quarter ended December 31, 2010.
XML 28 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 9 92 1 true 0 0 false 3 false false R1.htm 000990 - Document - Document And Entity Information Sheet http://tegal.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://tegal.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) false false R3.htm 001010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited) Sheet http://tegal.com/role/CondensedConsolidatedBalanceSheetsParentheticalUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited) false false R4.htm 002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://tegal.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) false false R5.htm 003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://tegal.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) false false R6.htm 006010 - Disclosure - Basis of Presentation Sheet http://tegal.com/role/BasisOfPresentation Basis of Presentation false false R7.htm 006020 - Disclosure - Inventories Sheet http://tegal.com/role/Inventories Inventories false false R8.htm 006030 - Disclosure - Product Warranty Sheet http://tegal.com/role/ProductWarranty Product Warranty false false R9.htm 006040 - Disclosure - Net Income Loss Per Common Share (EPS) Sheet http://tegal.com/role/NetIncomeLossPerCommonShareEps Net Income Loss Per Common Share (EPS) false false R10.htm 006050 - Disclosure - Financial Instruments Sheet http://tegal.com/role/FinancialInstruments Financial Instruments false false R11.htm 006060 - Disclosure - MEMS Capital Equipment related Asset Acquisitions and Sales Sheet http://tegal.com/role/MemsCapitalEquipmentRelatedAssetAcquisitionsAndSales MEMS Capital Equipment related Asset Acquisitions and Sales false false R12.htm 006070 - Disclosure - Geographical Information Sheet http://tegal.com/role/GeographicalInformation Geographical Information false false R13.htm 006080 - Disclosure - Recent Accounting Pronouncements Sheet http://tegal.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements false false R14.htm 006090 - Disclosure - Investments Sheet http://tegal.com/role/Investments Investments false false All Reports Book All Reports Process Flow-Through: 001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Mar. 31, 2010' Process Flow-Through: 001010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited) Process Flow-Through: 002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Process Flow-Through: 003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) tgal-20111231.xml tgal-20111231.xsd tgal-20111231_cal.xml tgal-20111231_lab.xml tgal-20111231_pre.xml true true